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IMPLANON™ is a subdermal single-rod ethylene vinyl acetate (EVA) implant 
containing approximately 68 mg of 3-ketodesogestrel or etonogestrel. It is one of 
the newest of the contraceptive implants, which is undergoing pre-introductory 
clinical trials in many parts of the world. This thesis is an evaluation of safety, 
contraceptive efficacy and acceptability of IMPLANON™ implants in 
Singaporean women. 
 
An open, randomized, group comparative, single-centre study was performed to 
assess possible differences in effects of IMPLANON ™ and NORPLANT® on 
carbohydrate metabolism, parameters of adrenal and thyroid function, lipid 
metabolism and liver function. Furthermore, contraceptive efficacy, safety, 
acceptability and vaginal bleeding patterns of both implants were evaluated and 
compared.  
 
Eighty (80) subjects were randomized to receive IMPLANON™ (n=40) or 
NORPLANT® (n=40) implants. For IMPLANON™ 37 subjects and for 
NORPLANT® 31 subjects completed two years of treatment. In the 
IMPLANON™ group three subjects (7.5%) of which one was lost to follow up, 
and in the NORPLANT® group nine subjects (22.5%) discontinued during the 
study. This led to a statistically significant treatment difference for cumulative 
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discontinuation rates (p=0.03).  For both implants good contraceptive efficacy 
was indicated by the absence of in-treatment pregnancies. None of the subjects in 
the IMPLANON™ group discontinued due to bleeding irregularities compared to 
four (10%) in the NORPLANT® group. IMPLANON™ users experienced less 
bleeding than NORPLANT® users although the bleeding pattern in 
IMPLANON™ users was more variable. A comparative safety profile with both 
treatments was obtained in terms of incidence and type of adverse experiences 
(AEs). Mean blood pressure and body mass index were slightly elevated in both 
groups. Statistically significantly higher systolic blood pressure values were 
observed in the NORPLANT® group at months 3 and 18. Implant insertion and 
removal was much faster for IMPLANON™ than for NORPLANT®. 
 
The use of IMPLANON™ and NORPLANT® had similar effects on 
carbohydrate metabolism. The results of the oral glucose tolerance tests revealed 
comparable increases from baseline in incremental AUCs (Area under the curves) 
and 2-hour responses for insulin and, to a lesser extent, glucose, indicating some 
degree of insulin resistance. Fasting concentrations of glucose, glycosylated 
haemoglobin (HBA1C) and insulin remained stable during treatment, except for 
an increase in fasting insulin levels observed at 24 months in both groups. 
 
With IMPLANON™ no changes were noted in the levels of thyroid hormones T3 
and T4. In the NORPLANT® group, T3 levels were not changed, but T4 was 
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decreased during treatment. The between-group difference in T4 was statistically 
significant at 6 and 24months. Thyroid binding globulin (TBG) levels were 
transiently decreased in both treatment groups, but less pronounced in the 
IMPLANON™ group. In both groups, an increase in resin uptake of free T3 was 
observed. Mean cortisol levels tended to increase in IMPLANON™ users and 
were decreased in NORPLANT® users. Between-group difference was only 
statistically significant at last measurement. Cortisol binding globulin (CBG) 
levels were decreased in both groups. Total testosterone levels were decreased in 
both groups. Sex hormone binding globulin (SHBG) levels were statistically 
significantly more decreased in NORPLANT® users at all assessments, while in 
the IMPLANON™ group near baseline values were seen at 12 months and 
increased levels at 24 months. 
 
The serum lipid pattern in the IMPLANONTM users was not significantly different 
from that of the NORPLANT users. For both the implant groups, there were no 
significant changes in the HDL/total cholesterol ratio and the HDL / LDL ratio, 
in spite of a lowering of the serum HDL levels. In both the groups, the HDL / 
total cholesterol ratio remained well above 0.2 and the HDL / LDL  ratio was 
above 0.3 at all sampling time. These results suggest that, like NORPLANT, use 
of IMPLANONTM implants is unlikely to contribute directly to any increased 
cardio-vascular risk.  
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With respect to liver function tests, serum bilirubin and gamma-glutamyl 
transferase (GGT) levels were significantly elevated during the use of both the 
implants, which suggested possible hepato-cellular dysfunction. However the 
mean value of these parameters were well within the normal clinical range. There 
were also no significant changes in serum transaminases, alkaline phosphatase 
and lactate dehydrogenase (LDH) levels.  
 
In a small non-comparative study of serial serum 3-ketodesogestrel levels in 10 
IMPLANON™ users, mean serum 3-ketodesogestrel levels of  273, 249 and 220 
pg/mL at the end of 1, 1½ and 2 years respectively. The serum levels were well 
above the concentration of 90 pg/mL required for consistent ovulation inhibition. 
 
It would appear from this thesis that IMPLANON™ implants offer a highly 
effective, acceptable and safe method of contraception. It has the potential for wider 
use in Singapore and will have a strong demand whenever it is made available to the 
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CHAPTER I :   THE BACKGROUND 
 
(a)  World population - the present and the future      
       .......It is likely that within the next 40 years there will be twice as many people 
on Earth, consuming three times as much food and fibre, seeking four times as much 
energy and engaging in five to ten times as much economic activity.  
           -  The World Commission on Environment and Development  (1987)              
                                              
 
The future would certainly be very different from the present.  Current levels of 
population growth are unprecedented in human history. World population was less 
than 300 million 1993 years ago, when Jesus Christ was born. It took some 1500 
years to double this number. The first billion landmark was reached at the beginning 
of 19th century and the second billion in 1927 (Demeny, 1985). It took less than 50 
years to double this number to 4 billion by 1976, and the fifth billion was reached 
only eleven years later, in 1987.  Today world population exceeds 5.6 billion and is 
growing by 90 million a year (1.8% per annum).  
 
What would be the world population like in the future ? The fertility decisions of the 
coming century would be critical in deciding the world population size at the end of 
the first century of the next millenium. If fertility declined from its 1992 level of 3.4 
children per woman and 2 child family became the norm, world population would 
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stop growing at 9 billion (Haub and Yanagishita, 1992).   If, instead, a family of 2.5 
children eventually became the norm during next century, world population would 
grow to 19 billion in 2100 and continue to grow (United Nations, 1992). The pace of 
fertility reduction is also critical. The world's ultimate population size would also 
depend on the number of years it will take to reach replacement level of fertility 
(around 2.1 children per couple) world-wide. If the level is reached in 2010 (the low 
projection of the United Nations), global population will stabilize at 8 billion; if it is 
reached in 2035 (medium projection), world population will stabilize around 10 
billion; however if it is reached only in 2065 (high projection), global population 
will reach 14 billion by the end of the 21st century (Figure 1.1). Furthermore, 
approximately 90% of this future population growth will occur in the developing 
countries and in the year 2050, six times more people will be living in the 




The world in general, and developing countries in particular, are increasingly facing 
a major challenge in the attempts to optimize the complex relationship between 
growing population, resources, environment and development.  To reach 
replacement-level fertility world-wide by about 2050 would require that 
contraceptive prevalence rise from the 1990 level of about 50% in developing 
countries to 73% by 2025, implying an increase by almost 50% between 1990 and 
2000 - from 381 million to 587 million couple users (Mauldin and Ross, 1991). 
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These ambitious targets can only be reached by making available a wider choice of 
safe, acceptable and affordable contraceptives and high-quality family planning 
services on a voluntary basis. 
 
(b) Limiting population growth - Health aspects 
Every minute another woman dies as a result of pregnancy.  More than half a million 
women, nearly all of them in the developing world, die each year in pregnancy and 
childbirth. The UN Population Fund estimates that half of those lives could be saved 
if family planning were universally available. Pregnancy-related complications 
cause one-quarter to one-half of deaths among women of reproductive age in 
developing countries. Failure to time and space pregnancies augment the risk of 
complications and deaths.  In Latin America, for example, half of all deaths among 
pregnant women are due to illegal abortions. Effective family planning could avoid 
the majority of such deaths. With 76% of the world population living in developing 
countries, their share is 85% of all births, 95% of all infant and childhood deaths and 
99% of all maternal deaths (United Nations Fund for Population Activities, 1987). 
 
The need for improved family planning information and services is not confined 
entirely to the developing world. Half of the pregnancies in the United States, for 
example, are unplanned.                                                  
18 
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Causes of population growth 
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   Table 1.1   Reproductive health in 1988 - UN and WHO estimate  
           
           PREVALENCE MILLIONS 
No access to fertility regulation 500 
Infertile couples 60 - 80 
Induced abortions 30 - 60 
Maternal deaths 0.5 
Infant deaths 9.6 
Child deaths 4.8 
Gonorrhoea 250 
Syphilis 50 
AIDS 50 - 100 
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Fertility regulation is one of the four fundamental pillars of reproductive health. 
Together with maternal care, infant and child care and prevention of sexually 
transmitted diseases, it provides the foundation on which any modern reproductive 
health policy rests. The problems relating to reproductive health form a major part of 
the health needs of most populations, including their needs of family planning. It is 
probably one of the greatest failure of our generation that out of roughly 50 million 
deaths which occur in the world each year, 15 million are infants and children under 
the age of five (WHO, 1989). The effective use of family planning will delay the age 
at first pregnancy and space further births. When integrated into primary health care, 
both of these will diminish infant, child and maternal morbidity and mortality and 
significantly reduce illegal abortions and health hazards. 
 
(c) Limiting population growth - the economic and environmental aspect.  
THE DEMOGRAPHIC TRAP.  The high rates of population growth in the 
developing world are the results of falling death rates, and of birth rates that have 
risen, and in some cases are still rising (Dyson and Murphy, 1985). Notestein's 
(1945) model of "demographic transition" from a high birth rates and death rates to 
low birth rates and death rates was largely built on the experience of the 
industrialized world. He described a first stage, when both birth and death rates are 
high and the population grows only slowly. During the second stage, living and 
health condition improves and death rates fall, but birth rates remain high and the 
population grows rapidly. In the third stage economic and social gains combine to 
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reduce poverty and lower the birth rate, so that birth and death rates are in 
equilibrium again, but at a much lower level. 
 
The essential feature of demographic transition is that it is a transition. Populations 
in rapid and sustained growth in the second stage are in danger of exceeding the 
capacity of their local ecosystems, especially if these are fragile, as in much of the 
tropics. The unstable second stage must be completed quickly, otherwise the 
population will enter the "demographic trap" (King, 1990). If the birth rate does not 
fall, the death rate will ultimately rise again, so the population is stuck in the trap and 
finds itself in an unsustainable state with a high birth and death rate, with ever 
increasing pressure on resources and with a rapidly deteriorating environment. 
Whether a population gets trapped depends on its rate of growth, and on the ability 
of the local environment to support that growth. The early signs of entrance into this 
"trap" would be a slowing of the expected fall in the child death rate followed by a 
rise. Ominously, UNICEF reported that after decades of decline, the infant mortality 
rate has stopped falling in at least 21 developing countries and is rising in others 
(UNICEF, 1987). Incipient ecological collapse is one of the possible causes. 
 
Obviously, the earth cannot sustain an ever increasing rise in world population. 
Already the effect is taking its toll on the environment; global warming, ozone 
depletion, and acid rain have all been caused by man through industrial expansion. 
Overexploitation of land in the developing world has caused grasslands to 
deteriorate, soil erosion to increase, and land to be slowly converted to desert. 
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Environmental changes are already affecting agriculture and are threatening food 
production throughout the world. Estimates show that the current food production is 
leaving one-fifth of the world's current population without enough food (Ehrlich and 
Ehrlich, 1990).  
 
The huge and rapidly growing cities of the developed world are in an ecological 
predicament which is no less grave. Many of the cities are barely viable, and the 
human condition of many of their citizens defies adequate description and promises 
to deteriorate. Ultimately, our world must arrive at a biologically sustainable 
economy or cease to exist (King, 1990). 
 
d) The need for family planning research. 
Adequate availability of family planning services and methods is now an essential 
human right. A variety of contraceptive methods have been developed over the last 
few decades. However, the present array of modern contraceptive methods is less 
than perfect. All currently available method has some drawbacks. The most effective 
reversible methods have some troublesome side effects and even poses significant 
health risks for certain groups of women. On the other hand, methods with the 
fewest side effects, tend to be least reliable in preventing undesirable pregnancies. 
This is reflected in the fact that, in the US, nearly half of unintended pregnancies 
(47%) occur to the 90% women using a contraceptive method (Forrest, 1994). In 
Singapore, one in three pregnancies is currently terminated despite the easy 
availability of a range of contraceptive methods. This frequent resort to induced 
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abortion clearly indicates that not every couple is readily accepting the range of 
fertility regulatory methods available.  
 
There is therefore the need for continued development and search for a much wider 
variety of safe, effective and acceptable methods of fertility regulation for potential 
users. We could be doing much more with existing technology but new technology 
would help. However, it is alarming to note, that in 1970 there were 13 major 
pharmaceutical companies that conducted contraceptive research and development 
and that by 1987 the number had dropped to four (WHO, 1989). The important 
reasons for the retrenchment of the industry include the high expenses of the animal 
toxicological studies required, the poor public image of the field due to negative 
publicity, the fear of litigation and unavailability of insurance to protect the industry 
in case of litigation (Djerrasi, 1989). Even more serious is the reduced public 
funding directed towards fundamental research and research training, since the 
repercussion of this will be long-lasting and will adversely affect contraceptive 
development in the 21st century. In the coming decade, it will be crucial to provide 
more funding for basic research and to bring the pharmaceutical industry back into 







e) The need for long-acting steroidal contraception 
In 1980 the World Fertility Survey demonstrated that the desire of individual 
couples to limit their fertility coincides remarkably well with the wishes of most 
physicians and social planners. About half of all married women in the world 
currently want no more children; nevertheless only a small proportion use any 
modern or traditional form of contraception. The most widely available methods, 
such as the pill and intrauterine device, are frequently either not selected or are 
discontinued. These and other methods simply do not meet the needs of many 
potential users. Barrier methods are coitus related, messy, inconvenient, and require 
genital manipulation and privacy; natural family planning techniques require long 
periods of abstinence; the pill requires a daily action, causes various side-effects, and 
 has been wrongly associated with health risks; sterilization is irreversible; and the 
IUD is convenient, but excessive bleeding and cramping and a complex insertion 
procedure deter its use. What is needed is an effective, safe and reversible method 
that can be administered by non-physicians in remote areas, that is totally 
independent of coital activity, and that does not require specialized facilities or 
supplies. Long-acting steroidal contraceptives fill these requirements more clearly 
than other methods currently in use. Moreover, experience suggests that a wide 
choice of contraceptive methods encourages acceptance and sustained use 
(Zeidenstein, 1980). Each additional method appears to contribute independently to 
the overall prevalence of contraceptive use (Potts and Selman, 1979). These factors 
indicate a need for further development and distribution of long-acting steroidal 
contraception, particularly the implant systems. 
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Keeping these broad principles in mind, the present study was undertaken to 
evaluate and aid the development of IMPLANON - a new, long-acting, progestin 
only, single-rod subdermal contraceptive delivery system, before it can be made 










 In this chapter, the development of steroidal contraceptive implants is briefly 
described. The first such implant was the progesterone only device - NORPLANT® 
implants containing levonorgestrel. The development of this novel 6-capsule 
contraceptive delivery system and the newer systems comprising of fewer implants 
is traced.  
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CHAPTER II  :  HISTORY OF THE DEVELOPMENT OF 
CONTRACEPTIVE IMPLANTS 
 
The most important new development in contraceptive research during the past 
years has been related to injectables and implants. In the pursuit of more convenient 
and reliable methods of hormonal contraception, whilst reducing the daily dose of 
steroid, several long-acting contraceptive steroid delivery systems have been, and 
are currently being, developed. These include injectable intramuscular oily prodrug 
depots based on new types of steroid esters, steroid releasing intravaginal or 
intrauterine devices, intramuscular injectables based on biodegradable polymeric 
microcapsules or microspheres, and subdermal implants based on non-biodegradable 
or biodegradable polymeric rods or capsules. Of implantable polymeric steroid 
delivery systems investigated, the only device that currently has reached the market, 
is NORPLANT®, developed by the Population Council, New York. The concept of 
contraceptive implants was born when Horacio Croxatto and Sheldon Segal 
proposed in 1967 that subdermal capsules of Silastic, Dow Corning's trade name for 
polydimethylsiloxane, could serve as the vehicle for long term, reversible, steroidal 
contraception in women. The idea was logically derived from two important 
observations : firstly, the results of a study by Folkman and Long (1964) which 
showed that polydimethylsiloxane tubes can be used as a reservoir for the prolonged 
release of a variety of lipophylic drugs, and secondly, the remarkable bio-
compatibility of silicone rubber, which has been used for a wide variety of prosthetic 
devices since 1950. Croxatto and Segal (1967) demonstrated that with the use of 
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such an implant in rats and rabbits, hormonal effects can be maintained for over a 
year. The daily release rate of the steroid was not significantly lower even when the 
capsule's contents were reduced greatly and the rate of release increased 
proportionately to the surface area of the capsule and decreased with increasing wall 
thickness. They also showed that different steroids are released from 
polydimethylsiloxane capsules at different rates; the ratios of release rates for 
estradiol, testosterone and progesterone, for example, were reported to be 1:20:75. 
Once these fundamental facts established the feasibility of the idea that an 
appropriate contraceptive steroid stored under the skin in a biologically inert 
polydimethylsiloxane capsule could provide effective long-term contraception, 
search began for the most suitable contraceptive compound. 
 
The first clinical trial was conducted in Santiago, Chile, using implants made of 
medical grade polydimethylsiloxane tubing filled with the synthetic progestin, 
chlormadinone acetate, and sealed at both ends with a medical grade adhesive 
(Croxatto et al, 1969). The tubing was identical to that manufactured by the Dow 
Corning Company for use as hydrocephalus drainage tubes, which by then had been 
used in over 100,000 people without serious episodes of foreign body reaction or 
evidence of neoplasia. Unfortunately this first trial was discontinued after a brief 
period when chlormadinone acetate was withdrawn from clinical investigations in 
the United States because of adverse toxic findings in beagle dogs (Hill et al, 1970). 
Subsequently, trials were started with implants containing megestrol acetate and this 
became the first steroid for which contraceptive effectiveness by the implant route of 
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administration was established. Between 1970 and 1978 many trials were conducted 
using megestrol acetate implants in which the number of implants ranged from one 
to six (Tejuja, 1970; Croxatto et al, 1971). From these studies it became clear that 
for megesterol acetate at least more than one implant was required to achieve 
sufficient blood levels to suppress fertility. 
 
During these early studies with progestin implants two safety concerns were raised 
which had to be resolved during the course of product development. Both these 
issues were related to the use of low dose progestin-only contraception without 
ovulation inhibition. The first was the occurrence of adnexal masses in some 
women, and second was the higher tubal pregnancy rate in contraceptive failures 
that was higher than would be expected in a comparable group of women not using 
any contraceptives. A third concern was the reports of an association between 
exposure to progestins during pregnancy and an increased incidence of fetal 
malformations like congenital heart defects (Janerich et al, 1974; Heinonen et al, 
1977). Although these epidemiologic studies pertained primarily to the use of high 
doses of progestin in women with a history of threatened abortion, even the 
possibility of minimal increase in risk of congenital abnormalities in contraceptive 
failures was of serious concern. These important safety issues led the Population 
Council's International Committee for Contraception Research (ICCR) to advocate 
that contraceptive implants should release steroids at sufficient rate to suppress 
ovulation in most cycles. It was reasoned that the most effective way to protect 
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against serious hazards like ectopic pregnancy and birth defects is to maximize the 
protection against conception itself, which is best achieved by ovulation suppression. 
 
By 1975, a number of progestins, including norethindrone, norgestrienone and 
levonorgestrel, had been tested as possible candidates for inclusion in subdermal 
implants. Norethindrone was particularly attractive because of its long safety record 
as a component of combination oral contraceptives. Unfortunately trials with as 
many as six capsules containing norethindrone (each three centimeters in length) 
indicated that the amount of the drug released was insufficient to provide adequate 
blood levels necessary to prevent conception. Coutinho (1978) reported a failure rate 
of nearly 20% in 112 women using four to six norethindrone capsules over an 
average period of use of less than one year. While norethindrone was a 
disappointment, promising results were obtained with both norgestreinone and 
levonorgestrel. Levonorgestrel was chosen as the progestogen for further 
development of implant contraception because of its higher potency per volume. 
 
By 1976, clinical trials of six levonorgestrel-containing Silastic capsules were 
underway in six countries, including the United States. In 1983, the Population 
Council licensed Leiras of Turku, Finland, to manufacture and distribute Norplant, 
and Finland became the first country to give regulatory approval to the method. By 
the end of 1992, 23 other countries including the United States, had granted 
approval. Both the World Health Organization (1984) and the International Planned 
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Parenthood Federation (1985) had recognized Norplant as a safe and effective 
method of  reversible fertility regulation. 
 
Unlike other routes of delivery of hormonal contraception, subdermal implants that 
provide sustained release of progestins do not cause peaks in progestin levels 
beyond those required for effective contraception, nor do they use estrogen. For 
these reasons sustained release progestin systems are without some of the health 
risks attributed to other hormonal methods of contraception - oral and depot 
injections, for example. Because the implants can be removed, their effects are 
completely reversible. However, they are still not completely free of minor problems 
and side-effects, which affect user acceptability and continued use of the method. 
Although Norplant six-capsule system has been found to be a safe, effective and 
acceptable form of contraception, they share common side-effects with all progestin-
only methods, the most common of which is irregular menstrual bleeding caused by 
erratic shedding of atrophic endometrium.  Some women experience weight gain, 
mood shifts and acne as well as other minor side-effects common to the progestins. 
In addition, proper placement of these six capsules and their subsequent removal are 
minor surgical procedures that require clinicians to obtain training in special 
techniques. 
 
To enhance user compliance, improved delivery systems with reduced number of 
implants, like Norplant-2, is under development. In contrast to the Norplant-6 
system where the steroid crystals are placed in the interior of silastic tubing, in 
32 
Norplant-2, the steroid is mixed with the polymer, forming a homogenous solid rod, 
and covered with a thin silastic tubing. The covered rod technology allows a higher 
release rate than the capsules and therefore makes possible a reduction in the number 
of implants required for contraception (Robertson et al, 1983). The release rate of the 
steroid can be modulated by changing the thickness of the silastic wall or by 
increasing or decreasing the total surface area of the implants. Norplant-2 consists of 
two rods containing levonorgestrel dispersed in Silastic elastomer which are each 
sealed inside Silastic tubing. This system releases the steroid at a rate of about 40-50 
µg/day with an effective lifetime of three years (Sivin, 1988). In addition to this, 
biodegradable implants are also being developed. Biodegradable implants would 
offer an additional advantage by obviating the need for surgical removal at the end 
of their effective lifetime. However, due to the degradation characteristics of the 
polymers employed, the biodegradable delivery systems currently investigated will 
all have a user's life of much less than two years (Singh et al, 1989; ICMR Task 
force on Hormonal Contraception, 1991). In addition, it may be difficult or 
impossible to remove a biodegradable implant some time after implantation. This 
may be important if the tailing down release of the remaining steroid is slow and 
prolonged.  
 
In recent years, a number of new implant systems containing newer, less androgenic 
progestogens are being developed. Nomegestrol acetate has been tested in a single 
capsule implant system (Uniplant), with an effective life-span of one year (Coutinho, 
1993). The South to South Cooperation in Reproductive Health is currently 
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conducting a multicenter trial of Uniplant with over 1300 subjects. Another 
progestin that has been tested by the Population Council is nor-progesterone ST-
1435 (Nestorone TM). Several clinical studies under way, using a single modified 
covered rod with an estimated release rate of 100 µg/day, have shown effectiveness 
for 2 years (Alvarez-sanchez et al, 1993). NV Organon has been developing a new 
type of polymeric contraceptive implant containing a selective progestogen, 3-keto-
desogestrel (etonogestrel). 3-keto-desogestrel is the biologically active metabolite of 
the progestogenic compound desogestrel. This new type of delivery system currently 
under development, called IMPLANONR , is based on a membrane-coated matrix 
device designed to release 3-keto-desogestrel for a period of  three years at a 
corresponding in vitro release rate of approximately 30 µg/ day at the end of its 
intended duration. The device consists of a single flexible coaxial rod containing 3-
keto-desogestrel crystals dispersed in a ethylene-vinyl acetate (EVA) co-polymer as 
the core, surrounded by an EVA rate-controlling membrane (Sam, 1991). The 











(a) Pharmacologic studies 
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The development of a new systemic steroidal contraceptive system is 
a long-drawn process. This chapter describes the various steps - animal and 
human studies required before a systemic contraceptive agent is marketable. 
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CHAPTER III - THE DEVELOPMENT OF A NEW SYSTEMIC 
CONTRACEPTIVE 
 
The development of a new systemic contraceptive agent is a long drawn and tedious 
process. Since contraceptives are often perceived as drugs of convenience rather 
than drugs that are necessary for the treatment of disease, the degree of safety 
required of them is often greater than that required for many other pharmaceutical 
agents. The development process begins with its synthesis as a compound at the 
chemists bench, progressing through animal testing, the filing of the Investigational 
New drug (IND) forms, the various phases of clinical testing, and finally, the filing 
of a new drug application for approval to market. This is usually followed by 
extensive post-marketing surveillance. Currently it is estimated that the length of 
time from the chemist's bench to the introduction of a new drug to the public is 10 to 
15 years. In 1979, the cost, including loss of interest on investment, was estimated to 
be more than 50 million dollars (Hansen, 1979). 
 
Development Procedure 
A. Pharmacologic studies : Following selection of the compound for future 
development, reproductive pharmacology studies in nonprimate and primate species 
are conducted in order to : 
  1. Elucidate possible mechanisms of action. Typically 
gonadotrophin suppression studies are conducted in several 
species. In addition the effect of the compound on the 
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reproductive organs is evaluated histologically and receptor 
binding studies are carried out. 
   
  2. Estimate further the degree of activity. Fertility studies in 
non-human primates such as the baboon and the rhesus 
monkey are ideally carried out at this point. Dose finding 
studies would be performed to assist in the choice of a future 
human dose. 
 
  3. Anticipate possible side effects. During the course of the 
reproductive studies with animals any potential toxicity 
problems are noted. 
 
B. Pharmaceutical development : 
 A production process for the raw materials is developed which will be 
simple, reproducible on a large scale and cost-effective. During 
pharmaceutical development, numerous aspects are considered, such as : 
  1. Optimum formulation 
  2. Stability of the formulation under usual and stress conditions. 
  3. Pharmacokinetic characteristics 
  4. Cost 
  5. Packaging, including the size of the package and compatibility of 
the dosage form with the packaging material. 
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C. Toxicological testing in animals and other non-human systems 
 Toxicological studies in animals must be conducted in a number of species. 
These studies include acute studies, subacute studies and chronic toxicity 
studies. Acute toxicity studies are conducted in at least two species to 
evaluate the ED50, which is the value representing that dose which would 
exert a particular effect in one-half the population of a certain species under 
specified condition. The LD50 , which represents the dose that is lethal to 
one-half population of a particular species under specified condition, is 
compared among the species studied. For subacute toxicity studies (90 days), 
at least two species are usually studied with observations including body 
weight, behaviour, haemograms, coagulation tests, hepatic and renal 
function tests and metabolic studies. For parentally administered drugs, 
irritation studies are conducted with histological examination of the injection 
sites. If these initial animal tests suggest that the drug is non-toxic in man, 
studies of the pharmacodynamics and pharmacokinetics of the new drug are 
carried out in a small number of subjects (10-20 volunteers) to determine the 
dose of  drug to be used in further human and animal studies. 
  
 Before clinical trials can be expanded to more than 50 subjects or for periods 
longer than 3 months, chronic toxicity i.e. 2-year toxicological studies in 
rats, dogs and monkeys must be completed. These studies are conducted 
with doses approximately 1 to 3 times, 10 times, and 50 times the expected 
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human dose (Goldenthal, 1969). The results of these studies serve as a 
guideline for the toxicologist in his subsequent studies of possible teratologic 
effects and possible effects on late fetal development, labour and delivery, 
lactation, neonatal viability and growth of the newborn (perinatal and 
postnatal studies). In the teratologic, perinatal and postnatal studies, at least 
two species are used, usually the mouse and the rabbit or rat. Long term 
carcinogenecity studies are performed to investigate the potential of the 
compounds to induce proliferative changes or neoplasia in laboratory 
animals. In general, rodents (rats, mice or hamster) are used and these are 
studied over 18-24 months. For contraceptive steroids, expanded clinical 
trials may begin following completion of the 2-year animal studies, provided 
that long-term carcinogenecity studies in dogs (7 years) and monkeys 
(estimated 10 years) are initiated, with doses approximately 1 to 2 times, 10 
times, and 50 times the estimated human dosage.  
 
D. Clinical trials 
 The stages of human testing of new contraceptive steroids and steroid-
releasing systems follow the conventional Phase I-III trial nomenclature used 
generally in drug development.  As with other drugs, the initial clinical 
studies of steroidal drugs are designed to confirm at the outset the prediction 
of the previous animal toxicity studies that the drug would be non-toxic in 




 Phase I 
 Phase I studies are limited to small numbers of subjects, usually 10 to 20, 
with concentration on pharmacokinetics, pharmacodynamics and safety 
aspects of the drug. Typically, a rising dose tolerance study is done at this 
time to find out the maximum tolerated dose and the dose range. 
   
 Phase II 
 Phase II studies are carried out with restricted population groups (50-100 
subjects) in specialized centres to evaluate efficacy and safety, with 
concentration on the selection of a dose to be studied in phase III. Effective 
dose range is established and data on preliminary evidence of efficacy are 
collected. Since, unlike therapeutic drugs, steroidal contraceptive drugs are 
intended for use in healthy people for prolonged periods of their 
reproductive life, it is important to ascertain the minimum effective dose at 
these initial stages of drug testing. During Phase II studies, effects on the 
menstrual cycle and other clinical effects are evaluated. Special attention is 
directed toward possible effects on endocrine organs including pituitary, 
thyroid, adrenal, pancreatic, and ovarian function. Additionally, evaluation 
of effects on the reproductive system including, breasts, hepatic function, 





 Phase III studies are done on more general population and include larger 
controlled studies. Large-scale clinical trials should be randomized between 
the test drug and a comparable established method of fertility regulation. The 
studies should be designed to have sufficient statistical power to demonstrate 
a clinically important difference between the treatment groups, either with 
regard to efficacy or side-effects. In Phase III the previously mentioned areas 
of study are continued, aiming to confirm efficacy and to obtain complete 
safety profile. The results would form the basis for the regulatory 
information for the drug. Additionally, long-term effects on the previously 
listed systems return to fertility after discontinuing the contraceptive, 
examination of the infant born to a woman for whom the contraceptive was 
ineffective and additional evaluations dictated by findings during Phase II or 
phase III studies, such as in-depth studies of carbohydrate metabolism 
(insulin secretion, glucose tolerance tests) are carried out. Generally proof of 
efficacy for new systemic contraceptives requires approximately 6000 to 
10,000 cycles of information.  
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 IMPLANON™ is a new single-rod subdermal contraceptive implant 
containing a relatively newer progestogen – 3-ketodesogestrel (etonogestrel). In this 
chapter, the physical, chemical, pharmacodynamic and pharmacokinetic 
characteristics of this new implant are described. The drug safety studies and the 
limited clinical trials done to date are also reviewed. 
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CHAPTER IV  -  IMPLANON :  PHARMACOLOGY, 
PHARMACODYNAMICS AND DRUG SAFETY 
 
IMPLANON is a non-biodegradable subdermal contraceptive implant, consisting of 
 ethylene vinyl-acetate co-polymer (EVA) as a carrier for the progestational 
compound 3-ketodesogestrel (3-keto-DSG or etonogestrel) and an ethylene vinyl-
acetate co-polymer membrane. 
 
A. CHEMISTRY AND PHARMACY  
   1.  Description 
 The implant has the appearance of an off-white flexible rod. The length of 
the rod is approximately 40 mm and the diameter is approximately 2.0 mm. 
 
   2. Composition  
 The total mass of the implant is 134 mg, comprising of 3-Keto-DSG (active 
constituent) approx. 68 mg and ethylene-vinyl acetate co-polymers approx.  
66 mg. 
 
   3. Identity of 3-keto-desogestrel (etonogestrel) 





 3.2 Physical description  : White to nearly white, 
crystalline powder 
 
 3.3 Molecular formula  : C22H28O2 
  (Figure 4.1) 
 
 3.4 Relative molecular mass : 324,44 
 
   4. Containers   
 Each implant is delivered in the needle of a sterile disposable, specially 
designed inserter, which is packed individually in an aluminium sachet. 
 
   5.  Manufacturing process 
 two types of ethylene-vinyl acetate co-polymers, differing in vinyl acetate 
content, are used. In the first step, 3-keto-DSG is thoroughly mixed with an 
EVA type with the higher vinyl acetate content. In the second step this 
mixture is co-extruded with a second type of EVA of lower vinyl acetate 
content. The extrudate (diameter approx. 2.0 mm) is cut into rods of approx. 
40 mm length, which are aseptically placed inside the needle of a disposable 
inserter. Finally the inserter with implant is sterilized in their aluminium 
sachet by gamma-irradiation (25 KGy). 
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6. Release properties 
 The daily release of 3-keto-DSG from the implant is controlled by the 
composition of the carrier and membrane, as well as by the length and 
diameter of the membrane. The IMPLANON™ implant has been designed 
in such a way, as to release approx. a mean of 60 µg/day during the first 
year. As for any long-acting implant system, the release of 3-keto-DSG 
declines slowly with time. Pre-clinical in-vivo and in-vitro data correlate and 
indicate that the decline in release rate and the plasma concentration of 3-
keto-DSG from the second to third year of treatment is minimal. 
 
 6.1. In-vitro release 
 Daily release of 3-keto-DSG  from the implant over time has been 
determined in vitro, by incubating implants in purified water at 37°C. In-
vitro release data have been obtained from different batches of implants. The 
initial in-vitro 3-keto-DSG  release amounted to 60-70 µg /day during week 
5-6, decreasing to about 35-45 µg /day at the end of first year, to about 30-40 
µg /day at the end of second year, and about 25-30 µg /day at the end of the 
third year. Similar figures were obtained with the other batches of implants.  
 
 6.2. In-vivo release  
 a) Female Beagle dogs 
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 Contraceptive implants containing 3-keto-DSG were studied in 
female beagle dogs in three different studies for treatment periods of 
three years or more. Dogs received either implants with an initial 
release rate of approximately 67 µg/day (Implanon) or 40 µg/day 
("leached implants"). The in-vivo release from these implants was 
studied in 4 dogs per study. 
 
 In the first study, during a 3 year treatment period the daily in-vivo release of 
3-keto-DSG decreased in the first year from about 70 µg/day to about 25 
µg/day, after three years of treatment (Geelen et al, 1993). At that time mean 
3-keto-DSG concentrations of approximately 136 pg/ml were measured. The 
second study was performed with implants that were subjected to steroid 
extraction in ethanol-water mixtures to obtain an initial release rate of 40  
µg/day to mimic the release starting at the second year of treatment. After 2 
years of treatment mean 3-keto-DSG plasma concentrations of 
approximately 140 pg/ml was obtained. In the first dog study it was shown 
that this corresponds to an in-vivo release rate of approximately 25  µg/day. 
The third study started in 1991 and is still ongoing. Preliminary data indicate 
that mean 3-keto-DSG plasma concentrations of approximately 200 pg/ml 
are measured after a treatment period of one year. There is a gradual decline 
to approximately 150 pg/ml after 3 years of treatment, which corresponds to 
an in-vivo release rate between 25 and 30 µg/day (NV Organon data on file). 
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 b) Human female 
 The "leached" implants with an initial release rate of approximately 40  
µg/day have been studied in a clinical setting (Davies et al, 1993). Findings 
were in agreement with those obtained in the female beagle dog. An absolute 
bioavailability study of 3-keto-DSG in women treated with IMPLANON™ 
implant has recently been completed. Based on preliminary results of plasma 
clearances of 3-keto-DSG and of plasma concentrations it was calculated 
that the in-vivo release after 3 months amounted to 60 µg/day and after one 
year to 46 µg/day. Declining plasma concentrations of 3-keto-DSG from 290 
pg/ml to 230 pg/ml were measured after a treatment period of 3 months and 
one-year (NV Organon data on file). 
 
 6.3. Ex-vivo release 
 A number of implants that have been in-situ for various lengths of time were 
subjected to ex-vivo measurements. Of the removed implants the in-vitro 3-
keto-DSG daily release and the remnant content were determined. When the 
in-vitro release rate was plotted against its in-situ time and compared to the 
corresponding release data of the reference implant, it was shown that ex-
vivo implants had a higher or comparable in-vitro release than the 
corresponding reference implant. In general it was concluded that the 
average in-vivo released amounts were 80% of the in-vitro released amounts 
of the reference implants (NV Organon data on file). Analysis of the remnant 
48 
3-keto-DSG content of the implants with similar residence time in-vivo and 
in-vitro supported this conclusion. Implants which had been in-situ 
contained on the average 125% of the amount measured for implants that 
had been subjected to in-vitro release for the same period of time. This 
observation together with the human clearance data show that there is no 
accumulation of 3-keto-DSG in the human body (Unpublished data from 
Organon SDG). 
 
B.  PHARMACOLOGY OF 3-KETODESOGESTREL 
     1. Animal pharmacology 
 1.1 Oral administration of 3-keto-DSG (van der Vies and de Visser, 
1983; Bergink et al, 1989) 
  After oral administration 3-keto-DSG has: 
   a) Strong ovulation-inhibiting activity 
   b) Strong progestational and anti-oestrogenic activity 
   c) No oestrogenic activity 
   d) Very weak androgenic/anabolic activity 
 
  
 1.2 Receptor affinity profile (Bergink, 1981) 
  In agreement with the animal pharmacological data 3-keto-DSG 
showed a strong affinity towards the progesterone receptor and no 
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affinity towards the oestrogenic receptor in rabbits. It showed a weak 
affinity towards the androgen receptor in rats. 
 1.3 Non-hormonal properties 
  3-keto-DSG had no effect on platelet aggregation in-vitro and did not 
induce acute cardio-vascular effects in the cat. No note-worthy anti-
inflammatory activity has been noted after subcutaneous 
administration of 3-keto-DSG to rats. In the light of favourable 
toxicological studies (as mentioned later), other pharmacodynamic 
parameters have not been studied in animals. 
  
    2. Human pharmacology 
    Since Desogestrel (DSG) is quickly and almost quantitatively converted to 
3keto-DSG after oral administration, the pharmacological data on DSG 
can be extrapolated. 
  
 2.1 Oral administration of DSG/ 3-keto-DSG  
     The minimal ovulation inhibiting dose of DSG/ 3-keto-DSG 
has been determined on the basis of the serum levels of LH, 
FSH and Progesterone during a treatment cycle , in 
comparison with a control cycle. Peripheral effects have been 
assessed by the effects on the endometrium, vaginal cytology 
and cervical mucus.  
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 2.1a.   Central effects - Effect on pituitary-ovarian axis. 
  In two dose finding studies with orally administered DSG, the lowest 
daily dose producing consistent ovulation inhibition was found to be 
60 µg (Viinikka et al, 1977; Cullberg, 1982a). The effect of 3-keto-
DSG on pituitary-ovarian axis has been studied in 13 healthy 
volunteers. Nine women received for 21 consecutive days an oral 
dose of 50 µg 3-keto-DSG daily, while 4 women received a daily 
dose of 25 µg. The total daily dose producing consistent ovulation 
inhibition was found to be 50 µg, which is in close agreement with 
the results from studies with DSG (unpublished data from Organon 
SDG). 
 
 2.1 b.  Peripheral Effects 
 The peripheral activities of DSG and 3-keto-DSG were primarily 
assessed in oestrogen-primed ovariectomized women (uterus in situ) 
(Cullberg et al., 1982b).  This model offers the possibility of 
measuring hormonal influences on endometrium, cervix and vagina 
under standardized conditions, due to the absence of endogenous 
ovarian hormones.  During each cycle, the women receive 50 µg EE 




 In a multicentre study on the effects of DSG in 15 ovariectomized 
women, 5 doses of DSG (15-30-60-125-250µg) were investigated.  
The lowest dose which induced a clear progestational effect 
(transformation of a proliferating endometrium into a secretory 
endometrium) was 30µg.  When using cervical mucus and vaginal 
cytology as criteria for progestational activity, the lowest active dose 
of DSG was 60 µg (unpublished data from Organon SDG). 
  
 In another multicentre study on the effects of 3-keto-DSG in twenty 
one healthy oestrogen-primed ovariectomized women, the 
progestational effects of a 7-day treatment with daily oral doses of 
125, 60, 30 or 15 µg of 3-keto-DSG on endometrium, cervical mucus 
and vaginal cytology, were studied and compared to those of 1.0 
mg/day of lynestrenol.  3-Keto-DSG in a dosage of 125 and 60 
µg/day showed similar effects as 1.0 mg lynestrenol.  The 30 and 15 
µg daily doses had only weak or no progestational effects 
(unpublished data from Organon SDG).  In another study with 3-
keto-DSG in five healthy women receiving a daily dose of 50 µg 3-
keto-DSG, inhibition of endometrial development was seen; but 
there were no uniform influences on cervical mucus or vaginal 
cytology (unpublished data from Organon SDG). 
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 The peripheral activity of DSG was also studied in healthy fertile 
women with ovulating cycles (Cullberg et al., 1982a; Skouby, 1976; 
Viinikka et al., 1976; Viinikka et al., 1977) and in women with 
pelvic endometriosis (Cullberg 1984).  The tested doses ranged from 
15 µg to 500 µg. A dose of 15 µg already had a pronounced effect on 
cervical mucus.  Although the amount and "ferning" were not yet 
affected, there was a decrease in "spinnbarkeit" and sperm 
penetration.  Vaginal cytology and endometrial morphology seem to 
be less sensitive to progestagen influence.  Although the observed 
effects are dose-related, the relationship is a non-linear one.  
Atrophic endometria have been found in women on 30 µg DSG but 
proliferating and secretory stages were observed in women who had 
been given 60 and 125 µg DSG.  Absence of "ferning" and decrease 
of the Karyopicnotic Index were obtained with 60 µg dose. Vaginal 
cytology Maturation Value was dose-dependently depressed.  
Absolute values did not correlate with the DSG dose but there was a 
good correelation between Maturation Value and Estradiol levels 
(Cullberg, 1984). 
 
 2.2  Non-oral Administration of DSG/3-keto-DSG 
 An implant system continuously releases the active component. It is 
therefore essential to establish the effect of such administration on 
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pituitary-ovarian axis as well as on peripheral target organs.  Three 
types of release system have been investigated:  vaginal rings 
releasing 3-keto-DSG, silastic implants containing crystalline 3-keto-
DSG and EVA-polymer implants releasing 3-keto-DSG. 
  
 The pharmacodynamic effect of a 3-keto-DSG releasing vaginal ring 
was studied in 20 normally ovulating women.  Ten women were 
given for 21 days a ring releasing 30 µg 3-keto-DSG/day, another ten 
women a ring releasing 15 µg/day, both starting on day 5 of the 
menstrual cycle.  Of the treatment cycles, none showed an ovulatory 
pattern in the group using a ring releasing 30 µg 3-keto-DSG per 
day, whereas in the group using the lower dose one ovulatory pattern 
was seen. The mean plasma levels of 3-keto-DSG were 142 and 100 
pg/ml respectively.  A comparison of the cervical mucus showed a 
significant reduction during treatment when compared with a control 
cycle. However, no significant differences between the two treatment 
groups were demonstrated (Jackson R. et al., 1989). 
 
 Eight healthy women using one silastic implant of 30 mm length 
with 3-keto-DSG were studied for 36-664 days (Olsson et al., 1990). 
 The release rate of 3-keto-DSG was quite constant and around 30 
µg/day. The mean plasma level of 3-keto-DSG at the end of one 
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month was 290 pg/ml and 160 pg/ml after 12 months. No ovulations 
were seen. One woman had amenorrhoea, while others had different 
bleeding patterns often with periods of spotting - a pattern indicative 
of suppression of endometrial development. 
 In another study using silastic and EVA-polymer implants containing 
5 different doses of 3-keto-DSG, Diaz et al (1991) showed that 
implants releasing over 30 µg/day and providing mean plasma levels 
above 90 pg/ml inhibit ovulation consistently, as evidenced by 
depressed progesterone levels.  
  
 2.3  Receptor Affinity Profile 
 3-keto-DSG displays strong affinity for the human progesterone 
receptor, no binding towards the human oestrogen receptor and a 
weak binding towards the human androgen and glucocorticoid 
receptor (Bergink, 1981; Bergink, 1984; Breiner, 1986; 
Kloosterboer, 1988; Kontula, 1983). 
  
 3.  Human Tolerance of 3-keto-desogestrel 
 In addition to animal toxicology studies, investigations have been 
conducted to assess the human tolerance towards 3-keto-DSG alone 
as well as in combination with ethinyloestradiol. 3-Keto-DSG given 
alone in an oral dose of 60 to 250 µg, as well as in combination with 
50 µg ethinyloestradiol for the same period did not produce any 
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relevant effect on laboratory and clinical parameters (unpublished 
data from Organon SDG) 
 
  
Summary of human pharmacological data  
   
  1.  In human tissues or cell suspension 3-keto-DSG displays no affinity 
for the oestrogen receptor, slight affinity for the androgen- and 
glucocorticoid receptor and very strong affinity (200% compared to 
reference compound) for the progesterone receptor. 
  
 2.  The lowest oral 3-keto-DSG dose necessary for consistent inhibition 
of ovulation is 50 µg.  At this dose follicle maturation is not 
completely suppressed. 
  
 3.  In oestrogen-primed ovariectomised women a daily oral dose of 60 
µg 3-keto-DSG produced a pronounced progestational effect on 
endometrium, cervical mucus and vaginal cytology; 30 and 15 µg 
daily doses had only a weak or no progestational effect. 
  
 4.  After subdermal or vaginal administration, a 30 µg dose of 3-keto-
DSG inhibits ovulation. 
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 5.  A plasma concentration of  >90 pg/ml is needed to obtain ovulation 
inhibition. 
 
C.  BIOTRANSFORMATION AND PHARMACOKINETICS OF 
DESOGESTREL / 3-KETODESOGESTREL 
 
 1. Animal data 
 In this section the results from biotransformation and pharmacokinetic 
studies with desogestrel and/or 3-keto-desogestrel (3-keto-DSG), 
administered orally to various animal species, have been summarised 
(Kopera 1988). 
 1.a) Absorption 
 After oral administration of [3H]-desogestrel or unlabelled 3-keto-DSG to 
dogs and rats the radioactivity and 3-keto-DSG were rapidly absorbed with a 
mean peak plasma time at 1 h in both dogs and rats.  During steady state 
conditions in the dog the mean plasma level at mean Cmax of 22.1 ±15.9 
nmol/l of 3-keto-DSG was reached after oral administration of 3-keto-
DSG/EE 150/30 µg/day, whereas in the rat during steady-state conditions a 
peak concentration of 2.96 ± 1.66 nmol/l was reached after oral dosing of 3-
keto-DSG 100 µg/day. 
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 The mean area under the curve of one dosing interval in the steady state per 
µmol dose in the dog was 112 ± 17.9 nmol/l.h after chronic oral 
administration of 3-keto-DSG/EE 150/30 µg/day, whereas in the rat it was 
57.3 ± 12.0 nmol/l.h after chronic oral administration of 3-keto-DSG 100 
µg/day (unpublished data from Organon SDG). 
 
 1.b) Distribution 
 After oral administration of [3H] DSG to dogs a biexponential decay of 
radioactivity in blood was observed with half-lives of 3.4 and 66.4 h.  After 
i.v. administration of labelled DSG to female rats, the compound was rapidly 
distributed over the body with highest levels of radioactivity measured in the 
lungs, heart muscle, liver, adrenal glands and the tongue 3 minutes after 




 The in-vitro metabolic pattern of labelled DSG has been studied in liver 
homogenates from rats and rabbits.  The main metabolites identified after in 
vitro incubation with DSG are 3-keto-DSG, 3α-OH-DSG, 3β-OH-DSG and 
3α-OH-5α-H-DSG.  These results were confirmed in an in-vivo bio-
transformation study in dogs. 
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 In the rat after intravenous administration of labelled DSG the biliary 
excretion of radioactivity was high.  Analysis revealed the presence of high 
amounts of conjugated metabolites.  Only trace amounts of unchanged DSG 
and the pharmacologically active metabolite 3-keto-DSG have been found.  
When bile from rats dosed i.v. with labelled DSG was infused 
intraduodenally in acceptor rats, the bile of the acceptor rats contained about 
43% of the radioactivity administered, indicating an enterohepatic 
circulation (EHC) of the biliary metabolites of DSG.  However, since only 
trace amounts of DSG itself and its biologically active metabolite 3-keto-
DSG were detected in the bile, their contribution to the EHC is considered to 
be minimal. 
  
 Oral pre-treatment of rats with the liver enzyme inducer sodium 
phenobarbitone resulted in an increased in vitro biotransformation rate of 
both DSG and 3-keto-DSG.  These results imply that drug interaction (ie. 
reduced efficacy) may occur when DSG or 3-keto-DSG-containing 
preparations are used concurrently with barbiturates. 
 
 1.d) Elimination 
 The elimination half-life of 3-keto-DSG during steady-state conditions was 
2.3 ± 0.1 h in the dog and 4.8 h in the rat, both after treatment with 3-keto-
DSG.  Steady state is reached within approximately 1 day in the dog. In the 
dog, 88% of labelled compounds were found to be excreted six days after 
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oral administration of DSG: 28.7% via the urine and 59.3% via the faeces.  
In the rat 14.7% of radioactivity was excreted in the urine and 72.2% in the 
faeces by the 6th day whereas 0.001% of the administered dose was excreted 
in the expired air within the first 24 hours. 
 
 In lactating rats it was shown that only a small amount of DSG and/or 
metabolites (<0.03%) was excreted in the milk.  Data on placental transfer 
are not available. 
  
 As far as accumulation is concerned, it appeared from studies in both the rat 
and dog that DSG and metabolites are readily removed from the body after 
discontinuation of treatment. 
 
  
2. Human data 
 In this section the results from biotransformation and pharmacokinetic 
human studies with desogestrel and/or 3-keto-DSG have been reviewed. 
 
 2.a) Absorption 
 After oral administration, desogestrel (DSG) was found to be rapidly and 
almost completely absorbed (most probably from the duodenum), with an 
absorption half-life of 0.2 hours (range 0.1 - 0.4 h) (Viinikka et al., 1979).  
During phase I metabolism DSG was almost completely converted in the 
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body, mainly into the pharmacologically active metabolite 3-keto-DSG 
(Viinikka, 1978, 1979).  After oral administration of DSG/EE 150/30 µg/d 
the plasma peak time of 3-keto-DSG was 1.2-1.8 h whereas plasma peak 
height ranged from 11.3 - 19.6 pmol/ml during steady-sate conditions.  The 
mean area under the curve was 59-150 pmol/ml.h (Back et al., 1987; 
Hasenack et al., 1986; Kuhl et al., 1989; Bergink et al, in press).  After oral 
administration of 3-keto-DSG/EE 150/30 µg/d, plasma peak time, plasma 
peak height and AUC were not statistically significantly different from those 
after administration of DSG/EE (Hasenack et al., 1986).  This points to a 
high first pass metabolism of DSG. 
  
 The minimum steady-state level for 3-keto-DSG as estimated on day 2, 24h 
after administration of the last tablet of a daily treatment for 21 days with the 
combination 150 µg DSG/30 µg ethinyloestradiol, was 2.1-2.5 pmol/ml.  
There was, however, a large inter-individual variability of plasma levels, a 
well known phenomenon with progestagens (Hasenack et al., 1986).  The 
inter-individual variation in the pharmacokinetic parameters, characteristics 
for rate and extent of absorption of orally administered desogestrel was 
similar to the variation found with orally administered norethisterone and 
levonorgestrel (Bergink et al., in press). 
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 The absolute bioavailability of 3-keto-DSG was approximately 75% after 
single dose administration of DSG (Back et al., 1987) and approximately 
80% during steady-state conditions (unpublished data from Organon SDG). 
 
 2.b) Distribution 
 The distribution half-life of 3-keto-DSG in women was 0.6 h with a central 
volume of distribution of 0.3 1/kg and a total volume of distribution of 1.7 
l/kg. In experimental studies, plasma protein binding of 3-keto-DSG and its 
metabolites (mainly to albumin and sex hormone binding globulin) after a 
single dose is 98% (Hammond et al., 1984). 
 
 2.c) Metabolism 
 Studies in female volunteers with radioactive-labelled desogestrel showed 
that the compound is almost completely metabolized.  Phase I metabolism 
(biotransformation) was shown to be rapid and include hydroxylation of the 
C3-atom, whereby 3α- and 3β-hydroxy-DSG was formed; they are 
subsequently dehydrogenized into 3-keto-DSG.  There was no indication for 
the bio-transformation of the 11-methylene-group (Viinikka et al., 1979).  
Hydroxylation and dehydrogenation are normal metabolic processes in the 
liver.  The rapid bio-transformation indicates, that this process does not 
constitute a burden to the liver (Hasenack et al., 1986). 
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 The active metabolite 3-keto-DSG is further reduced to 3α-OH-5α-H-DSG 
via 3-keto-5α-H-DSG (Viinikka, 1979).  Subsequently these degradation 
products are partly converted into polar metabolites by conjugation into 
sulphates and glucuronides (Viinikka et al., 1980).  Enterohepatic circulation 
has not been studied in the human.  However, data obtained in the rat suggest 
that EHC is probably not of importance for the progestagenic activity of 
desogestrel, since only some inactive metabolites undergo this pathway.  
Findings on other progestagens in the human support this inference (Orme et 
al., 1983; Adlercreutx et al., 1984). 
 
 2.d) Elimination 
 3-keto-DSG was found to disappear from the plasma with a mean 
elimination half-life of 21-22 h (Viinikka et al., 1979).  The mean plasma 
clearance after i.v. administration of 3-keto-DSG/EE 150/30 µg/d was 8.7 ± 
2.9 1/h (Back et al., 1987). As a result of the SHBG induction by EE, steady-
state conditions (no further increase in plasma concentration) were reached 
between 3-13 days of daily administration (Viinikka et al., 1979). 
 
 The excretion of DSG and its metabolites was shown to be via the urine and 
faeces, the ratio being 1.5:1 (Viinikka et al., 1980).  With regard to excretion 
via the milk, no human data are available.  However, based on data on DSG 
obtained in animal studies and human data of comparable progestagens, 
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probably only small amounts of the compound may be excreted with the 
milk.  With regard to placental transfer, no human data are available.  Based 
on results of steady-state studies and on excretion data (Viinikka et al., 




 3. Bio-availability following non-oral use 
 After intravenous administration of 150 µg 3-keto-DSG, the mean area 
under the curve (AUC 0-24) appeared to be 19.07 ± 6.49 µg.h/l (single dose) 
(Back et al., 1987).  Assuming a 100% bioavailability for implants releasing 
60 µg/day the calculated  
                        60 
 AUCO-24 =  --------------      x    19.07 = 7.63 µg.h/l 
                    150 
 
 3-Keto-DSG is bound to SHBG, the bioavailability of 3-Keto-DSG is 
therefore dependent on the SHBG concentration, the latter being under the 
influence of oestrogens and androgens.  As it is unlikely that a daily dose of 
60 µg 3-keto-DSG will increase SHBG levels, the above value seems 
therefore a reasonable estimate for the absolute bioavailability of 3-Keto-




 After oral administration of 150 µg of DSG with 30 µg EE daily under 
steady state conditions, the mean AUC0-24 was 51.3 ± 22.4 µg.h/l (Jung-
Hoffman et al, 1991).  A steady state AUC0-24 of 45.53 ± 24.4 µg.h/l of 3-
keto-DSG has been reported after oral administration of desogestrel and 3-
keto-DSG (Hasenack et al, 1986). These are about 7-8 times higher than that 
calculated for the implant.  Consequently the "burden" to the human body 
for an implant releasing 60 µg/day is considerably lower than that for the 
oral contraceptive. Moreover the exposure of the liver after subdermal 
application is considerably lower than that after oral administration. 
 
D. DRUG SAFETY 
(1) Safety studies with the drug 
Studies with DSG and 3-keto DSG alone and with DSG in combination with 
EE have been performed in order to assess the safety of the new oral 
contraceptive products.  The scope of these studies has largely been 
determined by the requirements of health authorities. 
 
DSG alone was extensively investigated prior to initiation of the first clinical 
trials.  Later on, safety studies with combinations of DSG and EE were 
carried out.  General and reproductive toxicity studies have also been 
repeated with 3-Keto-DSG itself, since pharmacokinetic and receptor 
binding studies revealed that DSG is rapidly converted to 3-Keto-DSG.  This 
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latter metabolite in the human is to be held responsible for the biological 
action. 
 
Because exaggerated pharmacological effects, due to hormonal activity of 
hormonally active compounds are well known, drug safety studies were 
designed to detect unexpected effects, not due to the hormonal profiles of the 
compounds.  The safety studies in animals included general toxicological 
studies, reproductive toxicity studies, postnatal studies, mutagenicity and 
carcinogenicity studies. As this study deals with the administration of 3-
Keto-DSG without added estrogen, the conclusions from the studies with 
DSG and 3-Keto-DSG are summarized here: 
 
 a) Administration of DSG and 3-Keto-DSG as a single dose (up to 106 
times the human dose) to rats and mice is not lethal and does not 
induce toxic effects. All observed changes can be attributed to the 
pharmacological activity of the compound. In all the studies, 
calculation of dose is based on a mean body weight of 60kg and an 
administered DSG-dose between 125 and 150 µg.  This corresponds 
to 2 to 2.5 µg/kg. 
 
 b) Chronic administration of DSG or 3-Keto-DSG to rats or dogs (doses 
up to approximately 250 times the human dose) is not lethal and does 
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not induce toxic effects.  All observed changes can be attributed to 
the pharmacological activity of the compound. 
 
 c) Oral administration of DSG or 3-Keto-DSG (up to approximately 
1000 times the human dose) during gestation to rats or rabbits has no 
effect on pregnancy-rate, foetal development and embryonic 
mortality.  
 
 d) Oral administration of DSG (up to approximately 1000 times the 
human dose) or 3-Keto-DSG (up to approximately 2000 times the 
human dose) to rats prior to mating has no effect on mating 
performance, litter parameters and fertility of the F1-generation (first 
generation). 
 
 e) Oral administration of DSG (up to approximately 1000 times the 
human dose) show no mutagenic activity. 
 
 f) DSG after chronic administration to mice or rats (up to 





(2)  Safety studies with implants 
For the assessment of the safety of implants from ethylene vinyl-acetate 
(EVA) and 3-Keto-DSG the following should be taken into consideration: 
 a) AUCs (area under the curve) for an implant releasing 60 µg/day is 
considerably lower than for the oral contraceptive Marvelon (150 µg 
DSG/30 µg ethinyloestradiol per daily tablet).  Marvelon has been 
registered in 48 countries and is widely availabe since 1981.  DSG 
and 3-Keto-DSG alone and the combination of DSG and 
ethinyloestradiol were extensively studied in subchronic and chronic 
preclinical drug safety studies.  All effects observed in these drug 
safety studies, and especially those at the relatively high dose levels, 
could be explained on the basis of the hormonal activities of the test 
compounds.  Repeated dose toxicity studies with 3-Keto-DSG were 
therefore limited. 
  
 b) Ethylene vinylacetate (EVA) is a polymer widely used for medical 
purposes viz intrauterine contraceptive devices: ProgestasertR, 
OmbrelleR, for ocular drug delivery: OcusertR, a pilocarpine 




 c) There is no indication for an interaction (chemical or 
pharmacological) between the ethylene-vinylacetate polymer and the 
active substance, this can be substantiated from the following 
information. 
  - Implants stored for 18 months at room temperature and 
ambient temperature show the same 3-Keto-DSG content as 
initially . 
  - Implants have been analyzed after termination of in vivo 
studies in rats and dogs.  Implants which have been in situ for 
3 months were found to contain less than 1% of substances 
chemically related to 3-keto-DSG, which is identical to the 
content before implantation. 
  - In vitro and in vivo release characteristics are very similar 
(22) and it is 3-keto-DSG which is released from the implant. 
  
Therefore the following safety studies have been performed, following the 
guidelines of BSI/USP XXI for medical polymers: 
  
 Systemic tests 
 - A 13-week study in dogs with silastic covered EVA implants as well 
as all-silastic implants, both containing 3-Keto-DSG. 
 - A similar study in rats. 
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 - Systemic acute parenteral toxicity of extracts of EVA implants, their 
related materials and implants containing 3-Keto-DSG in mice, in 
order to assess the possible toxic effect of soluble, diffusable material 
from the implant. 
  
 Local tests 
 - Tissue implantation test in rabbits to assess possible local effects in 
vivo; 
 - A 2 week safety study in rats with EVA implants containing 3-Keto-
DSG. 
  
 Cytotoxicity tests 
 - Incubation of EVA implants with mouse fibroblasts (agar overlay 
test); 
 - Incubation with mouse fibroblasts (cell growth inhibition test). 
  
The conclusions drawn from these studies can be summarized as follows: 
 a) Silastic covered poly-EVA implants and poly-EVA implants both 
containing 3-Keto-DSG and administered subcutaneously to rats and 
dogs do not induce systemic toxic effects. 
 
70 
 b) Intramuscular or subcutaneous administration of poly-EVA implants 
containing 3-Keto-DSG to rabbits and rats respectively cause only 
the formation of a thin capsule around the implants. 
 
 c) In vitro tests with saline, ethanol and cotton-seed oil extracts of 
implants and mouse fibroblast cells reveal only an inhibition of cell 
growth with an undiluted saline extract (1.5 implant/ml). 
 
 d) Extracts from EVA implants with saline or 5% ethanol in saline 
administered intravenously and with polyethylene glycol 40 or 
cotton seed oil administered intraperitoneally, both routes in mice, 
did not induce toxic effects. 
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E .  CLINICAL DATA 
 
A total of 20 studies have been started in Europe, S E Asia, USA, Canada and Chile. 
 At present 18 studies have been completed and 2 are ongoing. The number of 
subjects enrolled in these studies amounts to nearly 2400 subjects on 
IMPLANON™ and about 800 subjects on NORPLANT®.  Table 4.1 presents a 
summary of the research programme and the status of the data at the end of 1996, 
obtained after 2 to 5 years of treatment. 
 
1) 3-Keto-DSG serum concentrations in clinical studies. 
 In all studies the time course of 3-keto-DSG plasma concentrations was 
similar, starting with a fast decline followed by a gradual decrease. Stable 3-
keto-DSG concentrations were maintained from between 1 and 1½ years 
onwards.  In general, at the end of the third year 3-Keto-DSG plasma 
concentrations were around 160 pg/ml. 
 
 Early studies (Diaz et al, 1991; Olsson et al, 1990) indicated that a 3-keto-
DSG serum concentration of >90 pg/ml is needed to inhibit ovulation.  In all 
subjects 3-keto-DSG serum concentrations well above 90 pg/ml were 
measured.  In the vast majority of the women treated there was no indication 
of ovulation. Therefore the ovulation inhibiting 3-keto-DSG concentration of 
90 pg/ml could neither be confirmed nor refuted. 
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2) Evidence of ovulation 
 Serum progesterone concentrations were measured twice a week over 
periods of 4-6 weeks in a number of studies. Although it is generally 
accepted that progesterone concentrations ≥ 30 nmol/l (9.4 ng/ml) are proof 
of ovulation, according to Landgren et al (1980), progesterone 
concentrations ≥5 ng/ml (>16 nmol/l) sustained for at least 5 days are 
compatible with ovulation. To follow a conservative approach, all 
measurements of ≥ 5ng/ml were considered to be significant.   
 
 Results of two open phase II studies provided data of over 1400 treatment 
cycles.  Progesterone concentrations ≥ 5 ng/ml were observed in two 
subjects on one occasion each.  In the first subject, this was almost certainly 
a carry-over effect from the pre-treatment control cycle.  The progesterone 
concentration was 10 ng/ml.  No rises in progesterone concentrations were 
observed during further treatment.  One further subject displayed a single 
high concentration of 5.3 ng/ml (16.8 nmol/l) during the first measurement at 
the 3.5 year sampling point, following 4 days later by a measurement of 0.4 
ng/ml.  The values preceding the peak are not known and ovulation therefore 




 In one comparative study of IMPLANON™ and NORPLANT®, pelvic 
ultrasound investigations for follicular development were performed twice a 
week. This study provides data on 3-year experience with IMPLANON™ 
and NORPLANT®.  During the third year 7 subjects on IMPLANON™ and 
3 on NORPLANT® provided information.  Based on progesterone 
concentrations, supported by ultrasound results, no evidence of ovulation by 
either method was observed in the IMPLANON™ study population for two 
years.  During the third year of use, one subject ovulated from study day 928 
onwards.  Furthermore, another subject most probably ovulated around 
treatment day 957. 
 
 One subject on Norplant® ovulated at the 18 month time-point.  She 
discontinued immediately after this point in time. In a further two subjects on 
NORPLANT®, ovulations had, or may have occurred (NV Organon data on 
file).   
 
3) Pregnancy Rate 
 At present, approximately 60,000 cycles on IMPLANON™ have been 
completed: approximately 40,000 cycles during the first two years of use, 
14,000 cycles during the third year of use, and 4500 cycles during year 4 and 
5.  Thus far, no in-treatment pregnancy has been reported, which 
demonstrates the contraceptive effectiveness of IMPLANON™.  In view of 
the 14,000 treatment cycles obtained from the third year of use and the 
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additional 4500 treatment cycles obtained beyond that period, it appears that 
the implant provides reliable contraception for a period of 3 years. 
 
4) Safety 
 Progestagen-only contraceptive medication is generally associated with a 
number of side-effects such as disruption of the normal menstrual cycle, 
including amenorrhoea, weight gain, acne, breast tenderness and headache 
(McCann and Potter, 1994). The incidences of adverse experiences, reported 
in the European multicentre study is shown in Table 4.2. While mood related 
symptoms in the USA study were important reasons for early 
discontinuation, in the European multicentre study this was rarely the case.  
The incidence of mood related symptoms reported in that study, totals 3.6% 
during the first year of use. 
 
 When cumulative incidences were taken into account of the most frequently 
reported adverse experiences, only the symptom "Breast pain female (WHO 
Dictionary term)" did not decrease in frequency after one year.  Subjects 
who experienced acne or weight gain in general showed improvement of 
symptoms over time. 
 
5) Summary and Conclusion 
 At the end of the third year 3-keto-DSG release rates are approximately 25 
µg/day resulting in 3-keto-DSG serum concentrations of about 160 pg/ml.  
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As judged by progesterone concentrations and follicular development, 
ovulation during the use of of IMPLANON™ is rare and restricted to 
occurring after the second year of treatment.  No in-treatment pregnancies 
have been observed during IMPLANON™ use world-wide.  This 
observation includes over 18,000 cycles of exposure during 3-5 years of use. 
 The safety data reveal that the majority of the most frequently occurring 
adverse experiences are observed during the first year of use. 
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Table 4.1.   Summary of Clinical Research Experience (as on 31 .12. 96) 
 IMPLANON™ NORPLANT® 
Subjects treated   
≤ 1 year 1973 679 
1-2 years 1521 470 
2-3 years 715 118 
≥ 3 years 210 3 
   
Total no. of cycles 43119  (57081) * 11077  (15370) * 
Total woman years 3305     (4356) * 849      (1178) * 
  
*  Including three chinese studies (N= 316 IMPLANON™, N=100 NORPLANT®), 
excluding ‘leached’ Implant study (N=15), excluding ongoing studies (N=80 
IMPLANON™, N=25 NORPLANT®). 
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Table 4.2.   Adverse Experiences Developing in First Year of Use ( percent) 
 
 Study 1* Study 2* IMPLANON 
 Study** 
 Norplant® IUD Norplant® IUD  
Headache 16.7 7.0 18.5 10.2 10.9 
Ovarian enlargement 11.6 2.0 3.1 2.6 not reported 
Dizziness 8.1 4.0 5.6 5.9 1.6 
Breast tenderness 6.8 1.7 6.2 4.7 8.1 
Nervousness 6.8 2.0 6.2 2.4 2.2 
Nausea 5.1 1.7 7.7 4.0 2.4 
Acne 4.5 1.0 7.2 2.6 9.6 
Dermatitis 3.8 0.7 8.2 1.9 0.4 
Breast discharge 3.5 2.7 5.1 1.9 1.0 
Change in appetite 3.5 0.7 6.2 1.9 1.3 
Weight gain 3.3 1.0 6.2 0.9 6.6 
Hair growth or loss 1.8 0.5 2.6 0.5 4.1 
 
 * Source : Population Reports; November 1992. 





CHAPTER V -  THE STUDY SETTING, PROCEDURES AND MAIN 
OBJECTIVES 
 
(a) Centre selection 
 
(b) Procedures of insertion and removal of  Implanon™  implants 
 




IMPLANON™ is a new single-rod subdermal non-biodegradable 
contraceptive implant. The insertion and removal techniques are described in this 




CHAPTER V -  THE STUDY SETTING, PROCEDURES AND MAIN 
OBJECTIVES 
 
In 1990, a small number of pre-introductory phase III clinical trials of the 
IMPLANON subdermal implant contraceptive delivery system was started in 
selected countries, including Singapore. The trials were coordinated by NV 
Organon, the pharmaceutical company responsible for the development and 
manufacture of the implant. The primary aim of these trials was to ascertain the 
efficacy and acceptability of the IMPLANON contraceptive implant in different 
population groups.  
 
(a)  Centre selection 
The Department of Obstetrics and Gynaecology, National University of 
Singapore, was selected as the trial centre in Singapore, because of its 
established track record for carrying out pre-introductory clinical trials of 
various contraceptive devices, including NORPLANT system, in Singapore. 
In addition, the departmental research laboratory is the recognized regional 
reference laboratory of the World Health organization. The department is a 
WHO collaborative centre for research and has the personnel and facilities to 
conduct both clinical and basic research. It also houses a well staffed 




 (i) To provide services to the public in the field of human reproduction 
and fertility control including a full range of contraceptive methods 
 
 (ii) To function as a centre for advanced training and education in human 
reproductive technology and fertility control for medical and health 
personnel. 
 
 (iii) To conduct research in the field of human reproduction and fertility 
control.  
 
The department is also a WHO collaborative centre for research and has 
previously collaborated with Population Council and Family Health 
International (FHI) in various clinical trials with contraceptives. It has the 
personnel and the facilities, including excellent laboratory services, 
necessary to conduct clinical research. In the past, the department was 
responsible for carrying out pioneering pre-introductory clinical trials with 
Norplant. These data were presented to the Federal Drug Authority (FDA) of 
the USA prior to the registration of Norplant by the regulatory authority. 
Because of this background the Fertility Control Clinic of the department 
was selected as one of the study sites for evaluating IMPLANONTM 




(b)  Procedures of insertion and removal of IMPLANON implants 
Every woman recruited to the study was provided with a verbal explanation 
of the study together with written "subject information". Following this, the 
subject and the investigators signed a consent form indicating that the 
subject has been fully informed of the nature of the study. The subject 
received a copy of the subject information and of the signed consent form. In 
keeping with the principles of "Good Clinical Practice" (GCP), the subjects 
were told that they were at liberty to terminate their taking part in the study 
at their own request without compromise to possible future treatment. 
  
1. Insertion In all cases, the implants were inserted between the first and the fifth 
day of the subject's menstrual flow. The site of insertion was on the 
inside of the upper non-dominant arm, 6-8 cm above the elbow. The 
area of insertion was thoroughly cleansed with spirit and povidone-
iodine. About 2 ml of local anaesthetic (lignocaine 1%) was injected 
just below the skin along the insertion "canal".  No incisions were 
made prior to the insertion of the implants. The inserter needle was 
inserted directly into the subcutaneous anaesthetised "canal". The 
plunger seal was broken, rotated through 900 and the plunger was 
pressed slowly, while the inserter was being pulled out of the arm. 
The entry point was closed with a 2 cm piece of "steristrip". A 
pressure bandage with sterile gauze was applied to minimize 
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bruising. The woman was instructed to keep the bandage clean and 
dry for three days. 
 
2. Removal The implant was first located by palpation. The arm was cleansed 
with spirit and povidone iodine solutions. About 1 ml of lignocaine 
1% was injected under the implant. A 2 mm incision was then made 
near the proximal end of the implant. The implant was then gently 
pushed towards the incision until the tip was visible. The tip of the 
implant was grasped with a mosquito forceps and removed. In cases 
where the implant tip could not be pushed into the incision, a closed 
mosquito forceps was inserted into the incision. The tissues around 
the implant tip was gently dissected, while the implant was pushed 
towards the incision with the other hand. Closure of the incision and 
bandage was applied in the same way as for insertion. The woman 
was instructed to keep the bandage clean and dry for three days. 
 
 For Norplant implants, the procedure of insertion and removal 
followed standard techniques described elsewhere (The Population Council, 
1990).
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Insertion Of Implanon™ Implants 
 
































Figure 5.7 The plunger is pressed slowly, while the inserter is being pulled 









Removal of IMPLANON™ Implants 
 









Figure 5.11 A small area near the lower end of the implant is being  











Figure 5.13 The implant gently pushed towards the incision and the tip is 









(c)  The Objectives of the Thesis 
 The principal hypothesis to be tested was - "For Singaporean women the 
single-rod IMPLANON™ implant is an acceptable, safe and effective 
method of long-acting contraception for two-years and these parameters are 
at least comparable to the use of the six-rod NORPLANT contraceptive 
delivery system". 
 The specific objectives were : 
 1. To evaluate the acceptability, effectiveness, safety, side-effects and 
continuation rate with the use of IMPLANON™ implants and to 
compare the same with the users of NORPLANT® implant in 
Singaporean women at the end of two years of use. 
 
 2. To investigate the possible difference in effect of IMPLANON™ 
and NORPLANT® implants on carbohydrate metabolism, thyroid 
and adrenal function. 
 
 3. To investigate the possible difference in effect of IMPLANON™ 
and NORPLANT® implants on clinical chemistry at the end of two-
years of use, in terms of : 
   (i)    Liver function 
    (ii)    Lipid metabolism 
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CHAPTER VI :  A TWO YEAR COMPARATIVE  CLINICAL 
EVALUATION OF IMPLANONTM AND NORPLANT IMPLANTS IN 
SINGAPOREAN WOMEN : AN OPEN RANDOMISED STUDY 
 
(a) The Objective  
 










 The data presented in this two-year open randomized comparative clinical 
study in 80 volunteers suggest that the IMPLANONTM single-rod implant system is 
a highly effective, safe and acceptable form of contraceptive method among 
Singaporean women and is comparable to that of the NORPLANTimplant system. 
Discontinuation rates were significantly lower amongst the IMPLANON™ users 
compared to the NORPLANT® users. Because of its ease of insertion and removal 
the IMPLANON™ system has a greater potential for acceptability in the future 
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CHAPTER VI :  A TWO YEAR COMPARATIVE  CLINICAL 
EVALUATION OF IMPLANONTM AND NORPLANT IMPLANTS IN 
SINGAPOREAN WOMEN : AN OPEN RANDOMISED STUDY 
 
(a) The Objective of the Study 
 The objective of this open randomised clinical study was to evaluate the 
contraceptive efficacy, acceptability and safety of IMPLANONTM implants 
among Singaporean women and compare the same with the users of 
NORPLANT  implants. 
 
(b) Experimental design and selection of cases 
 This was a single-centre open randomised study in healthy Singaporean 
female volunteers requiring a long-term method of contraception, in which 
the contraceptive efficacy, acceptability and safety of IMPLANONTM and 
NORPLANT implants were studied by means of regular medical 
examination and assessment of events including vaginal bleeding patterns 
and subjective complaints.  
 
 Eighty volunteers were recruited for the study. The volunteers were 
randomised to receive either IMPLANONTM or NORPLANT implants, 
with 40 subjects in each arm. The volunteers were recruited over a period of 
nine months, starting in October 1992. The study period was 24 months with 
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the implant in situ and a subsequent follow-up period of three months after 
implant removal.  Subjects with NORPLANT inserted were allowed to 
continue treatment beyond the study period due to its claimed contraceptive 
lifetime of at least five years.  The inclusion and exclusion criteria used to 
recruit the volunteers were as follows : 
 
Inclusion criteria : 
• Age between 18-40 years, sexually active and of childbearing potential. 
• Good physical and mental health. 
• Normal cycles with a mean length of between 24-35 days and an intra-individual 
variation of plus or minus 3 days. 
  
Exclusion criteria : 
• Pregnancy or lactation 
• Within two months of a delivery or an abortion 
• Use of an injectable hormonal method of contraception within a period of 6 
months. 
• Use of an Intra-uterine device. 
• Removal of an implant within a period of 2 months. 
• Use of an oral contraceptive preparation within a period of 2 months. 
• Past or present significant gynaecological disorders. 
• History of ectopic pregnancy. 
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• History of pelvic inflammatory disease. 
• History of Herpes gestationis.  
• History of endocrine disorders. 
• History of abnormal breast discharge. 
• Past or present disturbance of liver function ie. cholestatic jaundice, jaundice   of 
pregnancy or jaundice due to previous oral contraceptive use, Rotor syndrome or 
Dubin-Johnson syndrome, Hepatitis. 
• History of hyperlipoproteinaemia. 
• Hypertension ie. systolic BP > 140 and/or diastolic BP > 90 mm Hg.       
• Anaemia ( Hb < 10 g/dl). 
• Use of one or more of the following drugs : sex steroids, hydantoins,barbiturates, 
primidone, carbamazepine, rifampicin and griseofulvin. 
• History of alcohol or drug abuse within 12 months. 
• Administration of investigational drugs within 3 months prior to the study. 
• Cervical Pap smear class III, IV or V diagnosed in the screening phase. 
 
(c) Methodology 
 Women who met all the selection criteria were fully informed about the 
purpose of the study, the open randomised nature of the study and the known 
risks and benefits associated with the use of the two contraceptive implants. 
A signed informed consent was obtained from each woman who volunteered 
to participate in the study. For each acceptor, a thorough physical 
95 
examination, including a gynaecological examination, was performed before 
insertion of the implant. They were then randomized to receive either 
IMPLANONTM or NORPLANT implants. 
 
 Following the insertion of the implant, the woman was requested to report to 
the clinic at 1, 3, 6, 9, 12, 15, 18, 21 and 24 months. At each of the above 
mentioned time-points the woman was asked about her physical well-being 
during the period covered since the previous visit and the implant site was 
inspected. An urine pregnancy test was also done. A general physical 
examination, including blood pressure and weight measurement, was done 
after 3, 6, 12, 18 and 24 months. A complete physical examination and 
gynaecological examination was performed after 12 and 24 months.  
Haemoglobin estimation was done at baseline (pre-insertion) and at removal. 
 
Subjects were asked to return to the clinic at three months after removal of 
the implant, whether this was the end of the study period or earlier. If a 
subject could not return to the clinic for her post-treatment evaluation, 
information was obtained by phone or mail on return of the menstrual cycle, 
possible return of fertility and use of contraceptives.  
 
Each subject was provided with a menstrual diary in which she recorded the 
bleeding pattern she experienced each day. She was instructed to record a ‘o’ 
if she experienced no bleeding or spotting on a given day, an ‘/’ if she 
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experienced spotting (any bloody vaginal discharge for which no protection 
is used or only one pad /tampon on a given day), and a ‘+’ if she experienced 
bleeding (any bloody vaginal discharge for which protection of two or more 
pads/tampons is used on a given day). Bleeding records from the diaries 
were collected every three months to assess vaginal bleeding patterns during 
the study. 
 
An adverse experience (AE) was defined as any new complaint or symptom 
emerging during the study period and any complaint or symptom that existed 
at screening visit and increased in severity or frequency during the study 
period. At each visit during the study, either scheduled or unscheduled, the 
subject was questioned and/or examined on the occurrence of AEs. A serious 
adverse experience (SAE) was defined as any experience that was fatal, life-
threatening, permanently disabling, required in-patient hospitalisation or 
prolongation of hospitalisation. Adverse experiences with any of the 
following outcomes were always considered serious : death, cancer, 
congenital anomaly, and overdose. 
 
Analysis of vaginal bleeding data 
The analysis of the bleeding pattern, as recorded by the subjects on the diary 
cards, was performed by reference period analysis as described in the WHO 
Special Programme of Research Training in Human Reproduction by Belsey 
et al.(1986), Belsey and Farley (1988) and by Rodriguez et al. (1976). 
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The reference period analysis defines a subject as the unit of analysis. All 
subjects’ diaries were divided into consecutive periods (‘reference periods’), 
starting with the day of implant insertion as first day of the first reference 
period (Day 1). One additional reference period (denoted as Period  #) was 
defined , which starts 28 days after implant insertion. Within each reference 
period, medically relevant bleeding-spotting (B-S) variables are summarised. 
 This analysis was based on the following subject response categories per 
day : bleeding, spotting, bleeding-free and missing response. 
 
The reference period analysis included all subjects treated (with some data 
excluded) who had at least one evaluable reference period, based on the 
following guidelines : 
• Analysis Period  
All bleeding data starting at the day of implant insertion and ending at the 
day of implant removal (or 24 -months implant removal assessment if 
implant was left in situ, or end of diary data if subject was lost to follow-up) 
were used for analysis. Bleeding data outside this analysis period were not 





• Length of Reference Period 
The length of the reference period was defined as 90 days. Shorter reference 
periods were not included in the analysis. A 90-day reference period was 
used for this study, because this duration was determined to be sufficient to 
allow several bleeding events to occur in a reference period. To be included 
in the analysis, a subject had to contribute at least one complete reference 
period of 90-day length. 
 
•  Interpolation Rule for Missing Values 
 If diary data with bleeding information were missing for <= 2 consecutive 
days, these missing values were converted to the same B-S response reported 
on the day immediately preceding the missing values (i.e., bleeding, spotting 
or bleeding-free was imputed). If this missing information occurred on the 
first one or two days of treatment, then the immediately following days were 
used for interpolation. 
 
• Exclusion of Reference Periods 
 If diary data with bleeding information was missing for >=3 consecutive 
days, the complete reference of this subject was excluded from analysis. If 
these missing values were spread across two reference periods, then both 
reference periods were excluded.  
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• Definition and Handling of Bleeding Events 
The analysis of vaginal bleeding patterns was based on the following 
standard WHO definitions used for summarisation of diary data (Belsey et 
al., 1986, with a modification used for infrequent bleeding ): 
1. a ‘bleeding-spotting episode’ was defined as any set of one or more 
consecutive bleeding or spotting days bounded at each end by at least 
one bleeding-free day; 
2. a ‘bleeding free interval’ was defined as any set of one or more 
consecutive bleeding-free and spotting-free days bounded at each end by 
at least one bleeding or spotting day; 
3. ‘amenorrhoea’ was defined as no bleeding or spotting throughout the 
reference period; 
4. ‘infrequent bleeding’ was defined as less than three (0,1 or 2) B-S 
episode starting within a reference period excluding amenorrhoea; 
5. ‘frequent bleeding’ was defined as more than five B-S episodes starting 
within a reference period ; and 
6. ‘prolonged bleeding’ was defined by at least one B-S episode starting 
within a reference period and lasting more than 14 days. 
 
The first two definitions (episodes and intervals) describe events which are 
summarised (with respect to number and length) within each single reference 




The following general conventions were used to handle these bleeding 
events in the analysis: 
Events Assignment  
All bleeding events (i.e., B-S episodes, bleeding-free intervals and prolonged 
bleeding) were assigned to the reference period in which they started, and 




The lengths of episodes and intervals were not truncated in any way if they 
overlapped two or more reference periods. Therefore, individual and mean 
event lengths of > 90 days were possible. This convention was used 
regardless of whether or not subsequent reference periods were excluded 
from analysis. 
Single-day Bleeding-free Intervals 
These intervals were analysed as they were recorded, that is, without treating 
them as part of the B-S episode surrounding them. 
 
The following conventions were used in addition to handle incomplete 
events (episodes and intervals).  These rules were applied in the order given 
below, with higher rules overriding following ones (thus, if an event was 
excluded from a statistic during one of these steps, it remained excluded). 
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• First Counted Event      
The first counted event (episode or interval) which was in progress or 
starting at implant insertion was excluded from all statistics (number of 
events and length of events), but only if it was a B-S episode (thus if it was a 
bleeding-free interval, it was included with its cut-off length starting from 
Day 1); however, the number of days of this event was always counted (from 
Day 1). 
 
• Last Counted Event 
 The last counted event (episode or interval) which was in progress at 
implant removal was included in the analysis with its cut-off (at implant 
removal) length if this event continued after the day of implant removal. 
The number of days of this event was always counted (ending at day of 
removal). 
• Events Bounded by Missing Values 
Events which were right-truncated or left-truncated by >= 3 consecutive 
missing values were included in the analysis with full known length. Missing 
value refers to absence of any record for a day in the menstrual diary. These 
events were always counted in the reference period in which they started (an 
exception was only the ‘first counted event’ considered above). For example, 
right-truncated events continuing into an excluded reference period were 
counted in the reference period in which they started with actual length. 
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Left-truncated events usually started in a reference period which was 
excluded from analysis. Therefore, only left-truncated events that started 




The following within-woman statistics were calculated for each subject for 
each reference period and are listed individually : 
• number of bleeding days, spotting days, B-S days ; 
• number and mean length of B-S episodes ; 
• mean length and range of lengths of bleeding-free intervals ; and 
• incidence of amenorrhoea , infrequent bleeding , frequent bleeding and 
prolonged bleeding. 
 
If the number of events starting within a reference period was 0, all length 
variables were defined as missing; also, if only one event occurred, the range 
(maximum minus minimum) of event lengths was set to missing. Based on 
these figures, summary statistics are presented per treatment group and 
reference period. The tables include mean, standard deviation (SD), 
minimum , maximum, median lower and upper quartiles and 5th. and 95th. 
percentiles. Similarly, the number and percentage of subjects with 
amenorrhoea, infrequent bleeding, frequent bleeding and prolonged bleeding 




 Cumulative discontinuation rates were calculated using the Kaplan-Meier 
method. The log-rank test was used to test times to discontinuation for 
treatment differences. Treatment differences in changes from baseline of 
blood pressure and body mass index were assessed by the two-sample 
Wilcoxon test. Vaginal bleeding pattern was evaluated by reference period 
analysis, as described previously. 
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(d) Results 
DEMOGRAPHICS AND OTHER SUBJECT CHARACTERISTICS 
Summaries of demographics, obstetric and contraceptive history and acne 
for all- subjects-treated are presented in Tables 6.1 and 6.2. Both treatment 
groups were comparable for demographic data at study entry. Overall age 
ranged from 19 to 39 with a mean of 29.2 years (SD 4.2). Body mass index 
ranged from 15 to 34 with a mean of 23.2 kg/m2 (SD 3.7).  
 
All subjects had at least one or more previous pregnancies. For both the 
IMPLANONTM and the NORPLANT group 40% of the subjects reported 
use of condom/diaphragm/spermicide as their last contraceptive method 
before study entry. The category of other contraceptive method was recorded 
by 30% of subjects in the IMPLANONTM group and 37.5% of subjects in the 
NORPLANT group, which for all cases was the withdrawal method. For 
each of the treatment groups two subjects recorded two of the given 
categories as their last method of contraception. 
 
A history of acne was reported by nine subjects (22.5%) in the 
IMPLANONTM group, and was categorised as either ‘occasional’ (n=7, 
17.5%) or ‘continuous mild’ (n=2, 5.0%). In the NORPLANT group seven 
subjects reported a history of acne, being either ‘occasional’ (n=4, 10.0%) or 
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‘continuous mild’ (n=3, 7.5%). No subjects had acne classified as 
‘continuous severe’. 
 
All subjects had regular menstrual cycles at screening. Baseline menstrual 
characteristics are presented in Table 6.3. The overall mean menstrual cycle 
length was 29.3 days (SD 1.5), with 1.8 days (SD 1.1) as mean variation of 
cycle length. Mean duration of menstrual bleeding was 5.6 days (SD 1.4). 
Both treatment groups were comparable regarding these menstrual bleeding 
characteristics.  
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Age (years)     
 Mean 29.1 29.2 29.2 
 SD  4.6  3.9  4.2 
 18-20   n  (%)  2        ( 5.0)   2        ( 2.5)     
 21-25  5        (12.5)  7       (17.5) 12        (15.0) 
 26-30 20       (50.0) 19      (47.5) 39        (48.8) 
 31-35  9        (22.5) 12      (30.0) 21        (26.3) 
 36-40  4        (10.0) 2         ( 5.0)  6         ( 7.5) 
     
Weight (kg)     
 Mean 58.1 56.5 57.3 
 SD 11.1  8.3  9.8 
     
Height (cm)     
 Mean 157.7 156.4 157.1 
 SD     5.1     4.9     5.0 
     
Body Mass Index 
(kg/m2) 
    
 Mean 23.3 23.1 23.2 
 SD   3.9  3.5  3.7 
 <20   8       (20.0)  6       (15.0) 14       (17.5)       
  
 >20-22   8       (20.0) 12      (30.0) 20       (25.0) 
 >22-24   7       (17.5) 10      (25.0) 17       (21.3) 
 >24-26   8       (20.0)  5      (12.5) 13       (16.3) 
 >26   9       (22.5)  7      (17.5) 16       (20.0) 
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  n %  n %  n % 
Number of previous 
pregnancies 
      
     0  0   0   0  
     1  0   1  (2.5)  1  (1.3) 
     2  18 (45.0) 15 (37.5) 33 (41.3) 
     3 10 (25.0) 12 (30.0) 22 (27.5) 
     >3 12 (30.0) 12 (30.0) 24 (30.0) 
       
Parity       
     0  0   0   0  
     1  4 (10.0)  3  (7.5)  7  (8.8) 
     2  20 (50.0) 24 (60.0) 44 (55.0) 
     3 15 (37.5) 11 (27.5) 26 (32.5) 
     >3  1  (5.0)  2  (5.0)  3  (3.8) 
       
Last contraceptive 
method 
      
     None  5 (12.5)  4 (10.0)  9 (11.3) 
     Oral  2  (5.0)  2  (5.0)  4  (5.0) 
     Implants  0   0   0  
     Injectables  0   0   0  
     IUD  3  (7.5)  1  (2.5)  4  (5.0) 
     Other contraceptives 12 (30.0) 15 (37.5) 27 (33.8) 
     Barrier/spermicide 16 (40.0) 16 (40.0) 32 (40.0) 
     Other contraceptives 
            and barrier  
 2  (5.0)  2  (5.0)  4  (5.0) 
       
Age at menarche       
     Mean 13.2  12.7  13.0  
     SD  1.5   1.5   1.5  
       
Acne       
     None 31 (77.5) 33 (82.5) 64 (80.0) 
     Occasional  7 (17.5)  4 (10.0) 11 (13.8) 
     Continuous mild  2  (5.0)  3  (7.5)  5  (6.3) 
     Continuous severe  0   0   0  
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Table 6.3   Menstrual Bleeding Characteristics at Screening 
 
Characteristic Implanon 
   (N=40) 
Norplant 
  (N=40) 
Overall 
(N=80) 
Cycle Length (days)     
 Mean 29.5 29.2 29.3 
 SD  1.7  1.4  1.5 
 Median 30.0 29.0 30.0 
 Min-Max 25 - 33 26 - 32 25 - 33 
     
Variation of cycle 
lengths (days) 
    
 Mean 1.8 1.9 1.8 
 SD 0.9 1.3 1.1 
 Median 2.0 2.0 2.0 
 Min-Max 0 - 4 0 - 5 0 - 5 
     
Duration of flow     
 Mean 5.5 5.7 5.6 
 SD 1.4 1.5 1.4 
 Median 5.0 6.0 6.0 
 Min-Max 3 - 8 3 - 9 3 - 9 
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DISCONTINUATION RATES 
Table 6.4 presents a summary of primary reasons for discontinuation. In 
the IMPLANONTM group three subjects (7.5%) and in the NORPLANT  
group nine subjects (22.5%) discontinued during the study. Cumulative 
continuation rates for both treatment groups are presented graphically in 
Figure 6.1. Statistically significant group differences were found for time 
periods to discontinuation (log-rank test, p=0.03). No subject in either of 
the treatment groups discontinued due to amenorrhoea. No subject in the 
IMPLANONTM group discontinued due to bleeding irregularities as 
primary reason compared to four in the NORPLANT group. 
Discontinuation due to AEs accounted for the discontinuation of one of the 
subjects from the IMPLANONTM group compared with two subjects from 
the NORPLANT group. One subject was lost to follow-up from the 
IMPLANONTM treatment group. 
110 
Figure 6.1 
Kaplan-Meier Continuation Rates for All Subjects 
 
No. of days implant in place 
















Table 6.4    Primary Reason for Discontinuation (All- Subjects-Treated 
Group) 
 
Primary Reason for Discontinuation Implanon Norplant 
    n    %    n    % 
     
  Amenorrhoea    0     0  
  Bleeding irregularities    0     4   10.0 
  Adverse Experiences    1   2.5    2     5.0 
  Other Reasons    1   2.5    3     7.5 
  Lost to Follow-up    1   2.5    0  
       
 Total    3   7.5    9    22.5 
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VITAL  SIGNS  
 
Clinically significant values 
Frequencies of clinically significant vital signs are summarised in Table 6.5, 
together with the criteria used. One subject (Subject 0050) in the IMPLANONTM 
group had a clinically significantly elevated diastolic BP value at the implant 
removal (Month 24) assessment. No clinically significant BP values were observed 
for any of the subjects in the NORPLANT® group.  
 
Three subjects on IMPLANONTM and four subjects on NORPLANT had a 
significant increase in BMI. 
 
Summary statistics 
For summary statistics on vital signs only assessments within the visit windows 
were used. Summaries of the original values and changes from baseline are 
presented in Tables 6.6 and 6.7. 
 
The NORPLANT group showed greater changes from the baseline in BP 
compared to the IMPLANONTM group at all visits. Statistical significant treatment 
group differences were found for systolic BP at Month 3 (p=0.038), and Month 18 
(p=0.030). Other assessments failed to exhibit statistical significant treatment 
group differences (Month 6, 12, 24 and last measurement). For diastolic BP, there 
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was no statistical evidence to  suggest a treatment group difference at any of the 
assessments. 
 
A slight mean increase from the baseline in BMI was observed for both groups 
after Month 6.  For BMI, there were no statistically significant results from the 
Wilcoxon test for treatment comparison, at any of the assessments. 
 
 
Table 6.5  Frequencies of Clinically Significant  Values of Vital Signs 
  Parameters 
Parameter IMPLANON™ NORPLANT® 
 Na Significant Na Significant 
  n %  n % 
Systolic BP (mm Hg) >140 and increase 
from baseline >20 at last assessment or at 
least two assessments 
40 0 0 40 0 0 
       
Diastolic BP (mm Hg) >90 and increase 
from baseline >10 at last assessment or at 
least two assessments 
40 1 2.5 40 0 0 
       
Body mass index (kg/m2) increase from 
baseline >10% at least once during 
treatment 
40 3 7.5 40 4 10.0 
 
a  Number of subjects with at least baseline value and one value during treatment 
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Table 6.6     Summary Statistics on Blood Pressure Changes 
 
            IMPLANON™            NORPLANT®  
  Change from 
baseline 
 Change from 
baseline 
P-value 
Assessment N Mean Mean SD N Mean Mean SD  
          
Systolic BP (mm Hg)          
    Baseline  40 111.4   40 105.6    
    Month 3 40 111.2  0.9  9.9 40 111.5 5.9 12.0 0.038 
    Month 6 38 113.3  2.1  10.9 38 110.4 5.0 11.5 0.33 
    Month 12 37 110.2 -1.3 11.0 36 111.1 5.5 13.0 0.057 
    Month 18 38 109.8 -1.1 12.3 33 111.4 5.5 12.8 0.030 
    Month 24 37 114.7  4.0 11.0 31 113.7 7.1  9.6 0.31 
    Last measurement 40 114.8  3.5 11.3 40 113.4 7.8 10.1 0.14 
          
Diastolic BP (mm Hg)          
    Baseline  40  73.7   40  72.3    
    Month 3 40  75.9  2.3  8.6 40  75.6 3.3  9.0 0.66 
    Month 6 38  74.1  0.7  9.1 38  74.5 2.7 10.4 0.14 
    Month 12 37  75.3  2.0  10.2 36  74.1 2.2  9.4 0.88 
    Month 18 38  73.6  0.3  9.0 33  75.3 2.8  9.9 0.25 
    Month 24 37  76.0  2.8  9.1 31  76.4 3.1 10.1 0.67 
    Last measurement 40  75.9  2.3  9.1 40  75.6 3.4  9.7 0.43 
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Table 6.7    Summary Statistics of Body Mass Index (kg/m2) 
                               IMPLANON™                                  NORPLANT®  
  Change from 
baseline 
% Change from 
baseline 
 Change from 
baseline 




  p-value∗ 
   Assessment N Mean Mean SD Median Mean N Mean Mean SD Median Mean  
              
Baseline 40 23.3     40 23.1      
Month 3 40 23.2 -0.1 0.9 -0.3 -0.4 40 23.1 0.0 0.9 0.4 0.1  0.58 
Month 6 38 23.6  0.0 1.2  0.6  0.1 38 23.1 0.0 1.3 0.6 0.2  0.95 
Month 12 37 23.6  0.1 1.4 -0.4  0.3 36 23.3 0.1 1.4 0.3 0.4  0.98 
Month 18 38 23.3  0.1 1.6  0.4  0.3 33 23.9 0.7 1.5 2.3 2.9  0.15 
Month 24 37 23.5  0.2 1.5  1.5  0.7 31 24.0 0.6 2.0 2.9 2.4  0.40 
Last 
assessment 
40 23.5  0.2 1.5  1.1  0.7 40 23.5 0.4 1.9 1.4 1.6  0.74 
 
∗ Results from Wilcoxon test on changes from baseline 
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IMPLANT  SITE , INSERTION  AND  REMOVAL 
Conditions of the implant site within the visit windows are summarised in 
Table 6.8. The majority of subjects reported no abnormalities during any of 
the assessments.  
 
Implant insertion and removal times are summarised in Table 6.9.  The 
time required for insertion showed a distinct difference between the two 
groups. For IMPLANONTM the mean insertion time was 1.3 minutes (SD 
0.6), which was almost one third of the mean insertion time of 3.6 minutes 
(SD 1.3) required for the insertion of NORPLANT. Insertion times 
ranged from 1.0 to 3.0 minutes with a median of 1.0 minute in the 
IMPLANONTM group and from 2.0 to 8.0 minutes with a median of 3.0 
minutes in the NORPLANT  group. 
 
The time required for implant removal also showed a distinct difference 
between the two treatment groups. For IMPLANONTM the mean time 
taken for removal was 1.6 minutes (SD 0.8) which was less than one 
quarter of the mean time required for the removal of NORPLANT, which 
had a mean of 6.7 minutes (SD 4.6) . Removal times ranged from 1.0 to 4.0 
minutes for IMPLANONTM; and 2.0 to 15.0 minutes, with a median of 5.5 
minutes for NORPLANT. 
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Complications at implant insertion and removal are summarised in Table 
6.10. No complications during implantation were reported for 
IMPLANONTM and NORPLANT  groups. For none of the subjects in the 
NORPLANT  group complications during removal were reported, while 
for one subject in the IMPLANONTM group (Subject 0035) significant 
fibrosis at the implant site was noted and the terminal end of the implant 




Table 6.8       Condition of Implant Site 
 
Condition IMPLANON™ NORPLANT® 
 Any time Last measurement Any time Last measurement 
 n % n % n % n % 
No abnormalities 36 90.0 40 100.0 35 87.5 40 100.0 
Pain 4 10.0 0 0 5 12.5 1 2.5 
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Table 6.9       Summary Statistics for Implant Insertion and Removal Time 
Time (minutes) IMPLANON™ NORPLANT® 
Required for insertion   
    n 40 40 
    mean 1.3 3.6 
    SD 0.6 1.3 
    Median 1.0 3.0 
    Min-Max 1.0 - 3.0 2.0 - 8.0 
Required for removal   
    n 39 10* 
    mean 1.6 6.7 
    SD 0.8 4.6 
    Median 1.0 5.5 
    Min-Max 1.0 - 4.0 2.0 - 15.0 
 









Table 6.10    Complications at Implant Insertion and Removal 
 
  IMPLANON™ NORPLANT® 
Insertion N 40 40 
      Complications n  (%)  0  0 
    
Removal    
      Complications N 39 10* 
 n  (%)  1   (2.6)  0 
 
*  Not applicable for subjects on Norplant   (n=30) who continued treatment after the study 
period 
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ADVERSE  EXPERIENCES 
All reported bleeding irregularities and amenorrhoea were excluded from 
the analysis of AEs. In both groups, most of the subjects reported at least 
one AE. Similarly, most of the subjects had AEs that were judged as 
possibly, probably or definitely related to the study treatment. 
 
Study Deaths 
No study deaths were recorded. 
 
Serious Adverse Experiences 
As shown in Table 6.11, three subjects (7.5%) of the IMPLANONTM group 
and one subject (2.5%) of the NORPLANT group reported SAEs during 
the study, all of which were all probably related to the study treatment. 
 
Discontinuations Due to Adverse Experiences 
One subject on IMPLANONTM (2.5%) and two on NORPLANT (5.0%) 
discontinued due to an AE as a primary reason. The subject on 
IMPLANONTM discontinued because of increased appetite and 
somnolence. The two subjects on NORPLANT discontinued because of 




Summary of Adverse Experiences 
The reported AEs were distributed over various body systems and WHO 
preferred terms. Tables 6.12 and 6.13 present frequencies of AEs by body 
system and WHO preferred term. 
 
Predominant body systems with regard to the number of subjects with an 
AE were (IMPLANONTM  vs NORPLANT ) ‘body as whole’ (55.0% vs 
40.0%) and ‘central and peripheral nervous system’ (45% in both groups). 
Events that were reported by more than 10% of subjects in either group 
were ‘influenza-like symptoms’ (32.5% vs 27.5%), ‘fever’ (15.0% vs 
10.0%) and ‘pain’ (17.5% vs 2.5%) in the former category, and ‘headache’ 
(45.0% vs 37.5%) and ‘dizziness’ (15.0% in both groups) in the latter 
category. 
 
In addition, 25% or more of the subjects had AEs within the categories 
‘skin and appendages’ (30.0% vs 37.5%), ‘gastro-intestinal system’ (37.5% 
vs 30.0%), ‘respiratory system’ (32.5% vs 35.0%) , ‘metabolic and 
nutritional’ (27.5% in both groups) and ‘application site’ (25.0% in both 
groups). Events within these body systems that were reported by more than 
10% of subjects in either group in the respective categories were : ‘genital 
pruritus’ (7.5% vs 15.0%). ‘rash’ (15.0% vs 12.5%) and ‘acne’ (5.0% vs 
12.5%); ‘abdominal pain’(27.5% vs 15.0% ) and  ‘nausea’ (12.5% vs 
15.0%); ‘coughing’ (12.5% vs 15.0%); ‘weight increase’ (20.0% vs 
122 
22.5%); and ‘injection site pain’ (15.0% in  both groups) and ‘injection site 
reaction’ (10.0% vs 12.5%). Finally, 27.5% of subjects on NORPLANT  
and 15.0% on IMPLANONTM had AEs within the category ‘reproductive 
disorders’, with 17.5% of NORPLANT  users and 7.5% of 
IMPLANONTM users reporting ‘leukorrhoea’. 
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Table 6.11    Serious Adverse Experiences (SAEs) 







Implanon       
 0035 Body as a whole- 
general disorders 
Fever 177 201 recovered 
  central and 
peripheral nervous 
system disorders 
Headache 177 201 recovered 
 0044 Neoplasm- 
dermoid cyst 
Teratoma 508 554 recovered 
 0067 Respiratory 
system disorders 
Asthma 11 13 recovered 
Norplant       
 0017 Neoplasm- 
ovarian cyst 
Ovarian cyst 480 continued present 
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Table 6.12     Adverse Experiences by Body System 
Body System IMPLANON NORPLANT 
 n % n % 
Skin & appendage disorders 12 30.0 15 37.5 
Musculo-skeletal system disorders 1 2.5 0  
Central & peripheral nervous system disorders 18 45.0 18 45.0 
Psychiatric disorders 7 17.5 5 12.5 
Gastro-intestinal system diorders 15 37.5 12 30.0 
Metabolic & Nutritional disorders 11 27.5 11 27.5 
Respiratory system disorders 13 32.5 14 35.0 
Red blood cell disorders 0  1 2.5 
Urinary system disorders 4 10.0 0  
Reproductive disorders, female 6 15.0 11 27.5 
Neoplasm 1 2.5 2 5.0 
Body as a whole - general disorders 22 55.0 16 40.0 
Application site disorders 10 25.0 10 25.0 
Resistance mechanism disorders 0  1 2.5 











WHO preferred term n % n % 
     
Skin & appendages disorders     
    Acne 2 5.0 5 12.5 
    Alopecia 1 2.5 4 10.0 
    Dermatitis fungal 1 2.5 0  
    Eczema 0  1 2.5 
    Pruritus 1 2.5 2 5.0 
    Pruritus genital 3 7.5 6 15.0 
    Rash 6 15.0 5 12.5 
Musculo-skeletal disorders     
    Skeletal pain 1 2.5 0  
Central & Peripheral nervous system disorders     
    Cramps legs 0  1 2.5 
    Dizziness 6 15.0 6 15.0 
    Headache 18 45.0 15 37.5 
    Migraine 0  1 2.5 
Psychiatric disorders     
    Anorexia 1 2.5 0  
    Anxiety 1 2.5 0  
    Appetite increased 2 5.0 0  
    Depression 1 2.5 0  
    Dyspareunia 0  2 5.0 
    Emotional lability 1 2.5 1 2.5 
    Libido decreased 0  1 2.5 
    Nervousness 2 5.0 3 7.5 
    Somnolence 1 2.5 0  
Gastro-intestinal system disorders     
    Abdominal pain 11 27.5 6 15.0 
    Constipation 2 5.0 0  
    Diarrhoea 2 5.0 0  
    Dyspepsia 0  2 5.0 
    Flatulence 0  2 5.0 
    Gastritis 1 2.5 0  
    Nausea 5 12.5 6 15.0 
    Toothache 1 2.5 0  
    Vomiting 3 7.5 2 5.0 
Metabolic and nutritional disorders     
    Weight decreases 3 7.5 2 5.0 
    Weight increases 8 20.0 9 22.5 
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WHO preferred term n % n % 
     
Respiratory system disorders     
    Asthma 3 7.5 1 2.5 
    Coughing 5 12.5 6 15.0 
    Haemoptysis 0  1 2.5 
    Pharyngitis 4 10.0 4 10.0 
    Rhinitis 4 10.0 4 10.0 
    Sinusitis 1 2.5 0  
    Sputum increased 2 5.0 1 2.5 
    Upper respiratory tract infection 0  3 7.5 
Red blood cell disorder     
    Anaemia 0  1 2.5 
Urinary system disorders     
    Cystitis 1   2.5 0  
    Face oedema 1 2.5 0  
    Urinary incontinence 1 2.5 0  
    Urinary tract infection 1 2.5 0  
Reproductive disorders, female     
    Breast pain female 1 2.5 3 7.5 
    Dysmenorrhoea 1 2.5 1 2.5 
    Leukorrhoea 3 7.5 7 17.5 
    Vaginitis 1 2.5 3 7.5 
Neoplasms     
    Breast fibroadenosis 0  1 2.5 
    Ovarian cyst 0  1 2.5 
    Ovarian teratoma 1 2.5 0  
Body as a whole - general disorders     
    Allergic reaction 1 2.5 0  
    Asthenia 1 2.5 4 10.0 
    Back pain 3 7.5 3 7.5 
    Chest pain 1 2.5 0  
    Fatigue 4 10.0 3 7.5 
    Fever 6 15.0 4 10.0 
    Influenza-like symptoms 13 32.5 11 27.5 
    Malaise 0  1 2.5 
    Pain 7 17.5 1 2.5 
    Rigors 2 5.0 0  
    Syncope 1 2.5 0  
Application site disorders     
    Injection site pain 6  6 15.0 
    Injection site reaction 4  5 12.5 
Resistance mechanism disorders     
    Infection 0  1 2.5 
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Mean SD Mean Median 
p-valuea 
Haemoglobin            
  Baseline 40 12.38 0.82   40 12.31 0.97    
  Removal 39 12.55 1.07 1.65 0.00 40b 12.55 1.29 2.46 1.58 0.62 
 
a Results of the Wilcoxon test on percent change from baseline 
b Including 30 subjects who continued with NORPLANT® after the study period 
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HAEMOGLOBIN LEVEL 
Plasma haemoglobin (Hb) level was determined at baseline and at removal. 
The summary statistics as presented in Table 6.14 do not indicate an 
overall effect of either implant on haemoglobin concentration. One subject 
on IMPLANON™ and one subject on NORPLANT® had clinically 
significantly low Hb value (9.5 g/dL and 5.9 g/dL respectively) at implant 
removal. The subject on NORPLANT® was apparently actively trying to 
lose weight and was restricting her diet severely.  
 
 
VAGINAL BLEEDING  
Discontinuation  Due  to  Bleeding  Irregularities  Or  Amenorrhoea 
Frequencies on all bleeding irregularities as primary reasons for 
discontinuation are presented in Table 6.15. There were no cases of 
discontinuation due to amenorrhoea in either of the treatment groups. Four 
subjects in the NORPLANT group and no subject in the IMPLANONTM 
group discontinued due to bleeding irregularities. Group comparison of 
time-periods to discontinuation due to bleeding irregularities was found to 






Reference Period Analysis 
In the NORPLANT group no reference periods were excluded due to 
missing data and in the IMPLANONTM group only one woman (Subject 
0065) had several reference periods excluded because of missing data. All 
women  (40 in each group) contributed at least one reference period to the 
reference period analysis. One subject of the NORPLANT group (Subject 
0039) had reference periods 1, # and 2 excluded from the analyses due to 
the use of norethisterone which was a prohibited medication according to 
the study protocol. 
 
Tables 6.16 - 6.19 present summary statistics for selected bleeding 
variables. Group statistics for these parameters are given by medians rather 
than by means since distributions were skewed. The median number of 
bleeding-spotting (B-S) days was highest at reference periods (RP) 1 and # 
(Table 6.16, around 30 days in both groups). Thereafter, the median 
number of B-S days ranged from 7 (RP 3) to 17.5 (RP 2) in the 
IMPLANONTM group, and from 17 (RP 6) to 22.5 (RP 2) in the 
NORPLANT group. The median number of B-S episodes in the 
IMPLANONTM group was 3 during RP 1 and #, 1 during RP 2 and 3, and 2 
in all other reference periods. In the NORPLANT group the median 
number of B-S episodes was 3 in all reference periods. So, from RP 2 
onwards, the number of both B-S days and B-S episodes was lower for 
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IMPLANONTM compared to NORPLANT . This difference appears to be 
particularly due to a higher number of bleeding days with NORPLANT, 
for which the median values from RP 2 onwards indicate 6-9 days more 
bleeding days per 90 day reference period than for IMPLANONTM  
(Figures 6. 2 and 6.3). 
 
The within-subject mean length (days) of B-S episodes and bleeding-free 
intervals displayed substantial variation, and particularly so in the 
IMPLANONTM group (Tables 6.18 - 6.19). The median value of the former 
was 13.5 and 10.0 at RP 1 and #, and ranged between 5.4 and 7.0 thereafter 
in the IMPLANONTM group; in the NORPLANT group, median values of 
8.5 and 7.4 were observed at RP 1 and  # , and a range of 6.3-7.7 thereafter. 
The median values of bleeding-free intervals ranged between 20.7 (RP 1) 
and 32.6 (RP 2) in the IMPLANONTM group and between 18.7 (RP 1) and 
26.8 (RP 6) in the NORPLANT  group.  
 
Table 6.20 presents the frequency table of bleeding pattern indices per 90-
day reference period. Except for frequent bleeding, a higher incidence of 
bleeding pattern indices was noted in the IMPLANONTM group. The most 
striking difference between IMPLANONTM and NORPLANTwas 
observed for amenorrhoea : in the IMPLANONTM group the incidence 
ranged from 21.1% to 36.1% from RP 3 onwards, while in the 
131 
NORPLANT  group this range was 0% to 11.1% (Figure 6.4). Infrequent 
bleeding was slightly more common among IMPLANONTM users than 
among NORPLANT users (respective ranges 25.0% -52.5% vs 23.5%-
38.9%), as was prolonged bleeding (ranges 12.8%-17.9% vs 6.5-13.9% 
from RP 2 onwards). The incidence of frequent bleeding was low in both 
groups (Figures 6.5, 6.6 and 6.7 ). 
 
In summary, it appears that IMPLANONTM users experience less bleeding 
than NORPLANT users, as reflected by lower number of B-S days and B-
S episodes, as well as by the lower contribution of bleeding (as opposed to 
spotting) to these. In line with this, a higher incidence of amenorrhoea was 
found in the IMPLANONTM group.  
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Table 6.15   Discontinuation Due To Bleeding Irregularities Or 
Amenorrhoea As Primary Reason 
 
 
Bleeding irregularities or amenorrhoea 




 n % n % 
Amenorrhoea 0  0  
Bleeding irregularities     
     Frequent irregular bleeding 0  2 5.0 
     Heavy menstrual flow 0  0  
     Prolonged menstrual flow 0  2 5.0 
     Spotting 0  0  
     Other bleeding problems 0  0  
     





Table  6.16 Menstrual Bleeding Parameters - Number of Bleeding-Spotting days in each Reference Period 
 
Variable Group Reference 
period 
Subjects  
         N 
Number of days 
    Min P25 Median P75 Max Mean SD 
No of Implanon 1 39 1.0 21.0 34.0 50.0 85.0 35.3 21.2 
Bleeding -  # 39 0.0 20.0 27.0 59.0 90.0 36.8 26.4 
Spotting  2 40 0.0 3.0 17.5 30.5 90.0 24.1 26.4 
days  3 39 0.0 0.0 7.0 22.0 84.0 15.5 19.4 
  4 39 0.0 0.0 9.0 21.0 79.0 14.8 19.0 
  5 38 0.0 2.0 14.5 27.0 57.0 16.8 15.8 
  6 38 0.0 3.0 13.0 22.0 51.0 15.3 14.8 
  7 36 0.0 0.0 10.5 21.5 80.0 14.8 18.2 
  8 35 0.0 3.0 12.0 21.0 54.0 15.8 15.5 
           
 Norplant 1 39 3.0 16.0 29.0 38.0 75.0 30.2 17.0 
  # 37 3.0 12.0 28.0 38.0 90.0 28.2 19.9 
  2 36 0.0 12.0 22.5 28.5 79.0 24.5 18.5 
  3 36 0.0 11.0 22.0 33.0 47.0 23.0 13.2 
  4 36 0.0 12.0 19.5 31.5 72.0 21.5 14.9 
  5 34 0.0 18.0 22.0 28.0 39.0 22.2 8.9 
  6 33 0.0 14.0 17.0 26.0 42.0 19.6 10.2 
  7 31 7.0 14.0 19.0 23.0 51.0 20.4 9.3 
  8 31 0.0 15.0 21.0 27.0 47.0 21.2 10.6 
 
#  Reference period of 90 days that starts at the 29th day of treatment 
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Table 6.17   Menstrual Bleeding Parameters - Number of Bleeding-Spotting Episodes in each Reference Period 
 
Variable Group Reference 
period 
Subjects 
          N 
Number of days 
    Min P25 Median P75 Max Mean SD 
No of Implanon 1 39 0.0 1.0 3.0 4.0 9.0 2.6 1.8 
Bleeding -  # 39 0.0 1.0 3.0 4.0 7.0 2.6 1.8 
Spotting  2 40 0.0 0.0 1.0 3.0 8.0 1.9 2.0 
episodes  3 39 0.0 0.0 1.0 2.0 4.0 1.4 1.3 
  4 39 0.0 0.0 2.0 3.0 5.0 1.7 1.5 
  5 38 0.0 1.0 2.0 3.0 7.0 2.1 1.7 
  6 38 0.0 1.0 2.0 3.0 7.0 1.9 1.6 
  7 36 0.0 0.0 2.0 3.0 6.0 1.8 1.7 
  8 35 0.0 1.0 2.0 3.0 6.0 2.1 1.6 
           
 Norplant 1 39 1.0 2.0 3.0 4.0 8.0 3.2 1.5 
  # 37 0.0 2.0 3.0 4.0 9.0 3.2 2.0 
  2 36 0.0 2.0 3.0 4.0 14.0 3.0 2.4 
  3 36 0.0 2.0 3.0 4.0 11.0 3.4 2.1 
  4 36 0.0 2.0 3.0 4.0 7.0 2.9 1.7 
  5 34 0.0 2.0 3.0 4.0 5.0 3.3 1.3 
  6 33 0.0 2.0 3.0 4.0 6.0 3.0 1.4 
  7 31 1.0 2.0 3.0 3.0 5.0 3.0 1.0 
  8 31 0.0 2.0 3.0 3.0 5.0 2.9 1.3 
 
#  Reference period of 90 days that starts at the 29th day of treatment 
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Table 6.18  Menstrual Bleeding Parameters - Mean Length (Days) Of Bleeding-Spotting Episodes In Each 
Reference Period 
 
Variable Group Reference 
period 
Subject
s  N 
Number of days 
    Min P25 Median P75 Max Mean SD 
Mean  Implanon 1 35 4.0 6.8 13.5 20.8 231.0 26.7 43.3 
length of  # 33 3.3 4.5 10.0 18.0 231.0 23.5 43.9 
Bleeding -  2 29 1.0 4.3 7.0 9.0 54.0 9.8 11.9 
Spotting  3 26 2.3 5.0 7.0 10.0 60.0 10.5 11.9 
episodes  4 27 1.0 4.0 5.4 10.3 81.0 10.2 15.3 
  5 29 1.7 5.3 7.0 9.8 28.5 8.8 6.3 
  6 30 2.0 5.0 6.3 8.7 24.0 7.8 5.2 
  7 22 4.0 5.0 6.4 9.5 61.0 10.2 12.3 
  8 27 3.0 5.0 6.8 8.8 10.5 6.8 2.4 
           
 Norplant 1 39 1.0 6.0 8.5 11.0 151.0 13.3 23.8 
  # 35 2.0 5.7 7.4 10.5 46.0 9.0 7.5 
  2 33 2.5 5.0 7.7 8.7 37.0 8.2 5.9 
  3 34 2.0 5.2 6.3 8.0 27.0 7.2 4.2 
  4 32 2.0 5.4 6.5 8.0 25.7 7.6 4.8 
  5 33 3.0 5.3 7.0 8.3 15.5 7.3 3.0 
  6 32 2.3 5.3 6.6 7.5 10.5 6.4 1.9 
  7 31 4.0 5.6 6.7 7.7 20.0 7.4 3.3 
  8 29 1.0 6.0 6.8 7.8 16.0 7.2 2.9 
 
#  Reference period of 90 days that starts at the 29th day of treatment 
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Table 6.19 Menstrual Bleeding Parameters - Mean Length (Days) Of Bleeding-Free Intervals In Each 
Reference Period 
 




Number of days 
    Min P25 Median P75 Max Mean SD 
Mean  Implanon 1 39 5.0 11.0 20.7 48.5 400.0 46.3 75.3 
length of  # 34 2.3 14.5 22.6 62.5 262.0 46.6 55.7 
Bleeding -  2 34 8.8 17.5 32.6 99.0 330.0 85.1 99.8 
Spotting  3 27 2.0 17.0 26.0 56.0 520.0 59.8 105.6 
episodes  4 26 4.5 19.5 25.1 32.0 411.0 54.7 87.8 
  5 29 6.7 18.7 28.5 49.0 138.0 41.9 38.8 
  6 30 3.0 15.3 28.5 77.0 274.0 56.0 88.8 
  7 23 5.7 15.5 21.7 42.5 199.0 35.1 40.0 
  8 27 6.7 16.7 26.7 50.5 137.0 36.7 29.5 
           
 Norplant 1 39 3.6 13.5 18.7 33.3 194.0 27.3 31.1 
  # 36 2.8 12.5 19.8 42.1 560.0 44.2 91.9 
  2 34 2.6 13.8 20.9 31.3 210.0 32.3 39.9 
  3 34 5.1 12.8 20.1 36.0 152.0 30.3 30.8 
  4 32 6.0 13.9 22.6 28.1 70.0 23.0 12.7 
  5 33 10.2 15.8 22.0 26.7 50.0 22.8 9.3 
  6 32 8.6 15.1 26.8 30.5 87.0 25.4 14.6 
  7 31 10.0 18.7 24.7 31.7 128.0 29.0 21.3 
  8 29 9.3 16.5 23.3 25.3 58.0 22.9 9.0 
 
#  Reference period of 90 days that starts at the 29th day of treatment 
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Table 6.20 Menstrual Bleeding Pattern Indices In Each Reference 
Period 
Bleeding pattern Reference Implanon Norplant 
indices period Subjects Event Subjects Event 
  N n % N n % 
Amenorrhoea 1 39 0 0 39 0 0 
 # 39 3 7.0 37 0 0 
 2 40 6 15.0 36 2 5.6 
 3 39 12 30.8 36 2 5.6 
 4 39 12 30.8 36 4 11.1 
 5 38 9 23.7 34 1 2.9 
 6 38 8 21.1 33 1 3.0 
 7 36 13 36.1 31 0 0 
 8 35 8 22.9 31 2 6.5 
        
Infrequent bleeding 1 39 19 48.7 39 13 33.3 
 # 39 16 41.0 37 13 35.1 
 2 40 21 52.5 36 14 38.9 
 3 39 19 48.7 36 10 27.8 
 4 39 14 35.9 36 9 25.0 
 5 38 13 34.2 34 8 23.5 
 6 38 17 44.7 33 10 30.3 
 7 36 9 25.0 31 10 32.3 
 8 35 12 34.3 31 8 25.8 
        
Frequent bleeding 1 39 1 2.6 39 2 5.1 
 # 39 2 5.1 37 4 10.8 
 2 40 0 5.0 36 2 5.6 
 3 39 0 0 36 3 8.3 
 4 39 1 0 36 3 8.3 
 5 38 1 2.6 34 0 0 
 6 38 1 2.6 33 1 3.0 
 7 36 1 2.8 31 0 0 
 8 35 1 2.9 31 0 0 
        
Prolonged bleeding 1 39 24 61.5 39 10 25.6 
 # 39 16 41.0 37 8 21.6 
 2 40 6 15.0 36 4 11.1 
 3 39 7 17.9 36 5 13.9 
 4 39 5 12.8 36 3 8.3 
 5 38 6 15.8 34 3 8.8 
 6 38 5 13.2 33 3 9.1 
 7 36 5 13.9 31 2 6.5 
 8 35 5 14.3 31 3 9.7 
 
#  Reference period of 90 days that starts at the 29th day of treatment
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USER SATISFACTION  
 
At the six months follow-up visit, user satisfaction questionnaires were 
provided to acquire information on the woman’s opinions and 
impressions about the methods.  Of the 80 subjects recruited to the 
study, 76 user satisfaction questionnaires were completed - 39 from the 
IMPLANONTM group and 37 from the NORPLANT group. The 
summarized data from these questionnaires is presented in Table 6.21. 
 
The responses given indicate that both the implant systems were 
associated with a reasonably high degree of user satisfaction. When the 
subjects were questioned about the one feature of the implants that was 
most attractive to them, the most frequently given response was the 
convenience or the ease of use (51.3 in the IMPLANONTM group, 54.0% 
in the NORPLANT   group). As expected, the feature least liked about 
the implants was its effect on the menstrual cycle and the resultant 
irregularities of vaginal bleeding (76.3% in the IMPLANONTM group, 
51.4% in the NORPLANT group). The insertion procedure or other 
side-effects were not perceived as significant drawbacks. With regard to 
discomfort during insertion of the implants, the majority of subjects in 
the IMPLANONTM group (53.8%) experienced no discomfort, while 
73.0% of the NORPLANT   group reported slight pain during the 
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insertion procedure. In both the groups, 5.4% said they felt “a lot of 
pain”.  
 
For the IMPLANONTM implant group, a second questionnaire set was 
given at the time of implant removal. Of the 40 subjects in the group, 38 
responded.  The summarized data from these questionnaires is presented 
in Table 6.22. 
 
There was no significant change in their opinion about the method.  The 
ease of use or convenience (50.0%) was still cited as the best liked 
feature and the menstrual disturbances was the least liked feature 
(52.6%). However, 26.3% did not find any disagreeable feature with the 
implant. When questioned about discomfort during removal of the 
implants, majority ( 71.0%) felt no pain, 23.7% felt slight pain, while 2 
subjects (5.3%) complained of a “lot of pain”. 
 
When asked, at the six-month follow-up, if they would recommend the 
method  to a friend, 76.9% of the IMPLANONTM group and 81.1% of 
the NORPLANT   group said they would. When asked if they would 
use a second set of the same implants after the present set was removed, 
similar number of women in each group ( 53.8% in the IMPLANONTM 
group and 56.8% in the NORPLANT group) responded in the 
affirmative. For the subjects in the IMPLANONTM group, when the same 
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questions were asked at the time of implant removal, there was no 
significant change in the responses (Table 6.22). 
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Table 6.21 User satisfaction at six months among the implant acceptors 
 
Question & Response IMPLANON a NORPLANT b 
 No. % No. % 
     
What is liked most about the implants ?     
        -  nothing 1 2.6 0  
        -  low risk of pregnancy 17 43.6 12 32.4 
        -  ease of use / convenience 20 51.3 20 54.0 
        -  lasts long 1 2.6 5 13.5 
     
What is liked least about the implants ?     
        -  nothing 8 20.5 12 32.4 
        -  menstrual changes 29 76.3 19 51.4 
        -  other side-effects 2 5.2 5 13.5 
        -  the way they look or feel 0  0  
        -  insertion procedure 0  1 2.7 
     
Discomfort during insertion ?     
        -  none 21 53.8 8 21.6 
        -  a little 16 41.0 27 73.0 
        -  a lot 2 5.2 2 5.4 
     
Would she recommend the method to a friend ?     
        -  yes 30 76.9 30 81.1 
        -  no 1 2.6 0  
        -  not sure 8 20.5 7 18.9 
     
Would she use a second set of implants ?     
        -  yes 21 53.8 21 56.8 
        -  no 4 10.3 3 8.1 
        -  not sure 14 35.9 13 35.1 
     
Did she receive enough information ?     
        -  yes 36 92.3 37 100.0 
        -  no 2 5.1 0  
        -  not sure 1 2.6 0  
 
a  Based on 39 respondents 
b  Based on 37 respondents 
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Table 6.22   User satisfaction after implant removal among 
IMPLANON™  implant users. 
 
Question & Response IMPLANON a 
 No. % 
What is liked most about the implants ?   
        -  nothing 3 7.9 
        -  low risk of pregnancy 15 39.5 
        -  ease of use / convenience 19 50.0 
        -  no menstrual periods 1 2.6 
   
What is liked least about the implants ?   
        -  nothing 10 26.3 
        -  menstrual changes 20 52.6 
        -  other side-effects 6 15.8 
        -  the way they look or feel 1 2.6 
        -  insertion procedure 1 2.6 
   
Discomfort during removal ?   
        -  none 27 71.0 
        -  a little 9 23.7 
        -  a lot 2 5.3 
   
Would she recommend the method to a friend ?   
        -  yes 33 86.8 
        -  no 3 7.9 
        -  not sure 2 5.3 
   
Would she use a second set of implants, if available ?   
        -  yes 20 52.6 
        -  no 11 28.9 
        -  not sure 7 18.5 
   
Did she at any time consider removing the implant ?   
        -  yes 13 34.2 
        -  no 25 65.8 
        If yes, why ?   
             - menstrual changes 5  
             - weight changes 1  
             - planning a pregnancy 2  
             - others 5  
 
a  Based on 38 respondents 
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CONTRACEPTIVE  EFFICACY 
None of the subjects became pregnant during treatment. Five post-
treatment pregnancies occurred. For subjects 0029 and 0067, who were on 
IMPLANONTM, the estimated date of conception was 41 and 121 days, 
respectively, after implant removal. For subjects 0022, 0040 and 0047, who 
were on NORPLANT, the estimated date of conception was 417, 42 and 
169 days, respectively,  after the removal of the implant. 
 
POST-TREATMENT  EVALUATION 
Table 6.23 presents frequencies of contraceptive methods that were used 
after implant removal. Of those subjects who elected a non-hormonal 
method of contraception or no-method at all, and who did not become 
pregnant, 13 subjects out of 17 (76.5%) of the IMPLANONTM group had 
their menses returned to normal pattern. Of the remaining 4 subjects, one 
subject (Subject 0072) had not experienced any bleeding since implant 
removal. In the NORPLANT group 6 out of 7 (85.7%) had menses 
returned to the normal pattern; the remaining subject (0022) did have a 
bleeding experience since implant removal. 
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Table 6.23 Post-treatment evaluation 
 
IMPLANON™ NORPLANT®  
n % n % 
Method     
     Oral contraceptives 6 15.4 2 20.0 
     Implants 13 33.3 0  
Injectables 1 2.6 0  
     IUD 2 5.1 1 10.0 
     Condoms etc 8 20.5 2 20.0 
     Other 3 7.7 2 20.0 
     
No Methoda 6 15.4 3 30.0 
     
Menses returned to normalb     
     Yes 13 76.5 6 85.7 
     No 4 23.5 1 14.3 
     
 
 
a One subject had been pregnant 
 b Only subjects who did not become pregnant and who did not use a 
hormonal method of contraception were evaluable for return of 
menses 
 Note : only subjects who had a post-treatment assessment were included 
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(e)  Discussion 
The data presented in this two-year open randomized comparative clinical 
study in 80 volunteers suggest that the IMPLANONTM single-rod implant 
system is a highly effective and acceptable form of contraceptive method 
among Singaporean women and is comparable to that of the NORPLANT 
 implant system.  For both implants good contraceptive efficacy was 
indicated by the absence of in-treatment pregnancies. 
 
A comparable safety profile with both forms of implants was obtained in 
terms of incidence and type of adverse reactions (AEs). Mean blood 
pressure and body mass index (BMI) were slightly elevated in both groups. 
Statistically significant higher systolic blood pressure values were observed 
in the NORPLANT group at months 3 and 18. 
 
Like all progestin-only implant systems, disruption of normal menstrual 
cycles seems to be the main drawback of the IMPLANONTM implants. 
However IMPLANONTM users experienced less bleeding than 
NORPLANT users, although the bleeding pattern was more variable. No 
subject in the IMPLANONTM group discontinued due to vaginal bleeding 
irregularities, compared to four (10%) in the NORPLANT group. 
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As expected, implant insertion and removal were much faster for the 
single-rod IMPLANONTM than for the six-rod NORPLANT implants. 
There were no complications of removal, except for one subject on 
IMPLANONTM who had a difficult removal. 
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CHAPTER VII  :   AN OPEN RANDOMIZED COMPARATIVE STUDY 
OF IMPLANONTM AND NORPLANT IMPLANTS ON 
CARBOHYDRATE METABOLISM, THYROID AND ADRENAL 
FUNCTION IN HEALTHY FEMALE VOLUNTEERS 
 
(a) The Objective  
 









 In this chapter, the effects of IMPLANON™ implant use on 
carbohydrate metabolism, thyroid and adrenal function has been compared with 
those of NORPLANT® implants. In this 2-year open randomized study of 80 
implant acceptors it was found that both the implants may induce mild insulin 
resistance but no significant change in glucose levels. Minimal changes in 
thyroid hormones and cortisol levels were seen, possibly secondary to 
alterations in the respective binding globulins in the serum. These alterations in 
carbohydrate metabolism, thyroid and adrenal function would have no clinical 
significance in the healthy women. While in the NORPLANT group, SHBG 
levels decreased, increased levels were found in the IMPLANONTM users at the 
end of two years.  These finding confirms the fact that 3-keto-desogestrel, released 
from IMPLANONTM implants, is significantly less androgenic than levonorgestrel, 
released from the NORPLANT implants 
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CHAPTER VII  :   AN OPEN RANDOMIZED COMPARATIVE STUDY 
OF IMPLANONTM AND NORPLANT IMPLANTS ON 
CARBOHYDRATE METABOLISM, THYROID AND ADRENAL 
FUNCTION IN HEALTHY FEMALE VOLUNTEERS 
 
 
(a)  Objective of the study 
The objective of the present study was to assess the possible differences 
in effects of IMPLANONTM and NORPLANT on carbohydrate 
metabolism and parameters of adrenal and thyroid function.  
 
(b) Experimental design and selection of cases 
 This was a single-centre open randomized study in healthy Singaporean 
female volunteers comparing effects of IMPLANONTM and 
NORPLANT implants on carbohydrate metabolism, thyroid and 
adrenal function. Eighty volunteers were recruited for the study. The 
volunteers were randomized to receive either IMPLANONTM or 
NORPLANT implants, with 40 subjects in each arm. The study period 
was 24 months. The criteria used for selection of cases has been described 





(c ) Methodology including Statistical and Analytical Methods 
The metabolic parameters  were determined prior to the insertion of the 
implant and after 6, 12 and 24 months of insertion. The parameters 
evaluated were : 
(i)  Carbohydrate Metabolism Parameters  
An oral glucose tolerance test (OGTT) was performed at baseline and 
after 6, 12 and 24 months of treatment. For the OGTT, 75 g glucose was 
ingested after an overnight fast (no food intake after 22.00 h on the 
previous night). Intravenous blood samples were taken just before the 
glucose load and after 30, 60, 90 and 120 min. Glucose and insulin were 
measured in fresh plasma samples. Haemoglobin A1C (HbA1C) an 
indicative parameter of mean plasma glucose concentrations over the 
previous 6-8 weeks, was also measured in the fasting blood sample. 
 
Plasma glucose was estimated using the glucose oxidase method 
(Cramp, 1937) and glycosylated haemoglobin was estimated  by affinity 
chromatography method using Pierce Glycotest Kits from Pierce, 
Rockford, Illinois,USA. 
 
To evaluate oral glucose tolerance, new parameters were derived from 
the time profiles for blood glucose and insulin concentrations : 
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-the incremental area under the curve (AUC), i.e. the AUC adjusted 
for the fasting value, calculated as : 
 30 x {(fc/2) + 30’c + 60’c + 90’c + (120’c/2) - 4fc}, where fc is 
the fasting concentration, and t’c is the concentration at time t’ 
(Gosland et al, 1990); 
-the (unadjusted) AUC (i.e. not adjusted for the fasting value), 
calculated as : 
30 x {(fc/2) +  30’c + 60’c + 90’c + (120’c/2)}, where fc is the 
fasting concentration, and t’c is the concentration at time t’. 
 
For all the carbohydrate parameters measured and the derived adjusted 
AUCs, summary statistics tables are given showing absolute values, 
changes from baseline and relative changes from baseline. For the 
incremental AUCs and 2-hour responses, the summary tables show 
absolute values and changes from baseline. All carbohydrate parameters 
measured , the derived incremental AUCs and 2-hour responses for 
glucose and insulin were statistically analysed. The first analysis model 
used was the linear additive ANCOVA, using change from baseline as 
dependent variable. Treatment was a factor in the model and the 
baseline value was fitted as a covariate. The model assumptions were 
checked. The F-test in the linear additive ANCOVA model was used for 
treatment differences. Also a non-parametric analysis, the two-sided 
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two-sample Wilcoxon test, was used. For both models two-sided 95% 
confidence intervals for treatment contrasts were calculated. 
 
(ii)  Parameters of Thyroid and Adrenal Function 
Triiodothyronine (T3), Thyroxine (T4), Thyroid binding globulin (TBG) 
and resin T3 uptake (RT3U) were determined in the fasting blood sample 
taken just prior to the glucose load. Cortisol, cortisol binding globulin 
(CBG), testosterone and sex hormone binding globulin (SHBG) were 
additionally assessed in the blood sample. Furthermore, albumin level 
was determined in the same fasting blood sample.  
 
T4, T3, and RT3U were measured by enzyme immunoassay (EIA) 
methods using kits from Serono-SRI. TBG levels were measured by 
radio-immunoassay (RIA) using kits from Nichols Institute, USA.  
Plasma cortisol and testosterone by radio-immunoassay (RIA) using 
WHO kits supplied under the auspices of the WHO Matched Reagent 
Programme. SHBG was measured by Immuno-radiometric assay 
(IRMA) using kits from Diagnostic Products Corporation, Los Angeles, 
USA., while CBG was measured by a radioimmunoassay (RIA) method 
using kits from Medgenix Diagnostics, Fleums, Belgium. Bromocresol 
green (BCG) binding assay method was used to measure albumin levels, 
using the COBAS MIRA analyzer and reagents from Roche Diagnostic 
Systems , Nutley, New Jersey, USA. 
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Summary statistics for absolute values, changes from baseline and 
relative changes from baseline, are presented. Treatment comparison of 
changes from baseline were performed  for each assessment and for last 
measurements using the two-sample Wilcoxon test. 
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(d) Results  
In the IMPLANONTM group three subjects (7.5%) and in the 
NORPLANT  group nine subjects (22.5%) discontinued during the study. 
Cumulative discontinuation rates and primary reasons for discontinuation 
have been presented earlier in Chapter VI. 
 
Carbohydrate  Metabolism  Parameters 
 
One subject in the IMPLANONTM group (Subject 0055) and three 
subjects in the NORPLANT group (Subjects 0008, 0071 and 0073) did 
not have Month 6 assessments for the OGTT. 
 
Blood Glucose Concentration Versus Time Profiles 
Figures 7.1 and 7.2 present the time profiles for mean glucose 
concentration at each assessment for IMPLANONTM and NORPLANT, 
respectively. At baseline , the highest level was reached at the first 
measurement (30 minutes) after glucose intake, followed by a gradual 
return to almost the starting values at 120 minutes. The curves obtained 
at 6,12 and 24 months treatment followed the same general pattern in 
both groups, but mean glucose concentrations after glucose intake were 
slightly higher than at baseline, particularly in the NORPLANT group 
at 24 months. 
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Blood Insulin Concentration Versus Time Profiles 
Figures 7.3 and 7.4 present the time profiles for mean insulin 
concentration at each assessment for IMPLANONTM and NORPLANT , 
respectively . At baseline, a steep increase was noted between 0 and 30 
minutes after glucose intake, followed by a plateau until 90 minutes, 
after which mean insulin levels started to decline again. During 
treatment, a comparable pattern was obtained in both groups, but mean 
insulin concentrations were higher than at the baseline; this was 
particularly so in the NORPLANT group at 24 months. 
 
AUCs and 2-hour Responses for Glucose and Insulin  (Table 7.1) 
The mean AUCs for glucose and insulin, adjusted for fasting values (i.e., 
incremental AUC) are presented in Table 7.1, together with the 
corresponding changes from the baseline. As can be seen from the 
standard  deviations, there was substantial inter-individual variation in 
glucose and insulin concentration profiles. For both glucose and insulin 
the incremental AUC values observed during treatment were higher than 
at the baseline in both groups. This increase was especially notable in 
the NORPLANT group at 24 months, where it amounted to about 70% 
and 90% for glucose and insulin, respectively. Statistically significant 
between-group differences were not observed at any time-point. 
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The 2-hour response for glucose at 6 and 12 months of treatment was 
about 5% higher than at baseline for both groups, while at 24 months an 
increase from baseline of 10% and 20% was observed for 
IMPLANONTM and NORPLANT, respectively. The 2-hour response 
for insulin showed a more pronounced increase with treatment, which at 
24 months amounted to about 70% for IMPLANONTM And 45% for 
NORPLANT. No statistically significant differences between the 
groups were found. 
 
Fasting Glucose, Insulin and HbA1C (Table 7.2) 
Fasting glucose levels displayed little inter-individual variation at any 
time-point and remained fairly stable during either treatment. There was 
no convincing indication for the existence of differences between 
groups: only the Wilcoxon test at the 6-month assessment reached the 
5% level (p=0.030), but this result was not supported by the ANCOVA 
results.  
 
Fasting insulin concentrations showed large inter-individual variation at 
all time-points. Only the results of the 24 months assessment indicated a 
mean increase from baseline in both groups. Between-group differences 
never reached statistical significance. 
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Mean fasting HbA1C was slightly elevated during both treatments 
(Figure 7.5). At 24 months the between-group difference was 
statistically significant. 
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Figure 7.1 Changes in Oral Glucose Tolerance in IMPLANON™ Implant 
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Figure 7.2 Changes in Oral Glucose Tolerance in NORPLANT® Implant 
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Figure 7.3 Plasma Insulin Levels during Oral Glucose Tolerance Test  in 
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Figure 7.4 Plasma Insulin Levels during Oral Glucose Tolerance Test  in 
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Figure 7.5 Fasting Glycosylated Haemoglobin A1C (Hb A1C) Levels  


















Table 7.1.    Carbohydrate Parameters - Incremental AUCs and 2-hour Responses of Glucose and Insulin 
 
Parameter              IMPLANON            NORPLANT Group comparison  Implanon - Norplant 
                       ANCOVAa Wilcoxonb 
Incremental AUC N Mean(SD) adj.  
Mean ∆c  
N Mean(SD) adj.  
Mean ∆c 
estimate (SE)d 95% CI p-value p-value 
           
AUC Glucose (mmol/l.min)           
  Baseline 40 146 (136)  40 144 (114)   
                
     
  Month 6 39 204 (158)  56 37 198 (124)  52   4.5 (27.1)  -49.5   58.5 0.868 0.779 
  Month 12 39 191 (181)  43 36 191 (170)  49  -5.6 (31.5)  -68.5   57.2 0.859 0.903 
  Month 24 37 218 (191)  67 31 277 (166) 130 -62.7 (37.7) -137.9   12.6 0.101 0.205 
           
AUC Insulin (nmol/l.min)           
  Baseline 40 38.0 (19.8)  40 39.5 (22.8)      
  Month 6 39 55.8 (37.9)  17.6 37 53.3 (36.6) 13.2   4.4 (7.4) -10.3   19.1 0.551 0.526 
  Month 12 39 49.5 (34.9)  11.2 36 46.3 (30.9)  7.2   4.0 (7.2) -10.4   18.4 0.581 0.560 
  Month 24 37 58.7 (31.9)  20.0 31 68.1 (47.1) 28.5  -8.5 (8.5) -25.4    8.4 0.317 0.618 
           
2-h response glucose (mmol/l)           
  Baseline 40 5.39 (1.33)  40 5.59 (1.15)      
  Month 6 39 5.69 (1.62) 0.24 37 5.82 (1.24) 0.30 -0.06 (0.30) -0.66   0.54 0.840 0.921 
  Month 12 39 5.75 (2.16) 0.31 36 5.75 (1.48) 0.23 -0.08 (0.38) -0.67   0.84 0.824 0.899 
  Month 24 37 6.09 (2.17) 0.62 31 6.60 (1.87) 1.10 -0.49 (0.44) -1.36   0.39 0.269 0.346 
           
2-h response insulin (pmol/l)           
  Baseline 40 336 (201)  40 364 (326)      
  Month 6 39 541 (536) 190 37 527 (427) 152  38.3 (110.1) -181.2   257.7 0.729 0.843 
  Month 12 39 525 (507) 172 36 435 (450)  60 112.8 110.1) -106.7   332.3 0.309 0.168 
  Month 24 37 584 (444) 229 31 556 (352) 170  58.9 (94.0) -128.8   246.7 0.533 0.546 
 
a     ANCOVA on changes from baseline, with factor treatment and baseline as covariate. 
b     Results of the Wilcoxon test (2-tailed) on change from baseline. 
c     Adj. Mean  ∆  are mean changes from baseline, adjusted for baseline differences between groups. 




Table 7.2.   Carbohydrate Parameters - Fasting Glucose, Insulin and HbA1C 
 
Parameter              IMPLANON            NORPLANT Group comparison  Implanon - Norplant 
                       ANCOVAa Wilcoxonb 
 N Mean(SD) adj.  
Mean ∆c  
N Mean(SD) adj.  
Mean ∆c 
estimate (SE)d 95% CI p-value p-value 
           
Fasting glucose (mmol/l)           
  Baseline 40  4.94  (0.39)  40  5.11  (0.48)      
  Month 6 39  4.93  (0.49) -0.05 37  4.85  (0.39) -0.20  0.15  (0.09) -0.03     0.33 0.095 0.030 
  Month 12 39  5.08  (0.61)  0.11 36  5.07  (0.47) -0.00  0.11  (0.11) -0.11     0.34 0.315 0.246 
  Month 24 37  4.93  (0.43) -0.03 31  4.95  (0.50) -0.09  0.06  (0.10) -0.14     0.26 0.562 0.228 
           
Fasting insulin (pmol/l)           
  Baseline 40 51.33  (54.24)  40 45.15  (24.07)      
  Month 6 39 43.38  (24.65)  -5.08 37 41.62  (24.04)  -6.59  1.50   ( 5.60) -9.67     12.67 0.789 0.670 
  Month 12 39 42.69  (37.32)  -6.04 36 49.14  (88.63)   0.54 -6.58  (15.61) -37.69   24.53 0.675 0.633 
  Month 24 37 72.54  (43.16) 23.84 31 60.45  (23.96) 13.70 10.14  ( 8.27) -6.37     26.65 0.224 0.216 
           
Fasting HbA1C (%)           
  Baseline 40  4.17  (0.47)  40  4.26  (0.40)      
  Month 6 39  4.32  (0.48)   0.13 37  4.27  (0.40)   0.05  0.08  (0.10) -0.11     0.27 0.395 0.251 
  Month 12 39  4.43  (0.57)   0.25 36  4.46  (0.51)   0.24  0.02  (0.11) -0.19     0.23 0.856 0.678 
  Month 24 37  4.39  (0.52)   0.22 31  4.26  (0.48)   0.04  0.19  (0.09)   0.01     0.37 0.044 0.014 
           
 
a     ANCOVA on changes from baseline, with factor treatment and baseline as covariate. 
b     Results of the Wilcoxon test (2-tailed) on change from baseline. 
c     Adj. Mean  ∆  are mean changes from baseline, adjusted for baseline differences between groups. 
d     Estimate of treatment difference for Implanon minus Norplant 
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Parameters  of  Thyroid  and  Adrenal  Function 
 
Thyroid Function (Table 7.3) 
Levels of thyroid hormones T3 and T4 displayed little change from baseline 
during IMPLANONTM use (Figure 7.6). A similar result was obtained for 
NORPLANT with regard to T3, but T4 was decreased by more than 10% at 
any treatment assessment (Figure 7.6). Inspection of the absolute mean 
values reveals that this decrease might have resulted from the relatively 
high baseline T4 values in the NORPLANT group. The between-group 
differences in change from baseline were approaching, or reaching, 
statistical significance at all time-points (respectively p-values at 6, 12, 24 
months and last measurement : 0.009, 0.062, 0.052 and 0.022) 
 
For TBG, a decrease was observed at 6 months for IMPLANONTM 
compared to baseline, followed by near-baseline values at 12 months and 
increased levels at 24 months; for NORPLANT a decrease was noted at 6 
and 12 months, while near-baseline values were reached at 24 months 
(Figure 7.7). The between-group differences were statistically significant at 
all assessments.  Resin uptake of free T3 appeared to be similarly elevated 
in both groups. 
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Adrenal Function  (Table 7.4) 
After a decrease from baseline observed at 6 and 12 months, median (total) 
cortisol levels had returned to baseline at 24 months and the last assessment 
in the IMPLANONTM group. In the NORPLANT group, decreases from 
baseline were noted at all time-points (Figure 7.8). The between group 
differences reached statistical significance at last measurement  (p=0.036). 
The levels of CBG showed increases from baseline with both 
IMPLANONTM and NORPLANT which were comparable, indicating that 
the differences in the cortisol levels cannot be explained by differences in 
the concentrations of its major binding  protein (Figure 7.8).  
 
IMPLANONTM and NORPLANT induced a comparable reduction in (total) 
testosterone levels. The major binding protein for testosterone, SHBG, was 
differently affected by the treatments (Figure 7.9). With IMPLANONTM, 
SHBG levels were reduced at 6 months and - to a lesser extent - at 12 
months, while at 24 months an increase was observed. With NORPLANT 
decreases from the baseline were noted at all assessments, and all were 






Albumin levels were slightly increased during both treatments, but never 
more than 5% (Table 7.5). Group differences did not reach statistical 
significance. 
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Figure 7.7 Changes in TBG Levels and T3–Resin Uptake in Implant Users  
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Figure 7.8 Changes in Plasma Cortisol and CBG Levels in Implant Users  
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Figure 7.9 Changes in Serum Testosterone and Plasma SHBG Levels in 
Implant  
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 IMPLANONTM  NORPLANT p-
value∗ 
   Absolute % change from 
baseline 
Absolute % change from 
baseline 
 
 N Mean SD Median Mean Median N Mean SD Median Mean Median  
T3  (nmol/l)              
    Baseline 40  1.60  0.28 1.60   40 1.59  0.37  1.60    
    Month 6 39  1.45  0.35 1.40 -7.62 -12.50 37 1.44  0.40  1.40  -4.32  -6.67 0.938 
    Month 12 39  1.67  0.37 1.70  6.07   6.25 36 1.65  0.36  1.60  10.89   2.63 0.992 
    Month 24 37  1.64  0.26 1.60  4.29   0.00 31 1.69  0.31  1.70  10.99   0.00 0.423 
    Last measurement 39  1.66  0.28 1.70  5.95   0.00 37 1.63  0.34  1.60   6.99  -5.56 0.876 
T4  (nmol/l)              
    Baseline 40 82.78 17.45 80.0   40 90.08 17.63  94.5    
    Month 6 39 81.49 16.18 77.0  2.10  -3.37 37 79.33 15.72  79.0 -11.78 -13.48 0.009 
    Month 12 39 82.00 16.28 83.0  4.10  -2.67 36 80.69 15.53  78.5 -10.36  -8.82 0.062 
    Month 24 37 79.19 13.57 79.0  1.70  -3.75 31 78.84 16.12  79.0 -12.37 -12.77 0.052 
    Last measurement 39 79.82 13.49 79.0  1.67  -3.75 37 78.97 16.45  77.0 -12.76 -12.77 0.022 
Resin T3 uptake 
(Uptake units) 
             
    Baseline 40 1.15  0.09 1.10   40 1.18  0.15  1.20    
    Month 6 39 1.34  0.25 1.30 17.62 25.00 37 1.31  0.28  1.30  12.43   9.09 0.340 
    Month 12 39 1.46  0.15 1.40 27.37 27.27 36 1.47  0.12  1.50  26.50  25.00 0.548 
    Month 24 37 1.40  0.15 1.40 22.50 18.18 31 1.42  0.17  1.40  21.90  18.18 0.916 
    Last measurement 39 1.41  0.15 1.40 23.45 23.08 37 1.41  0.19  1.40  21.46  25.00 0.779 
TBG  (µg/ml)              
    Baseline 40 25.09  5.07 23.85   40 26.58  4.62 26.58    
    Month 6 39 23.70  3.19 23.40 -4.58  -3.68 37 23.58  4.62 22.30 -10.40 -12.75 0.020 
    Month 12 39 25.16  3.51 25.80  1.68   1.92 36 24.41  3.52 25.10  -6.09  -7.42 0.029 
    Month 24 37 27.32  3.29 26.90  9.75 11.16 31 27.08  5.29 27.10   2.72   1.24 0.034 
    Last measurement 39 27.31  3.21 26.90 10.46 11.28 37 26.62  5.16 25.60   0.88  -1.63 0.008 
 
∗ Results of the Wilcoxon test on the percentage change from baseline 
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Table 7.4.    Parameters of Adrenal Function  (All-Subjects-Treated Group) 
 
Parameter  IMPLANONTM  NORPLANT p-value∗ 
   Absolute % change from 
baseline 
Absolute % change from 
baseline 
 
 N Mean SD Median Mean Median N Mean SD Median Mean Median  
Cortisol  (nmol/l)              
   Baseline 40 277.53 172.48 225.50   40 238.73 100.16 201.00    
   Month 6 39 211.41 100.48 191.00  -2.60 -20.39 37 192.54  98.17 166.00 -10.91 -21.79 0.823 
   Month 12 39 218.08  99.65 180.00   3.38 -14.97 36 185.75  91.69 165.00 -16.72 -30.40 0.282 
   Month 24 37 253.11 110.28 245.00 20.00   0.87 31 201.58  90.89 174.00  -8.60 -20.30 0.059 
   Last measurement 39 252.08 108.92 245.00 17.16  -2.72 37 186.68  90.36 169.00 -13.23 -24.90 0.036 
Testosterone (nmol/l)              
   Baseline 40   2.19   0.58   2.10   40   2.03   0.63   1.90    
   Month 6 39   2.02   0.56   1.90  -4.84 -14.29 37   2.07   0.67   1.90  14.77  -5.26 0.164 
   Month 12 39   1.80   0.85   1.60 -20.00 -20.00 36   1.65   0.61   1.60  -8.74 -17.16 0.445 
   Month 24 37   1.66   0.58   1.70   -23.93 -23.81 31   1.44   0.47   1.40 -20.10 -27.27 0.863 
   Last measurement 39   1.66   0.57   1.70 -23.64 -22.58 37   1.47   0.51   1.40 -19.67 -27.27 0.917 
CBG (nmol/l)              
   Baseline 40 574.68 131.70 625.00   40 570.88 136.21 596.00    
   Month 6 39 618.59 109.44 608.00  12.54   6.84 37 575.00  79.73 577.00   8.21   2.36 0.547 
   Month 12 39 645.51  98.87 654.00  17.21   8.62 36 626.08 149.76 620.00  15.15  11.34 0.746 
   Month 24 37 688.62  71.90 692.00  25.84  11.77 31 656.35  81.03 654.00  21.23  14.31 0.753 
   Last measurement 39 684.38  73.21 692.00  25.41  11.77 37 671.16 137.33 654.00  25.91  14.84 0.971 
SHBG (nmol/l)              
   Baseline 40  61.53  35.27  53.50   40  53.05  19.94  54.00    
   Month 6 39  35.36  20.81  29.00 -40.48 -44.12 37  22.57   7.23  22.00  -54.37 -53.85 0.004 
   Month 12 39  50.38  32.27  40.00 -11.71 -23.53 36  29.58   9.61  28.00 -40.52 -46.80 0.004 
   Month 24 37  72.97  60.59  53.00   23.98   4.49 31  42.13  15.75  37.00 -13.38 -17.07 0.014 
   Last measurement 39  71.74  59.54  53.00  23.20   4.49 37  40.65  15.21  36.00 -18.61 -25.00 0.002 
 













Parameter   IMPLANONTM   NORPLANT  
 N       Absolute % change from 
baseline 




  Mean SD Mean Median  Mean SD Mean Median  
            
Albumin  (g/l)            
    Baseline 40 45.70 3.11   40 44.78 2.19    
    Month 6 39 46.28 3.91 1.36 2.04 37 46.03 3.03 3.06 2.33 0.560 
    Month 12 39 46.82 3.05 2.48 2.27 36 46.31 2.30 3.45 4.35 0.671 
    Month 24 37 46.27 3.40 1.14 2.22 31 47.06 2.61 4.64 4.35 0.083 
    Last measurement 39 46.41 3.40 1.55 2.22 37 46.89 2.63 4.68 4.35 0.063 
            
 







Effects on carbohydrate metabolism 
Hormonal contraceptives remain one of the most effective reversible 
methods of family planning worldwide. Although first marketed in 
1957, it was not until the pioneering work of Waine et al (1963) that 
attention was drawn to the possible adverse metabolic effects of 
hormonal contraception.  In their studies, they reported alterations of 
carbohydrate metabolism from the use one of the first oral 
contraceptives (OC) which contained 150 µg mestranol and 10 mg 
norethynodrel. Since then, there have been innumerable studies of the 
effects of synthetic estrogens and progestins, alone and in combination, 
on carbohydrate metabolism. In early studies with combined oral 
contraceptives a consistent impairment of glucose tolerance was 
demonstrated by increases in fasting glucose and insulin levels, and the 
response of these parameters to a glucose challenge. Studies of the 
individual component steroids have suggested that these metabolic 
effects are related primarily to the progestogen in the pill (Spellacy, 
1976).  With changes in OC formulations, particularly by lowering the 
dose of each component, elevations in insulin and glucose levels have 
been minimized or eliminated entirely (Elkind-Hirsch and Goldzieher, 
1994). More specifically, as the progestin component was reduced in 
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low-estrogen formulations, there was a concomitant reduction in the 
alterations of carbohydrate parameters. 
 
Numerous studies haven examined the effects of progestins on glucose 
tolerance. High progesterone levels during the luteal phase (Jarret and 
Graver, 1968) or exogenously administered progesterone (Kalkhoff et 
al, 1970) have been associated with a deterioration of glucose tolerance 
and a decrease in insulin sensitivity. Progesterone and progestins appear 
to produce a mild but significant peripheral resistance to the 
hypoglycaemic effect of insulin. The degree of this change is dependent 
on the type of progestin, its dosage, and the frequency and the duration 
of its administration. Short-term studies with norgestrel, norethindrone 
and ethynodiol diacetate showed alterations in carbohydrate metabolism, 
whereas studies with megestrol did not (Spellacy et al, 1981). Studies on 
carbohydrate metabolism in women using OCs containing the “new” 
gonane progestins are conflicting. Luyckx et al (1986) compared the 
effects of a low-dose triphasic norgestrel containing OC to one 
containing desogestrel. They found a slight but significant deterioration 
of glucose tolerance with the former after 6 months of use, as assessed 
by the AUC during glucose tolerance testing. A large cross-sectional 
study of women receiving 9 different OCs (Godsland et al, 1990) 
revealed that the response of plasma glucose and insulin levels to an oral 
glucose tolerance test was greater with OC combinations containing 
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levonorgestrel than for those containing norethisterone or desogestrel. 
On the other hand, studies by van der Vange et al (1987) of women 
using seven different OC preparations consisting of a constant dose of 
ethinyl estradiol plus levonorgestrel, norethindrone, gestodene or 
desogestrel, showed no clinically significant changes in glucose 
tolerance after six months of use of any of them.  
 
As research continues on adverse metabolic effects of various hormonal 
contraceptives, so too are attempts to develop long-acting preparations 
and delivery systems, like contraceptive implants, that will improve 
effectiveness, safety and acceptability.  While the daily dose of 
progestogens in most orally administered products varies from 150 µg to 
2 mg, much lower daily doses of progestogens are released from these 
implants. In a study with NORPLANT implants, Konje et al (1992) 
found some alterations in carbohydrate metabolism occurring as early as 
one month after insertion but most marked by after 6 months of use. 
However, as with other progestin-only contraceptives, none of the 
glucose tolerance curves were either diabetic or suggestive of impaired 
glucose tolerance in these normal women. 
 
In our comparative study in 80 volunteers, the use of IMPLANONTM and 
NORPLANT, was associated with similar effects on carbohydrate 
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metabolism. For both IMPLANONTM and NORPLANT, the levels of 
HbA1c and fasting levels of glucose and insulin were constant over 
time, except for an increase in fasting levels at 24 months. These 
observations indicate that there has been no major change in glycaemic 
control during treatment. 
 
The results of the oral glucose tolerance tests at 6 and 12 months 
revealed, for both IMPLANONTM and NORPLANT, an about 5% 
increase in 2-hour glucose concentrations; at 24 months the increase was 
slightly larger, amounting to 12% for IMPLANONTM and 19% for 
NORPLANT. In all cases these values were well within the WHO 
criteria for normal glucose tolerance (WHO, 1980). The increase from 
baseline in incremental AUCs for glucose was more pronounced, 
amounting to 30-50% at 6 and 12 months; at 24 months an increase of 
90% was noted for NORPLANT. The incremental AUCs and 2-hour 
response for insulin were increased by about 50% by both types of 
implants. For all parameters studied, individual values outside the 
normal laboratory reference range were only occasionally observed. 
Statistically significant differences between IMPLANONTM and 
NORPLANT were not observed. 
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Interestingly, in a small non-comparative study with IMPLANONTM 
(N=25), for which 6 months results have been reported (Organon SDG 
files), no increase in glucose and insulin response was observed at 6 
months. Compared to baseline, mean values of glucose were similar, 
while those for insulin were even reduced by 20-30%. 
 
However, the findings in our study are in line with those reported by 
Konje et al (1991) for NORPLANT, where similar increases for 
glucose and insulin parameters were noted from 6-12 months treatment 
onwards. The results were confirmed by Shamma et al (1995) using the 
hyperglycaemic hyperinsulinaemic clamp technique. In contrast, Singh 
et al (1992) observed only small changes (about 15%) in 1-hour and no 
changes in 2-hour glucose responses when comparing treatment data up 
to 5 years with pre-insertion data. However, in their study a glucose load 
of only 50 G , instead of 75 G, was used, which could explain the 
differences with Konje et al (1991) and our comparative study. 
Significantly, in a subsequent study, Konje et al (1992) demonstrated 
that most changes in carbohydrate metabolism had reverted back to 
normal at 4 weeks after implant removal. 
 
While these effects are minimal, alterations in glucose and insulin levels 
per se are thought by some to increase cardiovascular risk (Haffner et al, 
1990). Consequently any lessening of carbohydrate and lipid metabolic 
184 
effects of contraceptive steroids is a prudent goal to pursue. As regards 
IMPLANONTM and NORPLANT implants, it can be concluded that 
both may induce mild insulin resistance but no significant change in 
glucose levels. These alterations in carbohydrate metabolism would 
have no clinical significance in the healthy women, but in women with a 
tendency to become diabetic, the changes may become clinically 
significant. 
 
Effects on thyroid function 
The effects of pregnancy and contraceptive steroids, especially estrogen 
therapy, on laboratory parameters of thyroid function are well known. The 
phases of normal menstrual cycle also exert detectable effects (Beck et al, 
1972). Thyroid studies performed during early clinical trials with oral 
contraceptives showed the expected changes due to estrogen induced rise 
in thyroid binding globulin (TBG). The progestins themselves appeared to 
have no effect on these laboratory parameters (Winikoff, 1968; Olsson et 
al, 1986). Goolden et al (1970) found that Progestin-only pills did not alter 
conventional plasma thyroid tests available at that time. Croxatto et al 
(1983) studied levels of T4, T3 and TSH in two groups of women, one 
using levonorgestrel releasing NORPLANT implants, and the other using 
a copper-IUD. They reported slightly lower levels of T3 in the 
NORPLANT implant group than in the IUD group.  T4 and TSH levels 
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did not differ significantly between the two groups. However, this was a 
cross-sectional study with sampling done after 37 months of use. In a 
longitudinal study over six months, Olsson et al (1986) found no change in 
thyroid function, except for the impact of a slight decrease in TBG level.  
 
In the present comparative study with IMPLANONTM and NORPLANT  
implants, no changes were noted in the levels of the thyroid hormones T3 
and T4.  In the NORPLANT  group, there was no change in T3 levels, but 
T4 was decreased during treatment. The between-group difference in T4 
was statistically significant at 6 and 24 months. TBG levels were 
transiently decreased with both treatments, but less pronounced in the 
IMPLANONTM group. The between-group differences were statistically 
significant at all time points. In both groups, an increase in resin uptake of 
free T3 was observed. However, it is important to note that at no time 
points, none of the thyroid function parameters  in either group, was 




Effects on adrenal function 
Synthetic progestins exhibit glucocorticoid-like activity that varies with the 
type of progestational agent and its concentration. The glucocorticoid 
activity may be of sufficient magnitude to exert a negative feedback effect 
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on the anterior pituitary, and cause a decrease in ACTH levels as well as 
lower cortisol levels. Natural progesterone is apparently devoid of 
glucocorticoid and negative feedback effect. In the present comparative 
study, mean cortisol levels tended to increase in IMPLANONTM users and 
were decreased in NORPLANT users. However, between-group 
difference was statistically significant only at the last (24 months) 
measurement.  
 
The results of the present study suggest that 3-keto-desogestrel, released 
from the IMPLANONTM implants, has negligible glucocorticoid activity 
and negative feedback effect on the pituitary. The increase in cortisol levels 
seen in IMPLANONTM users could be explained by a concomitant rise in 
CBG. CBG levels were increased in both groups. Ninety-percent of plasma 
cortisol is bound to CBG. This protein has high affinity but limited binding 
capacity. Complete saturation occurs at a plasma level of 20 µg/dl with 
about 10% free cortisol.  At higher concentrations free cortisol increases 
nonlinearly to about 30%, with the remainder being bound to albumin, 
which has low affinity but high capacity (Anderson, 1974).  Our results 
showed that albumin levels were minimally but non-significantly increased 
in both treatment groups. 
 
Only 1% to 3% of the plasma testosterone circulate in the biologically 
active, unbound form. Two circulating macromolecules bind sex steroids : 
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1) albumin, a low-affinity, high-capacity, binding protein, and 2) sex-
hormone-binding globulin (SHBG), a high-affinity, low-capacity binding 
protein that binds testosterone preferentially over estradiol (Anderson, 
1974). In women SHBG levels are two-folds greater than in men, and 
testosterone concentrations are much lower. Thus, in women, SHBG has 
many available binding sites. Estrogens stimulate and androgens inhibit 
SHBG production. Different progestational agents, depending on their 
intrinsic androgenicity, have different effects on SHBG production. 
Progesterone and synthetic pregnane derivatives do not have an effect on 
SHBG production, but synthetic progestagens derived from 19-
nortestosterone, decrease plasma SHBG levels. In the present study, 
compared with the IMPLANONTM group, SHBG levels were statistically 
significantly more decreased in the NORPLANT group, at all 
assessments. While in the NORPLANT group decreases from the baseline 
were seen at all time-points, in the IMPLANONTM users near-baseline 
values were seen at 12 months and increased levels at 24 months.  These 
findings are in accordance with the fact that 3-keto-desogestrel, released 
from IMPLANONTM implants, is significantly less androgenic than 
levonorgestrel, released from the NORPLANT implants. Total 
testosterone levels were reduced in both groups. This is believed to be 
mainly due to a fall in ovarian steroid production. 
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CHAPTER VIII :   EFFECT OF IMPLANONTM AND NORPLANT  
SUBDERMAL CONTRACEPTIVE IMPLANTS ON SERUM LIPIDS 
AND LIVER FUNCTIONS - A RANDOMIZED COMPARATIVE STUDY 
 
(a) The Objective  
 








 This chapter describes the results of a study of serum lipids and liver 
function in IMPLANON™ implant users compared to NORPLANT® users 
over a 2-year period. The serum lipid pattern in the IMPLANONTM users was 
not significantly different from that of the NORPLANT users.  There was 
slight decrease in HDL-cholesterol levels in both the groups but there were no 
significant changes in the HDL/total cholesterol ratio and the HDL / LDL ratio. 
Slightly elevated serum bilirubin and gamma-glutamyl transferase (GGT) 
levels, during the use of both the implants, suggested possible hepato-cellular 
dysfunction. However the mean value of these parameters were well within the 
normal clinical range.  
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CHAPTER VIII :   EFFECT OF IMPLANONTM AND NORPLANT  
SUBDERMAL CONTRACEPTIVE IMPLANTS ON SERUM LIPIDS 
AND LIVER FUNCTIONS - A RANDOMIZED COMPARATIVE STUDY 
 
(a)  Objective of the study 
The objective of the present study was to assess and compare the effects 
of IMPLANONTM and NORPLANT contraceptive implants on serum 
lipids and selected parameters of liver function. 
 
(b)  Subjects and Methods 
As described in Chapter VI, eighty healthy female volunteers were 
recruited for the study. The volunteers were randomized to receive either 
IMPLANONTM or NORPLANT implants, with 40 subjects in each arm. 
The study period was 24 months. Blood samples were drawn prior to the 
insertion of the implant and after 6, 12 and 24 months of use. The 
samples were obtained from fasting subjects, from the antecubital vein 
contralateral to the arm in which the implant or implants were inserted. 
The sera obtained were stored frozen in aliquots for the biochemical 
tests. The parameters evaluated were : 
(i) Serum Lipids  
Total Cholesterol (TC), High density lipoprotein cholesterol (HDL-C), 
Low density lipoprotein cholesterol (LDL-C), Triglycerides (TG), 
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Apolipoprotein A-I (Apo A-I) and Apolipoprotein B (Apo B) were 
estimated in each sample of blood.  
 
Total cholesterol, HDL-cholesterol and Triglyceride were measured by 
spectrophotometric analysis using a multipurpose auto-analyser, 
COBAS MIRA PLUS (Roche Diagnostic Systems, Basel, Switzerland). 
The kits used were from Boehringer Mannheim. LDL-cholesterol was 
calculated using the formula : LDL-C = TC - ( HDL-C + TG / 2.19) 
mmol/litre (Friedewald et al, 1982). The apolipoproteins (Apo A-I and 
Apo B) were measured by an immunoturbidimetric method using Cobas 
Mira Plus autoanalyser. The kits used were from Boehringer Mannheim. 




(ii)  Liver function  
Total bilirubin and unconjugated fraction; Albumin; Liver enzymes like 
Alanine transaminase (ALT), Aspartate transaminase (AST), Alkaline 
phosphatase (ALP), Gamma-glutamyl transferase (GGT) and Lactate 
dehydrogenase (LDH) were measured in each serum sample. Screening 
for Hepatitis-B surface antigen was done on the pre-insertion blood 
sample to identify positive cases. 
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Total and unconjugated bilirubin was estimated using simple 
photometry. For Albumin, the Bromocresol Green (BCG) Dye binding 
method was used. The Johnson & Johnson Vitros system was used for 
these measurements. The liver enzymes were measured by a rate assay 
method using the same Johnson & Johnson Vitros system.  Hepatitis -B 
surface antigen was detected using the MEIA (Microparticle Enzyme 




In each treatment group, comparison of changes from baseline were 
performed  for each assessment and for the last measurement using the 
Wilcoxon Matched-Pairs Signed-Rank test. Mann-Whitney U-test was 




(c )  Results 
In the IMPLANONTM group three subjects (7.5%) and in the 
NORPLANT group nine subjects (22.5%) discontinued during the study. 
Cumulative discontinuation rates and primary reasons for discontinuation 
have been presented earlier in Chapter VI. 
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Lipid metabolism  (Table 8.1a , 8.1b and 8.2) 
In the IMPLANONTM group, during the two-years of use, there were  
significant reductions in serum total cholesterol, HDL-cholesterol and 
LDL-cholesterol levels. A similar decrease was observed in the 
NORPLANT implant group. There were no statistically significant 
differences between the implant groups at any time period.  In both the 
groups, the decrease in these parameters was already apparent at six 
months of use. In the NORPLANT group there was also a significant 
decrease in serum triglycerides, while there was no significant change in 
the IMPLANONTM group (Figures 8.1 and 8.2). 
 
In both the implant groups, Apo A-I levels showed an initial decrease at 
six months of implant use, but the serum levels became near normal at 2 
years. There were significant increases in Apo B levels in both the 
groups, but the rise was only apparent after 1 year of use (Figure 8.3). 
There were no significant group differences in any of these parameters 
at any time period. 
 
The ratio HDL-C/TC ratio showed a significant increase (p= 0.03) in the 
NORPLANT group at 2-years, while there was no significant change in 
the IMPLANONTM group (Figure 8.4). There was no significant 
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difference between the groups at any point in time. The HDL-C/LDL-C 
ratio showed a decrease after 1year of use. The decrease was statistically 
significant in the IMPLANONTM group but was not so in the 
NORPLANT group. However, the HDL-C/LDL-C ratio returned back 
to pre-insertion levels in both the groups at 2 years (Figure 8.4). The 
Apo A-I /Apo B ratio decreased in both the groups, which reached high 
statistical significance from 1 year onwards (Figure 8.5). This was 
mainly secondary to a significant rise in Apo B level, rather than due to 
a decrease in Apo A-I levels (Figure 8.3). There was no significant 
difference between the groups in any of these ratios at any time period. 
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Figure 8.1 Changes in Serum Total Cholesterol and Triglycerides in 
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Figure 8.2 Changes in Serum HDL and LDL Levels in Implant Users   
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Figure 8.3 Changes in Serum Apolipoprotein A1 and B Levels in Implant 
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Figure 8.4 Changes in HDL/LDL Ratio and HDL/Total Cholesterol Ratio in 
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Figure 8.5 Changes in Apolipoprotein A1/ Apolipoprotein B Ratio in   
























 Table 8.1a      Changes in Selected Lipid parameters  
Parameter 
(mmol/L) 
                              IMPLANONTM                                   NORPLANT   p-valueb 
  Absolute (mmol/L) % change 
from 
baseline 






 N Mean SD p-valuea  N Mean SD p-valuea   
Total Cholesterol            
     Pre-insertion 40 5.36 0.86   40 5.49 1.01   0.198 
     6  months 39 4.88 0.77 0.000 -7.16 37 4.63 0.78 0.000 -14.75 0.206 
     12 months 39 4.82 0.82 0.000 -8.27 36 4.69 0.90 0.000 -14.07 0.470 
     24 months 37 4.72 0.58 0.000 -8.85 31 4.78 0.83 0.000 -10.65 0.786 
HDL Cholesterol            
     Pre-insertion 40 1.38 0.31   40 1.30 0.21   0.278 
     6  months 39 1.24 0.27 0.000 -9.24 37 1.14 0.18 0.000 -9.1 0.051 
     12 months 39 1.23 0.27 0.001 -9.59 36 1.12 0.22 0.000 -11.94 0.050 
     24 months 37 1.27 0.26 0.026 -5.78 31 1.21 0.20 0.087 -3.24 0.246 
LDL Cholesterol            
     Pre-insertion 40 3.55 0.79   40 3.75 0.96   0.397 
     6  months 39 3.38 0.74 0.049 -2.58 37 3.25 0.72 0.000 -11.73 0.581 
     12 months 39 3.40 0.74 0.232 -2.48 36 3.36 0.84 0.000 -9.43 0.811 
     24 months 37 3.19 0.54 0.027 -5.87 31 3.35 0.79 0.020 -6.9 0.698 
Triglyceride            
     Pre-insertion 40 0.88 0.33   40 1.09 0.47   0.013 
     6  months 39 0.82 0.39 0.065 -1.55 37 0.73 0.30 0.000 -26.89 0.444 
     12 months 39 0.78 0.26 0.014 -6.09 36 0.73 0.32 0.000 -30.25 0.201 
     24 months 37 0.86 0.35 0.795 2.25 31 0.80 0.34 0.000 -22.27 0.265 
 
a   Results of Wilcoxon signed rank test on change from baseline 
 









                              IMPLANONTM                                   NORPLANT   p-valueb 










 N Mean SD p-valuea  N Mean SD p-valuea   
Apolipoprotein A-1            
     Pre-insertion 40 121.70 20.55   40 121.17 13.48   0.896 
     6  months 39 111.68 13.88 0.002 -7.42 37 105.56 12.05 0.000 -11.96 0.041 
     12 months 39 116.58 14.52 0.084 -3.15 36 113.88 15.30 0.008 -5.48 0.277 
     24 months 37 119.17 20.75 0.672 -0.32 31 117.23 11.28 0.119 -1.97 0.213 
            
Apolipoprotein B            
     Pre-insertion 40 73.14 13.81   40 74.37 15.21   0.754 
     6  months 39 70.87 12.88 0.273 -0.74 37 69.71 16.33 0.001 -5.82 0.599 
     12 months 39 86.39 20.86 0.000 20.29 36 83.20 18.70 0.001 13.17 0.563 
     24 months 37 88.54 17.61 0.000 24.86 31 93.80 22.73 0.000 27.00 0.657 
            
 
a   Results of Wilcoxon signed rank test on change from baseline 
 









                              IMPLANONTM                                   NORPLANT   p-valueb 










 N Mean SD p-valuea  N Mean SD p-valuea   
HDL/TC ratio            
     Pre-insertion 40 0.26 0.05   40 0.24 0.05   0.108 
     6  months 39 0.26 0.06 0.219  37 0.25 0.05 0.182  0.640 
     12 months 39 0.26 0.05 0.199  36 0.24 0.05 0.626  0.248 
     24 months 37 0.27 0.05 0.667  31 0.26 0.05 0.033  0.479 
            
HDL/LDL ratio            
     Pre-insertion 40 0.41 0.13   40 0.37 0.11   0.225 
     6  months 39 0.39 0.12 0.089  37 0.37 0.10 0.803  0.614 
     12 months 39 0.38 0.11 0.031  36 0.35 0.10 0.451  0.367 
     24 months 37 0.41 0.12 0.934  31 0.38 0.11 0.410  0.325 
            
Apo A-I/Apo-B 
ratio 
           
     Pre-insertion 40 1.72 0.43   40 1.69 0.33   0.915 
     6  months 39 1.62 0.35 0.076 -5.81 37 1.58 0.36 0.076 -6.51 0.592 
     12 months 39 1.42 0.31 0.000 -17.44 36 1.43 0.35 0.000 -15.38 0.865 
     24 months 37 1.47 0.81 0.000 -14.53 31 1.31 0.28 0.000 -22.48 0.542 
 
a   Results of Wilcoxon signed rank test on change from baseline 
 
b   Results of Mann-Whitney U-test (2 unrelated samples non-parametric test) on group differences 
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Liver function  (Tables 8.3a and 8.3b) 
In both the implant groups, the most significant change was seen in the 
mean total and unconjugated bilirubin levels (Figure 8.6). At the end of 2 
years of use, the mean unconjugated bilirubin levels were more than seven-
folds greater than the mean pre-insertion levels for users of both type of 
implants (Table 8.3a). However, for none of the subjects at no sampling 
period, the total and unconjugated bilirubin levels exceeded the normal 
range in our population. 
 
The alanine transaminase (ALT) levels were significantly decreased in the 
NORPLANT group, while there was no appreciable change in the 
IMPLANONTM  group. On the other hand, the aspartate transaminase (AST) 
and lactate dehydrogenase (LDH) levels were significantly increased in the 
IMPLANONTM users during the first year of use which gradually returned 
towards pre-insertion values at 2 years (Figures 8.7 and 8.8). There was no 
consistent change in the levels of these two liver enzymes in NORPLANT 
users.  Alkaline phosphatase (ALP) levels decreased slightly in both the 
groups, although the reduction was only statistically significant in the 
NORPLANT group (Figure 8.8). The decrease was noted at all assessment 
periods following the implant insertion. In both the groups, the gamma-
glutamyl transferase (GGT) levels were significantly raised during the 
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implant use. The magnitude of the rise varied from 22.8 to 38.7 per cent 
above the pre-insertion baseline values (Figure 8.9).  Up to one year, the 
rise was significantly more in the IMPLANONTM users compared with the 
NORPLANT users. 
 
As discussed in Chapter VII there were no significant changes in serum 
albumin levels during the course of the treatment in any of the implant 
groups (Table 7.5).  
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Figure 8.6 Changes in Serum Total Bilirubin levels in Implant Users  
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Figure 8.7 Changes in Serum Tramnsaminase  (ALT and AST) Levels in  
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Figure 8.8 Changes in Serum Lactate Dehydrogenase (LDH) and Alkaline  
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Figure 8.9 Changes in Serum Gamma-glutamyl Transferase (GGT) Levels in  
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IMPLANONTM NORPLANT p-valueb 











 N Mean SD p-valuea  N Mean SD p-valuea   
Total Bilirubin (µmol/L)            
     Pre-insertion 40 3.42 1.64   40 2.25 0.54   0.001 
     6  months 39 6.71 4.18 0.000 108.31 37 5.75 4.92 0.000 149.54 0.050 
     12 months 39 9.59 3.95 0.000 215.42 36 9.58 4.76 0.000 331.71 0.717 
     24 months 37 9.32 4.32 0.000 196.01 31 9.26 3.98 0.000 317.20 0.975 
Unconjugated Bilirubin (µmol/L)              
     Pre-insertion 40 1.17 0.71   40 1.25 0.54   0.794 
     6  months 39 5.07 4.56 0.000 374.36 37 4.64 4.99 0.000 364.86 0.311 
     12 months 39 8.59 3.95 0.000 706.76 36 8.58 4.75 0.000 725.81 0.717 
     24 months 37 8.32 4.32 0.000 720.09 31 8.25 3.98 0.000 758.33 0.975 
Alanine transaminase (U/L)            
     Pre-insertion 40 23.80 11.85   40 23.80 8.14   0.546 
     6  months 39 20.94 14.90 0.089 -7.14 37 17.94 5.00 0.000 -19.46 0.983 
     12 months 39 23.61 12.69 0.576 7.10 36 15.30 3.29 0.000 -30.31 0.000 
     24 months 37 22.89 12.55 0.687 2.60 31 18.93 9.92 0.008 -15.83 0.041 
Aspartate transaminase (U/L)            
     Pre-insertion 40 21.3 9.41   40 21.60 7.06   0.334 
     6  months 39 23.74 8.70 0.032 21.02 37 19.16 3.79 0.214 -6.95 0.007 
     12 months 39 23.33 8.88 0.065 19.93 36 20.05 4.32 0.160 -2.56 0.152 
     24 months 37 20.59 6.74 0.402 5.23 31 21.77 7.31 0.749 4.67 0.367 
 
a   Results of Wilcoxon matched-pair signed-rank test on change from baseline 
 
b   Results of Mann-Whitney U-test (2 unrelated samples non-parametric test) on group differences 
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                              IMPLANONTM                                   NORPLANT   p-valueb 











 N Mean SD p-
valuea 
 N Mean SD p-
valuea 
  
Alkaline phosphatase (U/L)            
     Pre-insertion 40 66.50 43.03   40 67.70 17.36   0.129 
     6  months 39 60.05 20.00 0.504 -3.59 37 65.78 18.77 0.018 -3.95 0.169 
     12 months 39 59.25 17.24 0.376 -1.93 36 63.91 19.68 0.006 -6.08 0.364 
     24 months 37 59.51 18.63 0.431 -4.33 31 63.06 19.64 0.006 -3.11 0.509 
            
Gamma-glutamyl transferase (U/L)            
     Pre-insertion 40 25.05 19.52   40 18.60 6.00   0.039 
     6  months 39 33.69 27.91 0.000 37.38 37 21.94 8.25 0.001 22.80 0.002 
     12 months 39 33.00 26.03 0.000 38.67 36 23.16 6.89 0.000 32.04 0.008 
     24 months 37 33.10 28.78 0.000 36.06 31 24.83 7.52 0.000 38.28 0.229 
            
Lactate dehydrogenase (U/L)            
     Pre-insertion 40 449.35 152.47   40 387.97 66.59   0.006 
     6  months 39 511.92 137.51 0.001 18.47 37 405.54 58.37 0.091 5.74 0.000 
     12 months 39 488.23 125.80 0.001 14.56 36 392.25 59.20 0.665 1.43 0.000 
     24 months 37 436.05 85.02 0.441 2.43 31 401.90 120.32 0.890 2.74 0.010 
 
a   Results of Wilcoxon matched-pair signed-rank test on change from baseline 
b   Results of Mann-Whitney U-test (2 unrelated samples non-parametric test) on group differences
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 (d) Discussion 
Lipid metabolism 
Increased risk of coronary heart disease (CHD) is associated 
epidemiologically with elevated concentrations of total plasma 
cholesterol (TC) and low-density lipoprotein cholesterol (LDL), 
decreased plasma concentration of high-density lipoprotein cholesterol 
(HDL) and, in some circumstances, high levels of triglycerides (TG). 
Because of this relationship, and because clinical studies have shown 
that estrogen, progestins and androgens influence lipoprotein 
metabolism, the study of the effects of steroidal contraceptives on the 
lipid metabolism has generated intense interest. According to a number 
of studies, the use of combined OCs is associated with a small increase 
in risk for cardiovascular disease (Slone et al, 1981; Vessey et al, 1989). 
Initial drug safety reports indicated that the risk was primarily related to 
the estrogen dose (Meade et al, 1980), until it was recognized that the 
progestogen component possibly plays an important role in lowering 
HDL levels (Wynn and Niththyananthan, 1982). Estrogens increase 
HDL-cholesterol and TGs, whereas progestogens increase LDL-
cholesterol and decrease HDL-cholesterol. However, the ultimate effect 
of synthetic progestogens depends on the dose and the intrinsic 
androgenic properties of the progestogen used (Oster et al, 1982; Wahl 
et al, 1983). When combined with 30 µg of ethinylestradiol, oral 
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levonorgestrel is associated with an increase in LDL-cholesterol and a 
decrease in HDL-cholesterol levels  (Godsland et al, 1990; Notelovitz et 
al, 1989).  In contrast, levels of HDL-cholesterol in women taking 
desogestrel combinations were increased and LDL-cholesterol levels 
were unchanged (Crook et al, 1993; Godsland et al, 1994). This could be 
due to the fact that desogestrel is less androgenic compared to 
levonorgestrel. Studies with levonorgestrel releasing subdermal implants 
(NORPLANT and NORPLANT-2) show that they are associated with 
significant lowering of total cholesterol, triglycerides and LDL-
cholesterol (Singh et al, 1992a; Singh et al, 1992b; Singh and Ratnam, 
1997). However, there is also an associated decline in the HDL-
cholesterol levels which gradually returns back to normal with 
continued use. Our results in the NORPLANT users were similar 
(Table 8.1a). The serum lipid pattern in the IMPLANONTM users was not 
significantly different from that of the NORPLANT users, except that 
there was no significant reduction of triglyceride levels over two years 
in the IMPLANONTM users (Figures 8.1 and 8.2).  
 
The relationship of total cholesterol and the proportion of cholesterol in 
individual lipoprotein classes to coronary heart disease are complex. To 
help simplify these relationships, cholesterol values are often combined 
into one summary estimate to form a single risk factor with a 
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relationship to disease that is more easily described (Castelli et al, 
1983). A low HDL / total cholesterol ratio (<0.2) and a low HDL/LDL 
ratio (<0.3) have been found to be strongly associated with an increased 
risk of coronary heart disease (Kinosian et al, 1994; Kinosian et al, 
1995). In our study, for both the implant groups, there were no 
significant changes in the HDL/total cholesterol ratio and the HDL / 
LDL ratio, in spite of a lowering of the serum HDL levels. In both the 
groups, the HDL / total cholesterol ratio remained well above 0.2 and 
the HDL / LDL  ratio was above 0.3 at all sampling time (Figure 8.4). 
These results suggest that, like NORPLANT, use of IMPLANONTM 
implants is unlikely to contribute directly to any increased cardio-
vascular risk.  
 
Lipoprotein(a) or Lp(a) is a lipid-protein complex involved in the 
transport of cholesterol in the circulation. Lp(a) is composed of low-
density lipoprotein (LDL) attached to large glycoproteins, the 
apolipoproteins. As mentioned earlier, LDL itself is believed to play a 
major role in the development of atherosclerosis. LDL consists of a 
heterogeneous mixture of spherical particles containing a neutral lipoid 
core (primarily cholesteryl esters) surrounded by phospholipids, 
unesterified cholesterol, and protein. In recent years, researchers have 
focused on the apolipoprotein component of Lp(a) and have found that 
these lipid-protein complexes are independently associated with 
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atherosclerosis, thrombosis and CAD (Harduin et al, 1993). The major 
apolipoproteins present in Lp(a) are the apolipoprotein B and 
apolipoprotein (a). Apo-B is the portion of the Lp(a) molecule (the 
ligand) that is recognized by the receptor. Other lipid and apolipoprotein 
components may vary considerably in the LDL complex, but they all 
interact to maintain the apo-B molecule in a specific spatial orientation 
for receptor binding. The second major Lp(a) apolipoprotein is the apo 
(a), which has been described as a giant mutant of plasminogen. This is 
because approximately 80% of the amino acid sequence of the apo (a) is 
identical to that of plasminogen. Because of this homology, apo (a) is 
able to competitively inhibit the surface binding and activation of 
plasminogen. Blocking plasminogen activation prevents the formation 
of plasmin, a crucial component of clot lysis. Plasmin is also involved in 
the activation of a compound referred to as latent transforming growth 
factor-b (TGF-b), a potent inhibitor of smooth muscle cell growth in the 
vascular endothelium (Harduin et al, 1993; Grainger et al, 1993). The 
homology of apo (a) with plasminogen, with subsequent inhibition of 
plasminogen activation, could contribute to atherosclerotic plaque 
formation by two mechanisms : it prevents the activation of TGF-b, 
allowing smooth muscles to proliferate in the vascular endothelium, and 
it prevents clot lysis, adding fibrin and other debris to the growing 
atherosclerotic plug. Apolipopotein A-I (Apo A-I) is the major 
constituent of the HDL particle which is responsible for removing 
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excess cholesterol from the circulation. Like HDL-cholesterol, higher 
levels of Apo A-I is believed to be cardio-protective and reduces 
atherogenous risk. 
 
Since progestins are known to alter lipid metabolism, it is important to 
study the effects of long-term use of progestin releasing contraceptive 
implants like the NORPLANT or the IMPLANONTM  system on major 
apolipoproteins. Very little data is available on the effects of progestin 
releasing implants on these lipoproteins. A 2-year follow-up study with 
NORPLANT-2 users found that both Apo A-I and Apo B levels 
decreased significantly. At the end of 2 years, Apo A-I and Apo B levels 
were reduced by 23% and 27% respectively (Rabe et al, 1992). The 
available data on the effect of Implanon on apolipoproteins is 
conflicting. Masceranhas et al (1998) reported a decline in both Apo A-I 
and Apo B levels and a corresponding decrease in Apo A-I/Apo B ratio 
during the first 12 months of use in 30 Implanon users. Suherman et al 
(1999) did not find any significant change in Apolipoprotein levels over 
36 months of Implanon use in 45 users. Our results appear to be 
different from the previous studies. The results show that, in both 
Implanon and Norplant users, Apo A-I levels decrease initially (at 6 
months) but recover subsequently to reach near pre-insertion levels at 
two years of use. However, there was a significant rise in Apo B levels 
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in both the groups. After 2 years of use, the increase in Apo B levels 
was of the order of about 25% in Implanon users and 27% in Norplant 
  users.. Such increase in Apo B levels was paradoxical and resulted in a 
significant lowering or worsening of the Apo A-I/ Apo B ratio 
(atherogenous risk ratio).  These results may reflect population, dietary 
or ethnic differences compared to subjects in other studies. It is to be 
noted that our subjects had relatively higher body-mass index (BMI), 
pre-insertion cholesterol and LDL levels.  
 
Based on the results of the available studies, including the present one, it 
is difficult to conclude whether Implanon has any clinically meaningful 
effect on lipid metabolism in healthy women 
 
Liver function 
Although liver is not a classical target organ for sex steroids, it is 
influenced by sex steroids in numerous ways. This is true for both its 
morphological and functional aspects. The liver is inevitably more 
involved when the steroids are administered orally, due to the first-pass 
effect after oral ingestion. In non-enteral forms of steroidal 
contraception e.g. Injectables, implants etc., the impact on hepatic 
metabolism is less pronounced. 
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Long term studies with levonorgestrel implants, NORPLANT and 
NORPLANT -2, have shown that besides a significant increase in serum 
bilirubin there are no other significant changes in liver function to 
suggest possible hepatocellular dysfunction at the end of five years 
(Shaaban et al, 1984; Shoupe and Mishell, 1989; Singh et al, 1992 a and 
b).  Bala et al (1991) reported that there were no changes in hepatic 
tranaminases on short-term or long-term use of NORPLANT-2. In our 
study, a significant rise in total and unconjugated bilirubin level was 
observed in both IMPLANONTM and NORPLANT users. In both the 
groups, the rise was significant from 6 months assessment onwards. No 
significant difference was observed between the groups in the hepatic 
transaminases (AST and ALT) and in alkaline phosphatase (ALP) 
levels. There was a significant increase in gamma glutamyl transferase 
(GGT) levels, in both the groups of implant users, noticeable from 6 
months onwards. However, the raised mean levels of bilirubin and GGT 
remained within the normal range for the local population. It appears 
that there may be mild hepatocellular dysfunction associated with the 
use of both IMPLANONTM and NORPLANT , which is possibly of no 
clinical consequence to the healthy acceptor. However, caution should 
be exercised in using these implants in the women with pre-existing 
liver disease. 
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CHAPTER IX  :  STUDY OF SERUM LEVELS OF ETONOGESTREL 
(3-KETO-DESOGESTREL) IN HEALTHY SINGAPOREAN WOMEN 
USING IMPLANONTM IMPLANTS OVER A TWO-YEAR PERIOD 
 
 
(a) The Objective  
 










 This chapter presents the results of a small non-comparative study of serial 
serum 3-keto-desogestrel (etonogestrel) in 10 IMPLANON™ users over a 2-year 
period. In all the subjects, at all time points, the serum levels were well above the 






CHAPTER IX  :  STUDY OF SERUM LEVELS OF ETONOGESTREL 
(3-KETO-DESOGESTREL) IN HEALTHY SINGAPOREAN WOMEN 
USING IMPLANONTM IMPLANTS OVER A TWO-YEAR PERIOD 
 
(a)   Objective of the study 
The objective of this small study was to evaluate the serum 
concentration of etonogestrel (3-KDG) released from a subdermal 
IMPLANONTM implant as a function of time during two years after 
implant insertion. 
 
(b)       Experimental design and selection of cases 
This was an open non-comparative study of serial serum levels of 
etonogestrel in 10 healthy Singaporean subjects using IMPLANON™ 
implants. The study period was 24 months. The subjects were aged 
between 18 and 40 years; sexually active and of childbearing potential; 
good physical and mental health; normal menstrual cycles with a mean 
length of between 24-35 days and an intra-individual variation of at most 
plus or minus three days and body weight between 80%-130% 0f ideal 
body weight. The criteria used for selection of cases have been described 





A total of 10 subjects were enrolled and had IMPLANONTM implant 
inserted. A 10 ml blood sample was drawn prior to the insertion of the 
implant. Additional blood samples were obtained every 3 months after 
implant insertion (i.e. 3, 6, 9, 12, 15, 18, 21 and 24 months) and just prior 
to removal of the implant.  
 
Serum etonogestrel (3-keto-DSG) were determined by using radio-
immunoassay(RIA), after C18 solid-phase extraction. This was carried out 
at the Department of Drug Metabolism and Kinetics, NV Organon, Oss, 
The Netherlands. 
 
Summary of Etonogestrel assay procedure 
Bound etonogestrel was first released from carrier proteins by acid 
treatment (0.05mol/L HCL). Then the sample was extracted 
automatically on a C18 solid-phase column, using Gilson ASPEC XL 
workstation. The eluate obtained was evaporated to dryness and the residue 
was dissolved in 0.02 mol/L phosphate buffer, containing 1% BSA. 
Finally, etonogestrel was quantitated in duplicate by RIA, using 200 µL 
aliquots. Rabbit antiserum against Etonogestrel-3-O-CMO-BSA (Organon, 
R83-2198TO) and [3H].-etonogestrel were used. Tracer bound to anti-
etonogestrel was separated from unbound tracer using cellulose-coated 
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donkey anti-rabbit immunoglobulin. After precipitation of the second 
antibody complex, radioactivity (i.e. the unbound tracer) was determined in 
the supernatant. Etonogestrel concentrations in study samples were 
calculated from a standard curve that was included in each assay run. 
 
The acceptance limits were normal concentration ± 20% and the lower 
limit of quantitation of the assay was established at 20.0 pg/mL (the lowest 
standard concentration). Blank human serum samples (Q0) and blank 
human serum samples spiked with etonogestrel at three different 
concentrations (Q1 = 32.5 pg/mL, Q2 = 81.0 pg/mL, and Q3 = 325 pg/mL) 
were included in each run as quality control samples, to monitor assay 
performance during the study. 
 
(d)   Results 
A total of 10 subjects were enrolled for the study and had IMPLANONTM 
implant inserted. One subject discontinued the study due to bleeding 
irregularities (prolonged menstrual flow) after 15 months of use. No 
serious AE (adverse experiences) were reported during the study. 
 
 Descriptive statistics of the best-fitted etonogestrel concentrations (pg/mL) 
due to its release from the implant are presented in Table 9.1. During the 2-
year study period the mean etonogestrel serum concentration was found to 
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decrease with time from approximately 330 pg/mL (range: 199 through 
453 pg/mL) after 3 months to 220 pg/mL (range: 143 through 362 pg/mL) 
after 2 years with the implant in-situ. 
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Table 9.1 Serum concentrations (pg/ml) of etonogestrel released from IMPLANON™ implants 
 
 Number of months with the implant in situ 
 3 6 9 12 15 18 21 24 
n 10 10 10 10 10 9 9 9 
Mean 330 311 291 273 254 249 234 220 
SD 85 77 76 77 80 75 73 72 
Lowest 199 201 195 177 151 178 165 143 




(e)  Discussion 
Etonogestrel serum concentrations during the use of IMPLANONTM 
implants have been followed in a number of pharmacokinetic studies in 
Thailand, Indonesia, Finland/Sweden, China and the USA (NV Organon 
data on file). In all studies the time course of etonogestrel serum 
concentrations was similar, starting with a fast decline followed by a more 
gradual decrease. Stable etonogestrel concentrations were maintained from 
between 1 and 1½ years onwards. Similar results were seen in our small 
study, with mean serum etonogestrel levels of  273, 249 and 220 pg/mL at 
the end of 1, 1½ and 2 years respectively. 
 
An absolute bioavailability study of etonogestrel in women treated with 
IMPLANON™ has been completed recently (NV Organon data on file). 
Based on the preliminary results of plasma clearances of etonogestrel and 
of plasma concentrations it was calculated that the in-vivo release after 3 
months amounted to 60 µg/day and after one year to 46 µg/day. Declining 
plasma concentrations of etonogestrel from 290 pg/mL to 230 pg/mL were 
measured after a treatment period of 3 months and one year, respectively. 
These results are comparable to that found in our study.  
 
Early studies (Olsson et al, 1990; Diaz et al, 1991) indicated that 
etonogestrel serum concentration of > 90 pg/mL is needed to obtain 
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consistent ovulation inhibition. In our study, serum etonogestrel 
concentration, at the end of 2 years, was well above that level (minimum of 
143 pg/mL) in all cases (Figure 9.1). In fact, in various pharmacokinetic 
studies where IMPLANON™ implants were used for more than 2 years, 
the plasma concentrations were, in general, around 160 pg/mL at the end of 
the third-year. These results suggest that the implants are like to be 


















CHAPTER X  -  CONCLUSIONS 
 
Hormonal contraceptives have been more widely studied and intensively 
researched than any other medicinal agent in history. After more than forty 
years of evolution, the field of steroidal or hormonal contraception has matured 
considerably. A great deal has been learned about the ways such agents should 
be developed and tested, and what improvements would yield practical benefit. 
The overriding importance of factors which improve compliance, whether 
pharmacological or socio-cultural, is clear. 
 
When hormonal methods of fertility control were first introduced in the 
developing world it was not appreciated how strongly cultural, socio-economic, 
and psychological factors could interfere with the overall acceptability and use-
effectiveness of a contraceptive regimen. This lack of appreciation caused the 
practical failure of many international efforts to organize family planning in 
various areas of Asia or Africa. The need for acceptable, safe and effective 
forms of long-term hormonal methods of contraception stems from these 
considerations. In order to obtain a prolonged duration of action of a steroid 
hormone, three major approaches have been used. First, a novel molecule can 
be synthesized e.g. fatty acid esters of steroids or enol-ether derivatives. A 
second approach involves change in the physical form of the steroid that allows 
slow dissolution at the site of injection, such as the formulation of 
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medroxyprogesterone acetate as microcrystals. The third option is the use of 
polymeric devices, non-biodegradable or biodegradable, implanted 
subcutaneously or administered as an injection and capable of releasing the 
active compound during matrix erosion or by diffusion across the polymeric 
membrane. NORPLANT® was the first of these polymeric implants which has 
now been registered in over 60 countries, both developing and developed, and 
has been used by approximately seven million women world-wide. Norplant-II 
(Jadelle®), a second generation 2-rod system, has recently received FDA 
approval in the US. Both of these release levonorgestrel, which is a 19-
nortestosterone derivative. IMPLANON™ is a third generation single-rod 
implant system releasing the active metabolite (3-ketodesogestrel or 
etonogestrel) of one of the “newer” progestogens, desogestrel. It has been 
designed to release approximately 60 µg/day of 3-ketodesogestrel which would 
provide effective contraception for at least 2 years and possibly, for 3 years.  
 
One of the major advantages of 3-ketodesogestrel is that, being a gonane 
derivative, it is less androgenic than levonorgestrel, which is 19-nortestoterone 
derivative. Consequently, it was believed that a 3-ketodesogestrel releasing implant 
would produce less androgenic side-effects like acne, increased hair growth, oily 
skin etc. In addition, at least in theory, it should have less long-term adverse effects 
on the lipid profile and therefore, lesser cardio-vascular risk than levonorgestrel 
implants. A second perceived disadvantage of NORPLANT® is the difficulty and 
discomfort associated with the insertion and removal of six implants. Both 
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insertion and removal, especially the latter, could be time consuming and requires 
a fair amount of training. Complications of insertion and removal of 
NORPLANT® have recently led to a number of law suits in the United States, 
which has generated considerable controversy. It would appear that a fair measure 
of the problems stemmed from insufficient training in insertion and removal 
techniques and inadequate counselling regarding the side-effects of the implants. 
IMPLANON™ being a single-rod system, is significantly easier and quicker to 
insert and the same applies to the procedure of removal of the implant. In addition, 
insertion of NORPLANT® requires some amount of handling of the implants, 
thereby increasing infection risks if proper aseptic techniques are not strictly 
adhered to. IMPLANON™, on the other hand, is pre-packaged into the insertor 
needle and insertion involves no handling of the implant. 
 
The results of the various studies conducted by the author in Singapore clearly 
demonstrates the effectiveness, acceptability and comparative medical safety of 
IMPLANON™ contraceptive system in this population. In all these aspects it 
compares well with the available contraceptive implant system i.e. NORPLANT®. 
The contraceptive efficacy of IMPLANON™, over the period of its intended use, 
is comparable to that of the most effective female methods – sterilisation, the 
Copper T380 intrauterine device, the levonorgestrel releasing IUD, as well as that 
of NORPLANT®.  The high efficacy is due to the fact that 3-ketodesogestrel 
prevents pregnancy by at least three mechanisms: 1) inhibiting ovulation; 2) 
preventing normal sperm transport through the female genital tract, particularly 
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through the cervix;  and 3) retarding development of the normal secretory 
endometrium. Studies done elsewhere have confirmed its excellent reversibility. 
 
The major advantage of IMPLANON™ implants is its medium-term (2 years) 
unattended use after a single clinic visit. The major disadvantage is the 
accompanying disturbance of the menstrual cycle bleeding. Infrequent bleeding 
and amenorrhoea seem to be more common in IMPLANON™ users compared to 
NORPLANT® users. The excellent continuation rate seen in our study suggests 
that menstrual disturbances may not be a major problem hindering the 
acceptability of the implant.  
 
Our study showed a comparable general safety profile for both IMPLANON™ and 
NORPLANT® implants, in terms of both incidence and type of adverse 
experiences (AEs). The metabolic studies included in this thesis reveal only 
minimal, inconsistent and probably inconsequential changes in carbohydrate 
metabolism, thyroid, adrenal and liver function. The study of serum lipids shows a 
lowering of triglycerides, cholesterol and LDL and HDL concentrations. There 
was little change in high density lipoprotein/ total cholesterol and HDL/LDL 
ratios, which might imply that IMPLANON™ should not aggravate risk factors for 
atherosclerosis. However, our study found a small increase in Apo-B levels at the 
end of 2 years in both both Implanon and Norplant users. Such increase in Apo 
B levels was paradoxical and resulted in a lowering or worsening of the Apo A-
I/ Apo B ratio (atherogenous risk ratio).  These results may reflect population, 
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dietary or ethnic differences compared to subjects in other studies. Overall, the 
comparative paucity of major-side side-effects combined with its high efficacy, 
easy insertion and removal procedures, and reversibility, would make 
IMPLANON™ a highly acceptable contraceptive choice. 
 
It would appear that the IMPLANON™ contraceptive implants : 
1. Approaches the “ideal” contraceptive method for women who want a 
medium term (2 to 3 years) reversible method for birth spacing 
2. Provide an effective alternative for a woman, who has completed her 
family but does not want a permanent method such as sterilisation. 
3. Provide a method for women who do not entail taking contraceptive action 
either daily or before sexual intercourse 
4. The estrogen free composition of the implant would have a special 
appeal for women seeking contraception during lactation; for women for 
whom pills containing estrogens may be contraindicated; and for women 
seeking hormonal contraception who for logistic or motivational reasons 
are unsuccessful in using oral or injectable contraceptives over a long 
period of time. 
5. The single-rod system would be attractive to a woman who is motivated 
to use an implant but is anxious about the insertion and removal 






1. Counselling and Training. 
Following the introduction of IMPLANON™ implants in to the Family 
Planning services, adequate counselling for both the user and the service 
provider would be essential. 
i) Counselling of women 
Counselling is the key to ensure that the woman (and preferably the 
couple) make an appropriate contraceptive choice and that she learns to 
use the particular contraceptive method chosen safely and effectively. It 
is therefore essential that the woman is instructed in how the implant 
will be inserted and the care that must be taken to avoid any local 
infection in the early stages after insertion.  
 
A critical aspect in counselling regarding IMPLANON™ implants 
would be to explain to the couple that the commonest side effect is a 
change in menstrual bleeding pattern. The problem is no different to that 
which occurs with NORPLANT® implants and progesterone-only pills. 
 The first approach should therefore be counselling and reassurance. The 
woman should be told, both in advance and at the time, that in absence 
of other causes such as an infection which can be checked, this type of 
bleeding is not harmful even if prolonged for a few weeks. If however, 
the woman is not satisfied even after reassurance, she may be helped to 
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continue using the implants by prescribing a short course of one to three 
cycles of a combined low estrogen (30-35 µg ethinylestradiol) oral 
contraceptive. The experience in China with NORPLANT® implants 
has shown that the variation in discontinuation rate because of menstrual 
problems, at different centres in different phases, seems to be 
attributable more to the growing experience of staff and to a consequent 
difference in counselling than to any inherent population differences. 
 
ii) Counselling and training of service providers 
Since the insertion of the single-rod IMPLANON™ implant is a 
relatively simple procedure, it should be possible to train paramedical 
personnel in implant insertion. However, it is essential that adequate 
instruction is given to both the medical and paramedical provider 
personnel. In the case of NORPLANT® implants, experience over the 
past 10 years in Indonesia, with a competency based training (CBT) 
method has been particularly helpful. The method involves breaking 
down particular clinical skills to be taught into their essential component 
steps. Each step is then analysed to determine the most efficient and 
effective way to perform and learn the technique. Videos and/or 
anatomic models are very useful for this purpose. The same can be used 




2. Post-marketing surveillance 
Before a drug is marketed and is made widely available, it is difficult to 
generate enough information on rare or long-term side effects. 
Therefore, once the IMPLANON™ implant is marketed, appropriate 
surveillance activities have to be developed to evaluate its long term 
safety. This should be in the form of a well-organised, large, multi-
centric, controlled, long-term observational study.  In this context, of 
particular concern is the recent controversy regarding the venous 
thrombogenic risk of combined oral contraceptives containing the 
“newer” or third-generation progestogens, desogestrel and gestodene. 
Recent studies have indicated that women taking oral contraceptive pills 
containing the third generation progestogens had twice the risk of 
venous thromboembolism (VTE) compared with women taking OCs 
containing similar doses of estrogens but combined with second-
generation progestogens such as levonorgestrel (WHO Study, 1995; 
Bloemenkamp et al, 1995; Jick et al, 1995; Spitzer et al, 1996). Since 
then, the findings of these four studies have been scrutinised, and other 
investigators have suggested that confounding, bias, or both, may 
account for some of the apparent differences in incidence of VTE 
(Editorial, 1995; MacRae and Kay, 1995; Watt, 1995). An examination 
of factors not included in these recent studies has identified at least three 
potential biases that should be considered: 
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a) Prescription bias:  The third-generation OCs have been more 
extensively used by younger women, for shorter period of time, 
and by women with risk factors for thromboembolism than the 
second-generation OCs. 
b) Healthy user effect:  Women who were more susceptible to VTE 
have left the cohort of users of second generation OCs. The 
women who were left in the cohort, who are included in the 
recent studies, are less susceptible to VTE than those making up 
the cohort of women using third-generation OCs. 
c) Referral bias:  Women with risk factors for thromboembolism, 
who disproportionately receive third-generation OCs, are more 
likely to be referred to hospitals for possible symptoms of VTE. 
Thus, users of third-generation OCs have the potential to be 
over-represented among cases. 
 
None of the recent epidemiologic studies have been able to adjust for 
these three major biases. These biases are likely to contribute to, or even 
totally account for, the small increased risk of VTE observed for users 
of third-generation OCs when compared to that for users of second-
generation OCs (Rekers et al, 1996). This contention is further 
strengthened by another recent case-controlled study which showed a 
higher risk of venous thromboembolism associated with OCs 20 µg EE 
and desogestrel compared with 30 µg EE / desogestrel pills (Farmer et 
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al, 1996). The authors of this study themselves conclude that such an 
association is biologically implausible and is likely to be the result of 
preferential prescribing and thus, confounding. Interestingly, the 
absolute risk of VTE among OC users in general is lower in the new 
studies than in previously published studies. On the other hand, there is 
evidence of a decreased risk of acute myocardial infarction among users 
of third-generation compared with users of second-generation OCs 
(Lewis et al, 1996). Although the difference was not statistically 
significant, the results indicate a nearly three-fold difference. Acute 
myocardial infarction is not as common as VTE among young women, 
but the case fatality rate is higher. 
 
The apparent increased risk of VTE suggested by these four new studies 
(WHO Study, 1995; Bloemenkamp et al, 1995; Jick et al, 1995; Spitzer 
et al, 1996) cannot be explained by the differences in haemostatic 
changes reported in oral contraceptive users. Small differences in 
haemostatic variables have been found between women taking 
levonorgestrel combination and women taking desogestrel or gestodene 
combination by some authors (Bonnar et al, 1992; Weinges et al, 1995), 
but these changes were well within the wide range found in normal 
population. Others have found no differences in haemostatic and 
fibrinolytic factors between these pill types (Cohen et al, 1988; David et 
al, 1990). Although the issue of changes in haemostatic system 
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associated with the use of IMPLANON™ implants has not been 
addressed in this thesis, studies done elsewhere has shown no significant 
alteration in coagulation and fibrinolytic factors (data on NV Organon 
file). In addition, there has been no report of VTE in any of the 
completed or on-going studies with IMPLANON™ implants. Hence, the 
results of the four studies suggesting an increased risk of VTE 
associated with OCs containing third-generation progestagens, should 
not prejudice in any way the marketing and prescription of this new 
contraceptive implant. However, this further highlights the importance 
and the necessity of careful post-marketing surveillance and on-going 
epidemiologic studies. 
 
This thesis has highlighted the attributes of a very important new method of 
contraception. It is not ideal for everyone, but it is suitable to be made available, 
with good client information and provider training, as a first choice 





1. Adlercreutz H, Pulkkinen MO, Hinen EK, Korpela JT. Studies on the role 
of intestinal bacteria in metabolism of synthetic and natural steroid 
hormones. J Steroid Biochem 1984; 20: 217-29. 
 
2. Alvarez-sanchez F, Brache V, Faundes A.  Recent experiences with and 
future directions of contraceptive implants and injectable contraceptives. 
Curr Opin Obstetet Gynecol 1993; 5: 805-14. 
 
3. Anderson DC.  Sex-hormone binding globulin.  Clin Endocrinol 1974; 3: 
69.  
 
4. Back DJ, Grimmer SFM, Shenoy N, Orme ML’E. Plasma concentrations 
of 3-keto-desogestrel after oral administration of desogestrel and 
intravenous administration of 3-keto-desogestrel. Contraception 1987; 35: 
619-26. 
 
5. Bala Y, Dhall GI, Majumdar S. Short-term and long-term effects of 
Norplant-2 on plasma lipoproteins and glucose tolerance. Adv Contracept. 
1991; 7(1): 77-83. 
 
239 
6. Beck RP, Fawcett DM, Morcos F.  Thyroid function studies in different 
phases of the menstrual cycle and in women receiving norethindrone with 
and without estrogen. Am J Obstet Gynecol. 1972; 112: 369-73. 
 
7. Belsey EM,  Farley  TMM . The analysis of menstrual bleeding patterns. 
Contraception 1988; 38: 129-56.  
 
8. Belsey  EM, Machin D, d’Arcangues C.  The analysis of vaginal bleeding 
patterns induced by fertility regulating methods. Contraception 1986; 34 
:253-60.  
 
9. Bergink EW, Deckers GH, Kloosterboer HJ. Comparative selectivity of 
contraceptive progestins in in-vitro and in-vivo pharmacological tests. In : 
Oral contraception into the 1990’s. eds. HW Haibe and H Reckers. 
Parthenon Publ. Group, 1989. 
 
10. Bergink EW, Hamburger AD, Jager E de, Vies J van der. Binding of a 
contraceptive progestogen Org 2969 and its metabolites to receptor 
proteins and human sex hormone binding globulin. J Steroid Biochem 
1981; 14: 175-83.  
11. Bergink EW. Binding of contraceptive progestogens to receptor proteins in 




12. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, 
Vandenbrocke JP. Enhancement by factor V Leiden mutation of risk of 
deep-vein thrombosis associated with oral contraceptives containing a 
third-generation progestogen. Lancet. 1995; 346: 1593-1596. 
 
13. Bonnar J, Daly L, Sheppard BL. Effect of triphasic gestodene/ 
ethinylestradiol on coagulation, fibrinolysis and platelets. In: Genazzani 
AR, Skouby SO (eds). Triphasic gestodene – a new approach to oral 
contraception. Carnforth. Parthenon, 1992; 55-66. 
 
14. Breiner M, Romalo G, Schweikert HU. Inhibition of androgen receptor 
binding by natural and synthetic steroids in cultured human genital skin 
fibroblasts.  Klin Wochenschr. 1986; 64(16):732-737.  
 
15. Castelli WP, Abbott RD, McNamara PM. Summary estimates of 
cholesterol used to predict coronary heart disease. Circulation. 1983; 67 
(4): 730-734. 
 
16. Cohen H, Mackie IJ, Walshe K, Gillmer MD, Machin S. A comparison of 
the effects of two triphasic oral contraceptives on haemostasis. Br J 
Haematol. 1988; 69: 259-263. 
 
241 
17. Coutinho, EM. Clinical experience with implant contraception. 
Contraception. 1978; 18: 411-27. 
 
18. Coutinho E.  One year contraception with a single subdermal implant 
containing Nomegestrol acetate (Uniplant). Contraception 1993; 47: 97-
105. 
 
19. Crook D, Godsland IF, Worthington M, Felton CV, Proudler AJ, 
Stevenson JC. A comparative metabolic study of two low-estrogen-dose 
oral contraceptives containing desogestrel or gestodene progestins. Am J 
Obstet Gynecol. 1993; 169: 1183-1189. 
 
20. Croxatto H, Diaz S, Vera R, Etchart M, Atria P.  Fertility control in 
women with a progesterone released in microquantiles from subcutaneous 
capsules. Am J Obstet Gynecol 1969;  1: 1135-38. 
 
21. Croxatto H, Diaz S, Atria P, Cheviakoff S, Rosatti S, Oddo H. 
Contraceptive action of megestrol acetate implants in women. 
Contraception. 1971; 4: 155-9. 
 
22. Croxatto HB, Diaz S, Robertson DN, Pavez M. Clinical chemistry in 
women treated with levonorgestrel implants (Norplant) or a TCu 200 IUD. 
Contraception. 1983; 27(3):281-288. 
242 
 
23. Cullberg G.  Androgenic, anabolic, estrogenic and antiestrogenic effects of 
desogestrel and lynestrenol : effects on serum proteins and vaginal 
cytology. Contraception 1984; 30: 73-9. 
 
24. Cullberg G, Lindstedt G, Lundberg P-A, Steffensen K. Central and 
peripheral effects of desogestrel 15-60 mcg daily for 21 days in healthy 
female volunteers. Acta Obstet Gynecol Scand. 1982a; (suppl 111) : 21-8.  
 
25. Cullberg G, Eriksson O, Knuttson F, Steffensen K. Desogestrel, a new  
progestational compound. Acta Obstet Gynecol Scand.  1982b; (suppl. 
111):  13-9. 
 
26. David JL, Gaspard UJ, Gillain D, Raskinet R, Lepot MR. Hemostasis 
profile in women taking low-dose oral contraceptives. Am J Obstet 
Gynecol. 1990; 163: 420-3. 
 
27. Davies GC, Feng LX, Newton JR, Beek A van, Coelingh-Bennink HJT.  
Release characteristics, ovarian activity and menstrual bleeding pattern 
with a single contraceptive implant releasing 3-keto-desogestrel. 
Contraception 1993; 47: 251-61. 
 
243 
28. Demeny, P. ‘The World Demographic Situation’ . Center for Policy 
Studies, The Population Council Working Paper, No. 121, 1985. 
 
29. Diaz S, Pavez M, Moo-Young AJ, Bardin CW, Croxatto HB. Clinical trial 
with 3-keto-desogesrel subdermal implants. Contraception 1991; 44: 393-
408. 
 
30. Diczfaluzy, E.  Has family planning a future. Contraception. 1987; 35 : 1-
17. 
 
31. Djerrasi C.  The bitter  pill. Science 1989; 245:  356-61. 
 
32. Dyson T, Murphy M.  The onset of fertility transition. Popul Rev 1985; 
11:  399. 
 
33. Editorial. Whipping up panic about the pill. Nature. 1995; 377: 663. 
 
34. Ehrlich PR, Ehrlich AH.  The Population Explosion. New York, Simon 
and Schuster, 1990. 
 
35. Elkind-Hirsch K,  Goldzieher JW. Metabolism: carbohydrate metabolism. 
In : Pharmacology of the Contraceptive Steroids.ed. JW Goldzieher.  
Raven Press Ltd. New York, 1994. 
244 
 
36. Farmer RT, Laerenson RA, Thompson CR, Kennedy JG, Hambleton IR. 
Population based study of risk of venous thromboembolism associated 
with various oral contraceptives. Lancet. 1997; 349: 83-88. 
 
37. Folkman J, Long DM.  The use of silicone rubber as a carrier for 
prolonged drug therapy. J Surg Res .1964; 4: 139-42. 
 
38. Forrest JD.  Epidemiology of  unintended pregnancy and contraceptive 
use.  Am J Obstet Gynecol 1994; 170: 1485-9. 
 
39. Friedewald WI, Levy RI, Fredrickson DS. Estimation of the concentration 
of low density lipoprotein cholesterol in plasma, without the use of the 
preparative ultracentrifuge. Clin Chem. 1982; 18: 499-502. 
 
40. Geelen JAA, Wardt JTH vd, Voortman G, Maassen GCT, Eenink MJD. 
Release kinetics of 3-keto-desogestrel from contraceptive implants 
(Implanon ) in dogs : comparison with in vitro data. Contraception 1993; 
47: 215-26. 
 
41. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, 
Lawn RM. Proliferation of human smooth muscle cells promoted by 
lipoprotein(a). Science. 1993; 260: 1655-1658. 
245 
 
42. Godsland IF, Crook D, Simpson R, et al.  The effects of different 
formulations of oral contraceptive agents on lipid and carbohydrate 
metabolism. N Engl J Med. 1990; 323: 1375-81. 
 
43. Godsland IF, Crook D. Update on the metabolic effects of steroidal 
contraceptives and their relationship to cardiovascular disease risk. Am J 
Obstet Gynecol. 1994; 170: 1528-1536. 
 
44. Goldenthal EI. Contraceptives, estrogens and progestogens : a new FDA 
policy on animal studies. FDA papers. November, 1969: 15. 
 
45. Goolden AW, Bateman DM, Pleehachinda R, Sanderson C. Thyroid-
function tests in women taking norgestrel. Lancet. 1970; 1(7647): 624  
 
46. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. 
Cardiovascular risk factors in confirmed prediabetic individuals. Does the 
clock for coronary heart disease start ticking before the onset of clinical 
diabetes? JAMA. 1990; 263(21): 2893-2898  
 
47. Hammond GL, Langley MS, Robinson PA, Nummi S, Lund L. Serum 
steroid binding protein concentrations, distribution of progestogens, and 
246 
bioavailability of testosterone during treatment with contraceptives 
containing desogestrel or levonorgestrel. Fertil Steril 1984; 42: 44-51. 
 
48. Hansen RW. The pharmaceutical development process estimates of 
development cost and time and the effects of proposed regulatory changes. 
Issues of Pharmaceutical Economics , 1979. 
 
49. Harduin P, Tailleux A, Fruchart JC, Fievet C. Modulation of the 
expression of human LDL-Apo B-100 epitopes by lipids and 
apolipoproteins. Arterioscler Thromb. 1993; 13: 529-535  
 
50. Hasenack HG, Bosch AMG, Kaar K.  Serum levels of 3-keto-desogestrel 
after oral administration of desogestrel and 3-keto-desogestrel. 
Contraception 1986; 33: 591-6. 
 
51. Haub C, Yanagishita M.  1992 World Population Data Sheet.Washington, 
D.C., Population Reference Bureau, 1992. 
 
52. Heinonen OP, Slone D, Monson RR, Hook EB, Shapiro S.  Cardiovascular 
birth defects and antenatal exposure to female sex hormones. N Engl J 
Med . 1977; 296: 67-70. 
 
247 
53. Hill R, Averkin E, Brown W, Gagne WE, Segre E. Progestational potency 
of chlormadinone acetate in the immature beagle bitch - Preliminary 
report. Contraception. 1970; 2: 381-90. 
 
54. ICMR task force on Hormonal Contraception, 1991 
 
55. Jackson R, Newton JR.  The in vivo release characteristics of a 
multicompartment vaginal ring releasing 3-ketodesogestrel. Contraception 
1989; 40: 615-21. 
 
56. Janerich DT, Piper JM, Glebatis DM.  Oral contraceptives and congenital 
limb-reduction defects. N Engl J Med. 1974; 291: 697-700. 
 
57. Jarret RJ, Graver HJ. Changes in oral glucose tolerance during the 
menstrual cycle. Br Med J. 1968; 2: 528-9. 
 
58. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic 
cardiovascular death and non-fatal venous thromboembolism in women 
using oral contraceptives with differing progestogen components. Lancet. 
1995; 346: 1589-1593. 
 
248 
59. Kalkhoff RK, Jacobson M, Lemper D. Progesterone, pregnancy and the 
augmented plasma insulin response. J Clin Endocrinol Metab. 1970; 31(1): 
24-28  
 
60. King M.  Health is a sustainable state. Lancet 1990; 336: 664-667. 
 
61. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: 
predicting risks by levels and ratios. Ann Intern Med. 1994; 121 (9): 641-
647. 
 
62. Kinosian B, Glick H, Preiss L, Puder KL. Cholesterol and coronary heart 
disease: predicting risks in men by levels and ratios. J Investig Med. 1995; 
43 (5): 443-450. 
 
63. Kloosterboer HJ, Vonk Noordegraaf CA, Turpijn EW.  Selectivity in 
progesterone and androgen receptor binding of progestagens used in oral 
contraceptives. Contraception 1988; 38: 325-32. 
 
64. Konje JC, Otolorin EO, Lapido OA. Changes in carbohydrate metabolism 
during 30 months on Norplant. Contraception 1991; 44: 163-72. 
 
249 
65. Konje JC, Odukoya OA, Otolorin EO, Ewings PD. Carbohydrate 
metabolism before and after Norplant removal. Contraception 1992; 46: 
61-9. 
 
66. Kontula K, Paavonen T, Luukkainen T, Andersson LC. Binding of 
progestins to the glucocorticoid receptor. Biochem pharmacol 1983; 32: 
1511-18. 
 
67. Kopera H.  Desogestrel : Review of pharmacology and clinical trials. In: 
Female contraception. Eds. Runnebaum B, Rabe T, Kiesel L. Springer-
Verlag 1988; 156-63.   
 
68. Kuhl  H, Jung-Hoffman C, Heidt F. Serum levels of 3-keto-desogestrel and 
sex hormone binding globulin during 12 cycles of treatment with 30 µg 
ethinyloestradiol and 150 µg desogestrel. Contraception 1989; 38: 381-90. 
 
69. Landgren BM, Unden AL, Diczfalusy E.  Hormonal profile of the cycle in 
68 normally menstruating women. Acta Endocrinol 1980; 94: 89-98. 
 
70. Lewis MA, Spitzer WO, Heineman AJ, Thorogood M, MacRae KD. Third 
generation oral contraceptives and risk of myocardial infarction: an 
international case controlled study. Br Med J. 1996.; 312: 88-90. 
250 
 
71. Luyckx AS, Gaspard UJ, Romus MA, Grigorescu F, Meyts PD, Lefebvre 
PJ. Carbohydrate metabolism in women who used oral contraceptives 
containing levonorgestrel or desogestrel : a 6-month prospective study. 
Fertil Steril. 1986; 45 (5) : 635-42. 
 
72. MacRae K, Kay KC. Third generation oral contraceptive pills. Br Med J. 
1995; 311: 11-12. 
 
73. Mauldin WP, Ross JA. Family planning programs: efforts and results, 
1982-89. Stud Fam Plann 1991; 22(6): 350-367. 
 
74. McCann MF,  Potter LS. Progestin-only contraception: A comprehensive 
review. Contraception. 1994; 50 (Suppl.): 114-38. 
 
75. Meade TW, Greenberg G, Thompson SG. Progestogens and 
cardiovascular reactions associated with oral contraceptives and a 
comparison of the safety of 50- and 30-microgram oestrogen preparations. 
Br Med J. 1980; 280(6224):1157-1161. 
 
76. Mascarenhas L, van Beek A, Bennink HC. Newton J. Twenty-four months 
comparison of apolipoproteins A-I, A-II and B in contraceptive implant 
users (Norplant and Implanon) in Birmingham, United 
251 
Kingdom.[Published erratum appears in Contraception 1998; 58:389]. 
Contraception 1998; 58:215-9. 
 
77. Notelovitz M, Feldman EB, Gillespy M, Gudat J. Lipid and lipoprotein 
changes in women taking low-dose, triphasic oral contraceptives: a 
controlled, comparative, 12-month clinical trial. Am J Obstet Gynecol. 
1989;160(5 Pt 2):1269-1280. 
 
78. Notestein FW.  Population - the long view. In : Food for the world. ed. 
Schultz TW. Chicago; University of Chicago Press, 1945: 36-57. 
 
79. Olsson SE, Wilde L, Odlind V.  Aspects of thyroid function during the use 
of Norplant implants. Contraception 1986; 34: 583-7. 
 
80. Olsson SE, Odlind V, Johansson E. Clinical results with subcutaneous 
implants 3-ketodesogestrel. Contraception 1990, 42: 1-11. 
 
81. Orme ML’E, Back DJ, Breckenridge AM. Clinical pharmacokinetics of 
oral contraceptive steroids.  Clin Pharmacokinet  1983; 8: 95-136. 
 
82. Oster P, Arab L, Kohlmeier M, Mordasini R, Schellenberg B, Schlierf G. 
Effects of estrogens and progestogens on lipid metabolism. Am J Obstet 
Gynecol. 1982; 142(6 Pt 2):773-775. 
252 
 
83. Potts M and Selman P. Society and Fertility, Plymouth, MacDonald 
Evans, 1979. 
 
84. Rabe T, Thuro HC, Goebel K, Borchardt C, Grunwald K, Runnebaum B. 
Lipid metabolism in Norplant-2 users--a two-year follow-up study. Total 
cholesterol, triglycerides, lipoproteins and apolipoproteins. Contraception. 
1992; 45: 21-37. 
 
85. Rekers H, Norpoth T, Michaels MA. Oral contraceptive use and venous 
thromboembolism: a consideration of the impact of bias and confounding 
factors on epidemiologic studies. Europ J Contr Reprod Health Care. 
1996; 1: 21-30. 
 
86. Robertson D, Sivin I, Nash H, Braun J, Dinh J.  Release rates of 
levonorgestrel from silastic capsules, homogenous rods and covered rods 
in humans. Contraception 1983; 27: 483-95. 
 
87. Rodriguez G, Faundes-Latham A, Atkinson L. An approach to the analysis 
of menstrual patterns in the clinical evaluation of contraceptives. Stud Fam 
Plann 1976; 7: 42-51. 
 
253 
88. Sam AP.  Controlled-release contraceptive devices. In : Minutes of the Vth 
Int. Pharm. Techn. Symp., New Approaches to Controlled Drug Delivery. 
Eds  Hincal AA et al. Editions de Sant, Paris 1991; 271-84. 
 
89. Segal SJ, Croxatto HB. “Single administration of hormones for long-term 
control of reproductive function”. Paper presented at the XXIII meeting of 
the American Fertility Society, Washington, D.C., 14-16 April 1967. 
 
90. Shaaban MM, , Elwan  SI, El-Sharkawy  MM, Farghaly AS.  Effect of 
subdermal levonorgestrel contraceptive implants, Norplant, on liver 
function. Contraception 1984; 30: 407-12. 
 
91. Shaaban MM, , Elwan  SI, Abdalla SA, Darwish HA.  Effect of subdermal 
levonorgestrel contraceptive implants, Norplant, on serum lipids. 
Contraception 1984; 30: 413-19. 
 
92. Shamma FN, Rossi G, HajHassan L, Penzias AS, Connoly-Diamond M, 
Jones E, Diamond MP. The effect of Norplant on glucose metabolism 
under hyperglycaemic hyperinsulinaemic conditions. Fertil Steril 1995; 
63: 767-72. 
 
93. Shoupe D, Mishell DR. Norplant: subdermal implant system for long-term 
contraception. Am J Obstet Gynecol. 1989; 160(5 Pt 2):1286-1292. 
254 
 
94. Singh M, Saxena BB, Graver R, Ledger WL. Contraceptive efficacy of 
norethindrone encapsulated in injectable biodegradable poly-dl-lactide-co-
glycolide microspheres : Phase II clinical study. Fertil Steril 1989; 52: 
973-80. 
 
95. Singh K, Viegas OAC, Ratnam SS. Long-acting progestins - An Update. 
Adv Contraception. 1989; 5: 241-51. 
 
96. Singh K, Viegas OAC, Loke DFM, Ratnam SS. Effect of Norplant 
implants on liver, lipid and carbohydrate metabolism. Contraception 1992; 
45: 141-53. 
 
97. Singh K, Viegas OAC, Loke D, Ratnam SS. Effect of Norplant-2 rods on 
liver, lipid and carbohydrate metabolism. Contraception. 1992b; 45: 463-
472. 
 
98. Singh K and Ratnam SS. A study on the effects of Norplant implantable 
contraceptive on lipid, lipoprotein and apolipoprotein metabolism in 
Singaporean women. Contraception. 1997; 56: 77-83. 
 
99. Sivin I. International experience with Norplant and Norplant-2 
contraceptives. Stud Fam Plan 1988; 19(2): 81-94. 
255 
 
100. Skouby SO. The influence on the pituitary-ovarian function, cervical 
mucus and vaginal cytology of a new progestational compound. 
Contraception 1976; 14(5): 529-539  
 
101. Slone D, Shapiro S, Kaufman DW, Rosenberg L, Miettinen OS, Stolley 
PD. Risk of myocardial infarction in relation to current and discontinued 
use of oral contraceptives. N Engl J Med. 1981; 305: 420-424. 
 
102. Spellacy WN, Buhi WC, Birk SA. Prospective studies of carbohydrate 
metabolism in "normal" women using norgestrel for eighteen months.  
Fertil Steril. 1981; 35(2):167-171. 
 
103. Spellacy WN, Buhi WC, Birk SA. The effects of norgestrel on 
carbohydrate and lipid metabolism over one year. Am J Obstet Gynecol. 
1976; 125(7):984-986. 
 
104. Spitzer WO, Lewis MA, Heineman AJ, Thorogood M, MacRae KD. Third 
generation oral contraceptives and risk of venous thromboembolic 




105. Suherman SK, Affandi B, Korver T.  The effect of Implanon on lipid 
metabolism in comparison with Norplant. Contraception 1999; 60: 281-7. 
 
106. Tejuja S.  Use of subcutaneous Silastic capsules for long-term steroid 
contraception. Am J Obstet Gynecol. 1970; 107(6): 954-957  
 
107. The Population Council. Norplant manual for clinicians. New York. The 
Population Council, 1990. 
 
108. UNICEF. The state of the world’s children 1987: 91. 
 
109. United Nations Fund for Population Activities.  The State of World 
Population, New York, 1987. 
 
110. United Nations. Long-range world population projections: Two centuries 
of population growth.1950-2150. New York, UN, 1992, pp 45. 
 
111. van der Vange N, Kloosterboer HJ, Haspels AA.  Effects of seven low 
dose oral contraceptives on high density lipoprotein subfractions.  Br J 
Obstet Gynaecol 1987; 94: 559-67. 
 
257 
112. Vessey MP, Villard-Mackintosh L, McPherson K, Yeates D. Mortality 
among oral contraceptive users: 20 year follow up of women in a cohort 
study. Br Med J. 1989; 299(6714):1487-1491. 
 
113. Vies J van der, Visser  J de. Endocrinological studies with DSG. Arzneim 
Forsch/ Drug Res 1983; 2: 231-6. 
 
114. Viinikka L, Hirvonen E, Ylikorkala O, et al. Ovulation inhibition by a new 
low-dose progestagen. Contraception  1977; 16: 51-9. 
 
115. Viinikka L, Ylikorkala O, Nummi S et al.  Biological effects of a new and 
potent progestagen. A clinical study. Acta Endocrinol  1976; 83: 429-38. 
 
116. Viinikka L, Ylikorkala O, Vihko R, Wijnand HP, Booy M, Veen F van. 
Metabolism of a new synthetic progestogen, Org 2969, in female 
volunteers. Investigation in to the pharmacokinetics after an oral dose. Eur 
J Clin Pharmacol 1979; 15: 349-55. 
 
117. Viinikka L, Ylikorkala O, Vihko R, Hasenack HG, Nieuwenhuyse H.  
Metabolism of a new synthetic progestagen, Org 2969, in female 
volunteers. The distribution and excretion of radioactivity after an oral 
dose of the labelled drug. Acta Endocrinol 1980; 93 : 375-9. 
 
258 
118. Viinikka, L.  Radioimmunoassay of a new progestagen, Org 2969, and its 
metabolite. J Steroid Biochem 1978, 9 : 979-82. 
 
119. Viinikka, L. Metabolism of a new synthetic progestagen, Org 2969, by 
human liver in vitro. J Steroid Biochem 1979; 10 : 353-7. 
 
120. Wahl P, Walden C, Knopp R, Hoover J, Wallace R, Heiss G, Rifkind B. 
Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.  N 
Engl J Med. 1983; 308(15):862-867 
 
121. Waine H, Frieden EH, Caplan H, Cole T. Metabolic effects of Enovid on 
rheumatoid patients. Arthritis Rheum. 1963; 6: 796-800. 
 
122. Watt AH. Oral contraceptives and venous thromboembolism. Lancet. 
1995; 346: 1430-1431. 
 
123. Weinges KF, Wenzel E, Hellstern P, Geurts TB, Dieben TO. The effects 
of two phasic oral contraceptives on hemostasis and platelet function. Adv 
Contracept. 1995; 11: 227-37. 
 
124. Winikoff D, Oral contraceptives and thyroid function tests: the role of 
progestogens.  Med J Aust 1968; 2(1): 13-18. 
 
259 
125. World Health organization (WHO) Expert Committee on Diabetes 
Mellitus. Techn Rep Ser 1980; No. 646 
 
126. World Health Organization (WHO), World Health Statistics Annual. 
Geneva: WHO, 1989. 
 
127. WHO collaborative study of cardiovascular disease and steroid hormone 
contraception. Effect of different progestagens in low oestrogen oral 
contraceptives on venous thromboembolic disease. Lancet. 1995; 346: 
1582-1588. 
 
128. Wynn V, Niththyananthan R. The effect of progestins in combined oral 
contraceptives on serum lipids with special reference to high-density 
lipoproteins. Am J Obstet Gynecol. 1982; 142(6 Pt 2): 766-771.  
 
129. Zeidenstein G. The user perspective : An evolutionary step in 
contraceptive service programs. Stud Fam Plann. 11: 24-29, 1980. 
  
 
